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1A. Abstract 
 
Three members of the low-density lipoprotein receptor (LDLR) family, LDLR proper,     
very-LDLR (VLDLR) and LDLR-related protein (LRP) act as minor group human rhinovirus 
(HRV) receptors. Whereas ICAM-1, the receptor of the major group of HRVs, actively 
contributes to viral uncoating, minor group receptors were rather considered passive vehicles 
just delivering virus to the low pH environment of endosomes. However, the YWTD             
β-propeller domain of LDLR has been shown to be involved in the dissociation of bound LDL 
at acidic pH. We thus aimed to clarify whether it also actively contributes to HRV infection. 
No human cell line expressing LDLR in the absence of VLDLR or LRP is available. 
Therefore, CHO-ldla7 cells which are deficient in endogenous LDLR and are stably 
transfected to express either wild-type or β-propeller negative human LDLR were used to 
investigate low pH-triggered conversion of HRV2 and its release from the receptor. Lower pH 
was required for conversion when HRV2 was attached to the propeller-negative LDLR, 
indicating that the high-avidity receptor-binding stabilizes the virus in its native conformation. 
Infection assays showed a delay in intracellular viral conversion, degradation, as well as in   
de novo viral synthesis in the absence of the β-propeller domain. We conclude that the 
function of the β-propeller at low pH is also significant when the ligand is a rhinovirus; it 
facilitates viral conversion within endosomes by decreasing the virus-stabilizing effect of the 
high avidity LDLR binding, and thereby promotes infection.  
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1B. Zusammenfassung 
 
Drei Vertreter der low-density Lipoprotein Rezeptor Familie, LDLR selbst, very-LDLR, und 
LDLR related protein (LRP) werden von minor group Rhinoviren des Menschen (HRVs) als 
Rezeptoren verwendet. Während ICAM-1, der Rezeptor der major group der HRVs, aktiv am 
viralen uncoating beteiligt ist, wurden minor group Rezeptoren als passive Vehikel betrachtet, 
die das Virus in Endosomen transportieren, wo sie ein Milieu mit niedrigem pH vorfinden. 
Für die YWTD β-Propeller Domaine des LDL-Rezeptors wurde jedoch gezeigt, dass sie an 
der Abdissoziation gebundenen LDLs bei niedrigem pH beteiligt ist. Wir wollten daher 
herausfinden, ob sie auch aktiv an der Infektion mit HRVs teilnimmt. Es existiert keine 
humane Zell Linie, die LDLR in Abwesenheit von VLDLR oder LRP exprimiert. Daher 
wurden in unseren Untersuchungen CHO-ldla7 Zellen verwendet, die keinen endogenen 
LDL-Rezeptor exprimieren. Diese waren stabil transfiziert um entweder Wildtyp oder            
β-Propeller negative humane LDL-Rezeptoren zu exprimieren. Mit Hilfe dieser Zellen 
untersuchten wir den möglichen Einfluss des β-Propellers auf die Konversion von HRV2 in 
subvirale Partikel als eine Funktion des niedrigen pH und die Freisetzung des Virus vom 
Rezeptor. Wenn HRV2 an propeller-negativen LDLR gebunden war ein niedrigerer pH wurde 
für die Konversion benötigt. Dies deutet darauf hin, dass die hoch-avide Rezeptorbindung das 
Virus in seiner nativen Konformation stabilisiert. Infektionsversuche zeigten eine zeitliche 
Verzögerung in der intrazellulären viralen Konversion, im Abbau und in der viralen de novo 
Synthese in der Abwesenheit der β-Propeller-Domaine. Wir schließen daraus, dass die 
Funktion des β-Propellers bei niedrigem pH auch dann signifikant ist, wenn der Ligand ein 
Rhinovirus ist. Er erleichtert die virale Konversion im Inneren von Endosomen, indem er den 
Virus-stabilisierenden Effekt des mit hoher Avidität bindenden LDLR reduziert. Dadurch 
begünstigt er die Infektion. 
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2. Introduction 
 
2.1. Viruses 
 
Viruses are sub-microscopic, obligate intracellular parasites, mobile genetic elements most 
probably of cellular origin, being engaged in a long co-evolution with their host. Viruses 
depend on specific host cells supplying the complex metabolic and biosynthetic machinery for 
their propagation. The viral nucleic acid contains the genetic information necessary to 
program the host cell for virus production. Because of their limited size, viral genomes code 
for only a few structural and some non-structural regulatory proteins which are necessary for 
their replication. The various viral components are synthesized separately within the cell and 
then they self-assemble to form progeny particles. A fully assembled infectious virus is called 
a virion. Its genome (DNA or RNA) is protected by a protein coat and eventually by an 
additional lipid bilayer (envelope) derived from host membrane, modified with virus encoded 
glycoproteins. The pathological symptoms are usually caused by the actions of the virus itself 
(e.g. killing the cells it infects), as well as by the immune response of the host. Since viruses 
depend on host survival for their own survival, they usually do not kill the host organism, at 
least not before they spread. 
 
 
2.2. The family Picornaviridae 
Human rhinoviruses (HRVs), the subjects of our investigations, belong to the family 
Picornaviridae, which name refers to the small size and the ribonucleic acid genome of these 
viruses. All members of the family are small, non-enveloped, icosahedral viruses with a 
single-stranded messenger-sense RNA genome (Stanway, 1990). With more than 200 
serotypes this family comprises one of the largest groups of human and animal pathogens and 
has a considerable medical and economical importance. Picornaviridae is also one of the 
most diverse and oldest known virus families; poliomyelitis (caused by poliovirus) was 
reported already in Egyptian hieroglyphs, and foot-and mouth disease virus was the first 
animal virus discovered in 1898.  
Picornavirus research has yielded numerous landmark discoveries in the development of 
modern virology and even biology in general, like the propagation of viruses in cultured cells, 
the development of inactivated and attenuated vaccines to prevent poliomyelitis, the 
demonstration of the first RNA-dependent RNA polymerase activity of an animal virus, the 
discovery of polyproteins as precursors of viral polypeptides, the first chemical structure of 
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the genome of an autonomously replicating RNA virus, the first 3D atomic resolution of an 
animal virus, the discovery of an internal ribosomal entry site to initiate translation of the 
uncapped picornavirus RNA, etc. (Semler and Wimmer, 2002).  
 
Picornaviruses were originally classified on the basis of pathogenesis, biophysical properties 
(particle density, pH sensitivity), as well as serological relatedness. For example enteroviruses, 
cardioviruses, and hepatitis A viruses are acid stable surviving at pH 3, whereas rhinoviruses 
and aphthoviruses are labile at pH < 6. Due to the continuously increasing amounts of 
sequence and structural data, their classification is currently based on phylogenetic properties, 
and the family Picornaviridae is currently grouped into 8 genera (Table 1), Enterovirus, 
Cardiovirus, Aphthovirus, Hepatovirus, Parechovirus, Erbovirus, Kobuvirus, and Teschovirus. 
 
Picornaviridae 
Genus Species 
 
Enterovirus 
Human enterovirus A 
Human enterovirus B  
Human enterovirus C  
Human enterovirus D  
Simian enterovirus A  
Bovine enterovirus 
Porcine enterovirus A  
Porcine enterovirus B 
Human rhinovirus A  
Human rhinovirus B 
Cardiovirus Encephalomyocarditis virus (EMCV)  
Theliovirus (ThV) 
Aphthovirus Foot-and-mouth-disease virus (FMDV)  
Equine rhinitis A virus (ERAV) 
Hepatovirus Hepatitis A virus (HAV) 
Parechovirus Human parechovirus (HPeV)  
Ljungan virus (LV) 
Erbovirus Equine rhinitis B virus (ERBV) 
Kobuvirus Aichi virus (AiV) 
Bovine kobuvirus 
Teschovirus Porcine teschovirus (PTV) 
   
Table 1. Classification of the family Picornaviridae based on the 8th International Committee for the 
Taxonomy of Viruses (ICTV) report (http://www.picornaviridae.com) 
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The taxonomy of Picornaviridae is continuously changing (http://www.picornaviridae.com). 
The Picornavirus Study Group has proposed some revisions including new genera, 
provisionally named “Sapelovirus”, “Senecavirus”, and “Tremovirus”. The two human 
rhinovirus species have been moved to the genus Enterovirus which now also includes the 
recently discovered species C of HRVs (see below), and the former genus Rhinovirus does 
not exist any more. Three other picornaviruses, duck hepatitis virus 1, seal picornavirus 1, and 
human cosavirus, whose genomes have recently been sequenced, have been proposed to 
belong to novel genera.  
 
The genus Enterovirus contains the most species and virus types. Poliovirus, which belongs 
to the human enterovirus C species and comprises 3 types, is the best studied member of the 
family. Coxsackieviruses, echoviruses, human-, simian-, bovine-, and porcine-enteroviruses 
also belong to this genus. These viruses infect mainly humans, spread through the faecal-oral 
route, and are transmitted directly from person to person. They are able to pass through the 
acidic environment of the stomach (they are stable at pH 3 or even below), and infect 
primarily cells of the intestinal epithelium and lymphoid cells of the gut. In addition to milder 
symptoms like common cold, intestinal disorders, and diarrhea, enteroviruses cause also 
severe illnesses as myositis, carditis, pharyngitis, pneumonitis, meningitis, and encephalitis. 
By entering the blood stream some strains can lead to systemic infections and sometimes even 
to infections of the central nervous system by crossing the blood-brain barrier. Human 
rhinoviruses, the most important etiologic agents of the common colds, have recently been 
integrated into this genus. They are adapted to replicate in the nasopharyngeal region, and 
especially during spring and autumn infect many people causing mild respiratory illness 
which often sets the stage for more severe infections by bacteria or other viruses.  
 
Aphthoviruses infect the naso- and oropharyngeal regions of their hosts and they spread in the 
air. Equine rhinitis A virus is specific for horses. Foot-and-mouth disease virus (FMDV) 
infects cloven hoofed animals, especially cattle, goats, pigs, and sheep, causing the formation 
of blisters in the mouth and between the claws. It might lead to death of young animals 
through inflammation of the heart muscle, so it is of tremendous economic importance.  
 
Cardioviruses, represented by Encephalomyocarditis virus (EMCV) and Theilovirus (ThV), 
infect a number of different species, including humans, other primates, pigs, different rodents, 
birds, and even mosquitoes. Infection occurs orally and causes various symptoms depending 
on the particular virus and host, like gastrointestinal infections, acute myocarditis, 
encephalitis or abortions in sows. Human infection has been reported to involve the central 
nervous system but not to cause myocarditis (Scraba and Palmenberg, 1999).  
 
Hepatoviruses include the human hepatitis A virus which causes roughly 50 % of acute viral 
hepatitis cases in humans. Transmission occurs via the faecal-oral route by uptake of 
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contaminated food or water. Replication occurs mainly in hepatocytes, but the virus is 
presumed to travel to the intestine via the bile duct.  
 
Parechoviruses, comprising human parechovirus (HPEV) and Ljungan virus (LV), mainly 
cause diarrhea with eventual respiratory complications and are rarely associated with 
encephalitis and flaccid paralysis (Stanway and Hyypia, 1999). 
 
The genus Kobuvirus consists of Aichi virus, Bovine kobuvirus, and a third candidate species 
that has recently been described in pigs (Porcine kobuvirus). Aichi virus was first recognised 
in 1989 as the cause of oyster-associated non-bacterial gastroenteritis in man (Yamashita et al., 
1995). 
 
The genus Erbovirus contains a single species, Equine rhinitis B virus (ERBV) with two 
serotypes, ERBV-1 and ERBV-2, causing acute respiratory disease in horses. 
 
The genus Teschovirus consists of a single species, Porcine teschovirus causing 
encephalomyelitis in pigs. 
 
2.3. Human rhinoviruses  
 
HRVs account for more than 50 % of mild infections of the upper respiratory tract and thus 
are the major cause of the common cold in humans (Tyrrell and Parsons, 1960). The 
symptoms are sneezing, nasal obstruction, sore throat, headache, cough, and malaise. These 
viruses are sensitive to low pH (below pH 6) and require a temperature not exceeding 34°C; 
therefore, they grow best in the outer layer of the nasal mucosa. However, there are an 
increasing number of reports on replication of HRVs also in the lower airway system (Hayden, 
2004; Mosser et al., 2002). Most of the respiratory illnesses caused by human rhinoviruses are 
benign, but symptoms may persist for several days, and the resultant interruption in school 
and work days may be substantial. Moreover, HRV infections can predispose to 
complications both in the upper and lower respiratory tract, and are connected with sinusitis, 
otitis media, exacerbation of asthma, chronic bronchitis, and cystic fibrosis (Heikkinen and 
Jarvinen, 2003; Pitkaranta and Hayden, 1998), especially in older adults and infants. HRVs 
spread from person to person, usually by direct contact or indirectly through the air.  
 
HRVs are divided into two groups based on their receptor specificity. Most of the types (87; 
members of the major group) bind to human intercellular adhesion molecule 1 (ICAM-1) 
(Greve et al., 1989; Staunton et al., 1989; Tomassini et al., 1989). The remaining 12 types of 
the minor group attach to members of the low-density lipoprotein receptor (LDLR) family 
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including LDLR, very-LDLR (VLDLR), and LDLR-related protein (LRP) (Gruenberger et al., 
1995; Hofer et al., 1994; Marlovits et al., 1998b; Marlovits et al., 1998c). 
 
The 99 types of HRVs are phylogenetically classified into 2 species, HRV-A and HRV-B 
(Tidona and Darai, 2002). While the species HRV-A comprises both major and minor 
receptor group members, all types of the species HRV-B belong to the major receptor group.  
 
Human rhinovirus A involves the following 74 types: HRV-1, 2, 7, 8, 9, 10, 11, 12, 13, 15, 
16, 18, 19, 20, 21, 22, 23, 24, 25, 28, 29, 30, 31, 32, 33, 34, 36, 38, 39, 40, 41, 43, 44, 45, 46, 
47, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 71, 73, 74, 75, 76, 
77, 78, 80, 81, 82, 85, 88, 89, 90, 94, 96, 98 and 100.  
Minor group viruses are underlined. HRV type 1 is divided into two subtypes, HRV-1A and 
HRV-1B. 
 
Human rhinovirus B involves the following 25 types: HRV-3, 4, 5, 6, 14, 17, 26, 27, 35, 37, 
42, 48, 52, 69, 70, 72, 79, 83, 84, 86, 91, 92, 93, 97 and 99. 
 
Based on sequence analysis, human rhinovirus 87 turned out to be an enterovirus, most 
closely related to enterovirus 68 (Blomqvist et al., 2002; Savolainen et al., 2002). Recent 
observations showed that two serotypes, HRV23 and HRV25 earlier considered as major 
group viruses, rather behaved like minor group ones (Vlasak et al., 2005b). Furthermore, 
based on the high similarity in amino acid sequence of the capsid protein VP1 of HRV8 and 
HRV95, and of HRV-Hanks (H) and HRV21, the two pairs are now considered only two 
types.  
 
Recently, a new phylogenetic group was identified but its properties with respect to receptor 
binding and entry have not been elucidated yet. These viruses have been called HRV-A2 due 
to their closer relationship with HRV-A in some analyses (Arden et al., 2006; McErlean et al., 
2007) whereas others named them HRV-X (Kistler et al., 2007) or HRV-C (Lamson et al., 
2006; Lau et al., 2007; Lee et al., 2007; McErlean et al., 2008). The taxonomic position of 
these viruses will be considered by the International Committee on Taxonomy of Viruses 
(ICTV) Picornaviridae Study Group in consultation with other HRV researchers. 
 
2.4. The HRV genome 
 
The first picornaviral RNA to be completely sequenced and cloned was that of type 1 
poliovirus. Since then, sequence analyses of other species have shown that all picornaviruses 
share a similar genome organization. The single stranded RNA is infectious, as it is being 
directly translated after reaching the cytoplasm of the host cell. The central part of the ~7.1 kb 
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messenger sense HRV RNA encodes for a 2200 amino acid polyprotein in a single open 
reading frame (ORF). As shown in Fig.1, the coding region is flanked with substantially 
conserved untranslated regions (UTR), the 5’ UTR (0.6-1.5 kb) containing an internal 
ribosome entry site (IRES) (Jackson, 2005; Pelletier and Sonenberg, 1988), regulatory 
sequences, and a small 3’ UTR with poly-A tail. The IRES is about 400-450 nucleotides 
upstream of the translational start site (Andino et al., 1990). The cis-acting elements are 
required for translation, RNA replication and virulence. Instead of a cap structure well known 
for cellular mRNAs, a small virus encoded protein called VPg (virion protein genomic) is 
covalently linked via a phophodiester bond to the 5’ UTR of the viral RNA. VPg has been 
shown to be essential for the protein-primed replication of both positive- and negative-
stranded RNA (Nomoto, 1977; Wimmer, 1982).  
 
 
 
 
Figure 1. Genome organisation of picornaviruses. All structural and non-structural proteins and the 3 major 
cleavage intermediates together with their main biologic functions are shown (Whitton et al., 2005). 
 
The central protein coding part of the picornavirus genome can be divided into three regions: 
P1, P2, and P3. The P1 region codes for the structural proteins (capsid proteins VP1 to VP4), 
while the P2 and P3 regions code non-structural proteins. The RNA is first translated into a 
polyprotein which is subsequently autocatalytically cleaved by viral proteases. Some 
intermediate cleavage products also have important functions in the replication cycle, usually 
different from that of the end products. The detailed functions of the different viral proteins 
are summarized in Fig. 1. Viral proteases such as 2A, 3C and the leader protein L in cardio-, 
aphtho-, erbo-, kobu-, and teschoviruses, are involved in the co-translational cleavage of the 
polyprotein and in the inhibition of host cell functions (Bernstein et al., 1985; Palmenberg et 
al., 1979; Toyoda et al., 1986). To promote the expression of the viral RNA, rhinoviruses 
inhibit the cellular cap-dependent translation via the cleavage of the cap binding protein 
eukaryotic initiation factor 4G (eIF4G) by the viral protease 2A. Proteins 2B and 2C 
determine the host range (Lomax and Yin, 1989; Yin and Lomax, 1983) and also play a role 
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in the rearrangement of the intracellular membrane network (Cho et al., 1994), while 2C, 3AB, 
VPg and RNA-polymerase 3Dpol are important for the replication of viral RNA (Flanegan et 
al., 1977; Li, 1988; Nomoto, 1977; Pallansch et al., 1980; Semler, 1981b; van Dyke et al., 
1982). Recently, the complete sequences of all rhinoviruses and isolates known so far have 
been published, and are available in the GenBank (Palmenberg et al., 2009).  
 
 
2.5. Capsid structure and functions 
                         
The protein coat of the non-enveloped rhinoviruses has several functions: it protects the RNA 
from environmental damages (such as nucleases), determines host range and tissue tropism by 
specific receptor recognition, delivers the viral RNA into the cytoplasm of host cells, selects 
and packs the viral genome during replication, and determines antigenicity.  
 
The spherical capsids of human rhinoviruses are assembled from 60 protein subunits called 
protomers, each of which are composed of four structural proteins, viral protein 1 (VP1), VP2, 
VP3 and VP4 (Fig. 2). Five protomers build up a pentameric unit characterised by a five-fold 
axis, and twelve such pentamers form an icosahedral capsid with a diameter of ~30 nm. Three 
dimensional structures of five rhinoviruses at < 3 Å resolution have been determined by X-ray 
crystallography, HRV1A (Kim et al., 1989), HRV2 (Verdaguer et al., 2000), HRV3 (Zhao et 
al., 1996), HRV14 (Arnold and Rossmann, 1990; Rossmann et al., 1985) and HRV16 
(Hadfield et al., 1997; Oliveira et al., 1993).  
 
 
                         
 
Figure 2. The icosahedral capsid of human rhinoviruses. Four viral proteins (VP1-VP3 external, VP4 internal) 
form a viral protomer, five such protomers are assembled into a pentamer, and twelve pentamers build up an 
icosahedral capsid. Around each five-fold axis there is a deep surface depression, called the canyon (Rueckert, 
1996).  
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In the absence of significant sequence similarity, the proteins VP1 to VP3 share the same 
overall conformation, a wedge shaped β-barrel (the so-called “Swiss roll”) built by eight 
antiparallel β-strands (Fig. 3) (Fields et al., 1996; Rossmann et al., 1985). The loops 
connecting the β-strands can accommodate extra segments leading to variations that give each 
subunit and each picornavirus its distinctive morphology and antigenicity. The external 
surface of the capsid is formed by VP1, VP2 and VP3, (molecular masses around 30 kD), 
VP1 being the immune-dominant and the most surface exposed one.  
 
 
 
 
Figure 3. Structures of rhinovirus proteins. The topology of the polypeptide chain in a β-barrel jelly roll is 
shown at the left. The β-strands, indicated by arrows, form two antiparallel sheets juxtaposed in a wedge like 
structure. The two α-helices (purple cylinders) are also conserved in location and orientation. The loops 
connecting the β-strands in VP1, VP2 and VP3 vary considerably in length and conformation, particularly at the 
top of the β-barrel which corresponds to the outer surface of the capsid. (Flint et al., 2000) 
 
 
While the carboxyl termini of these three proteins are at the surface of the virion, the amino 
termini face the interior. The smallest (7 kD) capsid protein VP4 lies at the inner surface close 
to the RNA and is in conjunction with the amino termini of VP1 and VP2. The picornavirus 
capsid is highly flexible, it temporarily exposes deeply buried parts of VP4 and the N-termini 
of VP1 proteins; this process is called viral „breathing” (Fricks and Hogle, 1990; Lewis et al., 
1998; Li et al., 1994). The amino-terminal glycine of VP4 is linked to a myristic acid which is 
required for the assembly of the pentameric subunits and may also play a role in the release of 
VP4 during the uncoating process (Ansardi et al., 1992; Chow, 1987; Moscufo and Chow, 
1992). The overall folding pattern is well preserved in proteins VP1, VP2 and VP3 in all 
studied rhinoviruses to date. The structural differences, determining the morphology and 
antigenicity of the types are mainly located at the external surface loops which connect the   
β-strands (Verdaguer et al., 2000).  
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2.5.1. The canyon and the hydrophobic pocket 
 
In entero- and rhinoviruses each star-shaped plateau at the fivefold symmetry axes is 
surrounded by an about 15 Å deep and 12 Å wide cleft, called the „canyon” (Fig.4). It is 
formed by the junctions of VP1, VP2 and VP3. Conserved residues at the canyon floor 
constitute the attachment site for cellular receptors, as shown for major group rhinoviruses 
and ICAM-1 (Olson et al., 1993; Rossmann et al., 1985). 
 
 
                                  
 
Figure 4. Schematic structure of the picornavirus capsid showing the canyons with grey circles. The 
enlarged view of a triangle shows the position of the pocket beneath the canyon floor. Modified after (Zhao et al., 
1997). 
 
In contrast, the minor group receptors bind at the star-shaped plateau at the fivefold axis, and 
not in the canyon (Hewat et al., 2000; Verdaguer et al., 2004). The function of the canyon was 
primarily proposed to hide the receptor binding site from the host immune surveillance 
(canyon hypothesis (Rossmann, 1989a, b)). However, the X-ray structure of an HRV14-Fab 
complex has challenged this hypothesis, showing that the antibody bound deep inside the 
canyon, to an epitope including conserved residues which also take part in receptor binding 
(Smith et al., 1996). Based on the present view, the canyon rather provides a conformationally 
sensitive region that may have a role in capsid destabilization during the uncoating process.   
It is also supported by the observation that ICAM-1 triggers viral uncoating and the 
subsequent RNA release (Rossmann et al., 2000).  
 
Beneath the canyon floor there is a hydrophobic „pocket” (Fig.4). This area of the virus is 
fairly well conserved and is frequently found occupied by a sphingosine-like fatty acid or 
similar hydrophobic compound with a polar head group stemming from the cell (Rossmann et 
al., 2002). This so far chemically uncharacterized molecule is called natural pocket factor 
which is believed to play an important role in the viral life-cycle preventing premature RNA 
release by stabilization of the virion. The structures of a number of picornaviruses have been 
studied with different molecules bound within the pocket (Hogle et al., 1985; Oliveira et al., 
1993; Smyth et al., 2003). 
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2.6. The HRV infection cycle 
 
As depicted in Fig.5, after specific attachment and cell entry, HRVs of both receptor groups 
end up in endosomal compartments. For major group HRVs either ICAM-1 alone or in 
concert with the low pH environment triggers conversion into subviral particles and 
concomitantly RNA release (uncoating) (Bayer et al., 1999; Bayer et al., 1998; Brabec et al., 
2003; Neubauer et al., 1987; Nurani et al., 2003). The replication takes place in the cytoplasm. 
The viral RNA is first translated into a polyprotein, and then structural and non-structural 
proteins are produced via autocatalytic cleavages. A viral protease (2Apro) stops the cap-
dependent translation of the host cell, cleaving eIF4G (this step is called host cell shut off). So 
the infected cell becomes a virus factory, producing viral proteins via IRES-dependent 
translation. The RNA replication takes place at virus induced membranous structures. First, a 
limited quantity of negative stranded RNA is produced. These serve as templates for the 
synthesis of positive strands. Finally, new viruses are assembled and leave the cell by lysis. 
 
 
 
 
Figure 5. The infection cycle of picornaviruses. „©”represents the m7G cap, present on most host mRNAs. 
Positive-stranded viral RNA is shown in purple and negative-stranded RNA in red. dsRNA, double-stranded 
RNA; IRES, internal ribosome entry site. (Whitton et al., 2005)  
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2.6.1. Cell attachment and internalization 
 
Human rhinoviruses (except of the types of HRV-C whose receptor is so far unknown) can be 
divided into two main groups based on receptor specificity (Abraham and Colonno, 1984; 
Uncapher et al., 1991): major group viruses bind to intercellular adhesion molecule 1   
(ICAM-1) (Greve et al., 1989; Tomassini et al., 1989), whereas serotypes of the minor group 
were shown to bind various members of the low density lipoprotein (LDL) receptor family, 
like low-density lipoprotein receptor (LDLR), the LDLR-related protein (LRP), and the   
very-low-density lipoprotein receptor (VLDLR) (Hofer et al., 1994; Marlovits et al., 1998b; 
Marlovits et al., 1998d). Some major group HRV serotypes can also bind to heparan sulphate 
(Khan et al., 2007; Vlasak et al., 2005a).  
 
While in major group HRVs the receptor binding site is located at the floor of the canyon, in 
minor group HRVs it is situated at the star-shaped dome of the five fold axis (Fig.6). 
 
The binding site of ICAM-1 has been located at the base of the canyon by cryo-electron 
microscopy image reconstruction analysis of receptor-bound structures of HRV3 (Xing et al., 
2003), HRV14 (Kolatkar et al., 1999) and HRV16 (Olson et al., 1993).  
 
The VLDL receptor footprint in HRV2 is located at the star-shaped dome of the icosahedral 
fivefold axis, formed by the BC and HI loops of VP1 (Hewat et al., 2000). LDL-receptors, 
exemplified by V33333 (a concatemer of ligand-binding repeat 3 of human VLDLR), bind 
minor group rhinoviruses via multiple receptor modules by adopting a ring-like conformation 
around the vertices of the virion. As a result of this unique geometry, low-affinity interactions 
cooperate to achieve high avidity binding to twelve different HRV types featuring a single 
conserved lysine and a diffuse positive surface potential (Querol-Audi et al., 2009). 
 
 
 
           
Figure 6. Comparison of the binding sites of V3 and ICAM-1 at the viral pentamer. Complexes between 
virus and soluble receptors were solved for HRV16 biding to a two-domain ICAM-1 by cryo-EM (PDB entry 
1d3e) (Kolatkar et al., 1999), and for HRV2 binding to modules V2-3 of human VLDLR by X-ray (as V2 and 
V3 were undistinguishable, the model was done with V3; PDB entry 1v9u) (Hewat et al., 2000). The binding 
surface areas of both receptors are shown in cyan. Note that the binding modules of V2-3 molecules come so 
close to each other that they appear to form a ring (Fuchs and Blaas, 2008). 
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Cell entry by the minor group HRV2 occurs via clathrin-dependent endocytosis (DeTulleo 
and Kirchhausen, 1998; Snyers et al., 2003), however, when this pathway is blocked, HRV2 
might also exploit other endocytosis routes (Bayer et al., 2001). 
 
For the major group virus HRV14, DeTulleo and Kirchhausen demonstrated inhibition of 
entry upon expression of the dominant negative mutant dynaminK44A (DeTulleo and 
Kirchhausen, 1998), and deduced that uptake was clathrin dependent. However, in view of the 
recent discovery of many pathways requiring dynamin function this is questionable. This is 
even more so as ICAM-1 does not possess clathrin entry motives and replacement of its 
cytoplasmic tail with a glycosylphosphatidylinositol anchor did not abrogate infection 
(Staunton et al., 1992). Investigations about HRV14 internalization presently ongoing in our 
lab also indicate that it is not clathrin dependent and rather appears to occur via a particular 
type of macropinocytosis (Khan et al., 2010). 
 
 
2.6.2. Uncoating at low endosomal pH and RNA release into the cytoplasm 
 
In vitro incubation at pH ≤ 3 inactivates all HRVs and this property was originally used for 
their classification (Tyrrell and Chanock, 1963). However, most HRVs already convert into 
subviral particles and thus lose infectivity at much higher pH values. For example, HRV2 
readily experiences conformational modifications below a threshold pH of 5.6 in vitro and in 
vivo (Gruenberger et al., 1991; Prchla et al., 1994), and is inactivated within a range of about 
0.6 pH units, following a sigmoid progression. On the other hand, some major group viruses 
were found to be more stable (Khan et al., 2007).  
 
Following cell entry, HRVs of both receptor groups end up in endosomal compartments. For 
major group HRVs ICAM-1 (either alone or in concert with the low pH) triggers conversion 
into subviral particles and concomitantly uncoating and RNA release occurs (Nurani et al., 
2003). In contrast, structural changes and infection of minor group HRVs, exemplified by 
HRV2, exclusively depend on the low endosomal pH, and it was believed that the function of 
LDL-receptors were limited to virus delivery (Baravalle et al., 2004; Brabec et al., 2003).   
 
During infection native virus is first converted into subviral A-particles that still contain RNA 
but have lost the innermost capsid protein VP4. They no more attach to their respective 
receptors and are hydrophobic because of externalization of the amphipathic VP1 N-termini 
that are believed to insert into the lipid bilayer (Lonberg Holm et al., 1976). In a next step the 
RNA is transferred into the cytosol leaving empty hydrophilic subviral B particles behind. 
These processes happen at the endosomal membrane and are strongly coordinated. VP4 is 
able to induce membrane permeability (Davis et al., 2008), and most probably this protein is 
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responsible for pore formation observed during RNA release of minor group rhinoviruses. 
While the minor group virus HRV2 opens a pore in the membrane and the endosome remains 
largely intact, structural transition of the major group virus HRV14 results in disruption of the 
endosome (Fuchs and Blaas, 2008; Prchla et al., 1995; Schober et al., 1998). In case of HRV2 
empty particles are left inside the endosome and are shuttled to lysosomes for degradation. 
Conversely, as HRV14 disrupts the endosome, not only the RNA but also viral proteins arrive 
into the cytosol. Therefore, the capsid of HRV14 is degraded to a much lesser extent, as it 
fails to reach the lysosomes. 
 
The exact mechanism of RNA release and the exit point of RNA are not known. Since the 
uncoating intermediates (the 135S particles) are not stable for the long time needed for 
crystallization, no structural data about the RNA release are available. The present models for 
uncoating of the two rhinovirus groups (Hewat et al., 2002; Hewat and Blaas, 2004) are based 
on differences found between the 3D-structures of native and empty capsids of HRV2 and of 
HRV14 by cryo-electron microscopy, so there are still a lot of open questions.  
 
 
2.6.3. Translation of the viral RNA, polyprotein processing and “host cell shut-off” 
 
 
IRES 
 
As the viral RNA is released into the cytoplasm, VPg is removed from its 5’ end by cellular 
esterases (Gulevich et al., 2002), and translation is initiated by the protein synthesizing 
machinery of the host cell. In contrast to most cellular mRNAs, the translation of picornaviral 
RNA is not initiated in a cap-dependent manner, but at an internal ribosome entry site (IRES). 
This conserved region containing highly ordered secondary structures is situated in the          
5’ UTR of the viral RNA, and is about 450 nucleotides long.  
 
 
Polyprotein processing  
 
First, a large polyprotein precursor is synthesized which is then co-translationally processed 
into structural and non-structural viral proteins through a sequence of autocatalytic cleavages 
performed by virally encoded proteases. Figure 7 shows the processing events of rhino- and 
enteroviruses. Right after its translation, the 2A protease (2Apro) adopts a three-dimensional 
structure competent for proteolytic processing. The first cleavage occurs between the            
C-terminus of VP1 and the N-terminus of 2Apro in cis, at the P1/P2 junction, thereby 
separating the precursors of structural and non-structural proteins (Sommergruber et al., 1989; 
Toyoda et al., 1986). Further cleavages are performed by the protease 3Cpro and its precursor 
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3CDpro. Precursor proteins (e.g., 2BC, 3AB, 3CD) have different functions as the mature 
cleavage products. The 3CDpro undergoes an intramolecular self-cleavage (Palmenberg and 
Rueckert, 1982) which sets the 3Cpro and the RNA-dependent RNA-polymerase 3Dpol free. 
Then, 3Cpro cleaves in trans at all other cleavage sites (Palmenberg et al., 1979; Semler, 
1981a) located within the P1, P2, and 3AB precursors. Finally, the cleavage of VP0 into VP4 
and VP2 occurs upon virus assembly, which sets up the metastable state of the capsid. This 
maturation cleavage is thought to be autocatalytic and dependent on RNA encapsidation 
(Hindiyeh et al., 1999).  
 
            
 
Figure 7. Cleavage pattern of picornaviral polyprotein processing. The primary cleavage is carried out by 
the 2A protease between its own N-terminus and the C-terminus of the P1 region. The viral protease responsible 
for the majority of polyprotein processing is the 3C protease, and its precursor 3CD. Numbers in brackets 
indicate the size of the proteins in kD (Figure adapted from B. Krenn). 
 
 
Host cell shut off  
 
The viral proteases also have several cellular targets; they cleave transcription and translation 
factors as well as cytoskeletal proteins (Joachims et al., 1999; Kuyumcu-Martinez et al., 2004; 
Neznanov et al., 2005; Seipelt et al., 2000). The cleavage of the cap-binding protein 
eukaryotic initiation factor 4G (eIF4G I, and its isoform eIF4G II) by 2Apro leads to the 
inhibition of cap-dependent protein translation (Gradi et al., 1998; Haghighat et al., 1996; 
Kräusslich, 1987). This so called “host cell shut off” is a common strategy applied by viruses 
to facilitate the expression of their genomes by making the cellular translation factors 
available for virus production. Fig. 8 compares cap dependent and IRES dependent translation. 
After cleavage of eIF4G, its C-terminal fragment is no longer able to attach to the 5’ cap, but 
instead it binds to the viral RNA with much higher affinity (Pestova et al., 1996).  
 16
  
 
Figure 8. Cap-dependent (A) and IRES-dependent (B) initiation of translation. Arrows indicate the targets 
of the viral 2Apro and 3Cpro [modified after (Flint et al., 2000)]. 
 
 
2.6.4. Viral RNA replication 
 
For reviews see: (Agol et al., 1999; Andino et al., 1999). The positive-stranded HRV genome 
is amplified through a negative-stranded full-length RNA complement which serves as a 
template for the synthesis of new positive sense RNA strands. During the replication process 
three different forms of the viral RNA have been identified: ssRNAs with positive polarity, 
replicative intermediates with one positive and a few nascent negative strands, and full length 
double stranded replicative forms. In an infected cell, positive strands are present in vast 
excess over negative strands. Most of the non-structural viral proteins and several cellular 
proteins are involved in RNA replication. The virally encoded RNA-dependent RNA 
polymerase 3Dpol in conjunction with several other viral and cellular proteins performs the 
priming and synthesis of both positive and negative stranded progeny RNA molecules. 
 
The replication occurs at the cytoplasmic surface of virus-induced membrane vesicles which 
build rosette-like structures around the replication complex (Bienz et al., 1992; Bienz et al., 
1983; Egger et al., 2002). This compartmentalization helps to select the viral RNA out of the 
big pool of cellular RNA molecules, ensures a high local concentration of replicative proteins 
and RNA, and protects the templates even from nuclease attack. These membranes are 
thought to originate either from coat protein complex II-coated vesicles (Rust et al., 2001) or 
from autophagosomes (Jackson et al., 2005; Suhy et al., 2000). Phospholipid synthesis is also 
required for vesicle formation, which is triggered by the viral proteins 2BC and 2CATPase 
(Aldabe and Carrasco, 1995; Cho et al., 1994), and by a combination of 2BC and 3A (Suhy et 
al., 2000).  
 
The assembly of the replication complex is driven by various cis-acting elements of the viral 
RNA. There is a cloverleaf structure at the 5’ end which binds to 3CD and to the cellular 
poly-C binding protein, and is thought to have a regulatory role in the translation-to-
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replication switch and in the assembly of the preinitiation complex (Gamarnik and Andino, 
1998, 2000; Teterina et al., 2001). An internal RNA hairpin (cis-acting replication element 
(cre)) is involved in the recognition of viral RNA by the viral replicase complex. In the 3’ 
UTR, sequences with conserved tertiary structures similar to “kissing” loops (Melchers et al., 
1997; Pilipenko et al., 1996) or pseudoknots (Kusov et al., 1996) have been shown to interact 
with 3AB-3CDpro (Harris et al., 1994). The preinitiation complex contains the RNA template 
and precursors of non-structural viral proteins (3AB, 3CD). 3AB anchors the viral protein 
VPg (3B) to virally induced membranes (Gerber et al., 2001; Towner et al., 1996). 3Dpol 
directly uridylates VPg which is then rapidly cleaved from its membrane-anchor by 3CDpro. 
VPg-pU-pU-OH hybridizes with the 3’ poly(A) tract of the RNA template and serves as a 
primer for 3Dpol (Paul et al., 1998), allowing for the synthesis of negative stranded RNA and 
the generation of a double stranded RNA intermediate. During elongation of negative strands, 
both homologous and non-homologous recombination events occur (Duggal and Wimmer, 
1999; Jarvis and Kirkegaard, 1992). The genomic RNA must be first translated before it can 
serve as a template for replication (Novak and Kirkegaard, 1994). The reason for this is 
unknown; maybe the translation provides short-lived protein precursors (like 3AB and 3CD) 
which are necessary for replication.  
 
Negative strand synthesis starts with the production of a short-lived intermediate containing 
the initial genomic RNA and its complementary negative-stranded RNA. Then, the new 
positive strands are synthesized whereby two adenines at the 3´ end of the negative stranded 
RNA serve as a VPg-pU-pU-OH primer binding site. RNA replication by the viral          
RNA-dependent RNA polymerase is error-prone and hence is accompanied by numerous 
mutations which result in an antigenic drift and a population of quasispecies, an important 
feature of viral evolution (Agol, 2006; Ward et al., 1988). As soon as positive strand synthesis 
has completed, the viral RNAs are released from the membrane-bound replication complexes. 
The new positive viral RNA strand can either be used as a template for further polyprotein 
synthesis or will be assembled into new virus particles.  
 
 
2.6.5. Assembly, maturation, and release of new virus particles from the host cell 
 
At later stages of infection, when the concentrations of both the newly synthesized genomic 
viral RNA and capsid proteins are high enough, assembly begins. First, VP1, VP3, and VP0 
are assembled to 5S protomers. Then, five protomers form a 14S pentamer (Verlinden et al., 
2000). Subsequently, the genomic VPg-RNA is packaged to form non-infectious 150S 
provirions, either via nucleation of 14S pentamers around the RNA genome or via threading 
the RNA into a preformed empty capsid; the underlying mechanism is not known. Finally, the 
short-lived provirion undergoes the maturation cleavage (Lee et al., 1993); VP0 is cleaved 
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into VP4 and VP2 by an autocatalytic mechanism (Bishop and Anderson, 1993; Basavappa et 
al., 1994). This cleavage sets up the metastable state of the capsid, thereby generating the 
infectious virion. While in cell culture the mature virus particles leave their host cells by lysis 
showing a cytopathic effect (CPE), in the nasal mucosa they are released by an unknown 
mechanism, without appreciable cell damage (Winther, 1994).  
  
 
2.7. HRV and the common cold 
     
2.7.1. Pathogenesis and clinical manifestations 
 
Human rhinoviruses cause ~50 % of common colds and are a big economic burden in terms 
of lost working days. The incidence of infection is increased in fall and spring, with an 
average of 5 to 7 episodes per year in children, and 2 to 3 episodes per year in adults (Turner, 
1997, 2001). HRV is transmitted by hand-to-hand contact or via aerosolization. The major 
entry point is normally the nose, and eventually the eyes (in this case drainage into the 
nasopharynx would occur through the nasolacrimal duct). In the nasal cavity the viruses target 
ciliated and non-ciliated epithelial cells by attachment to specific receptors. Lower respiratory 
epithelial cells are also susceptible to rhinovirus infection (Gern et al., 1997; Hayden, 2004; 
Mosser et al., 2002; Papadopoulos et al., 2000; Papadopoulos et al., 1999), however, the 
optimal growth temperature of most types (33°C) corresponds to the temperature of the nasal 
mucosa. The infection develops very quickly, after 8-10 hours progeny virus is already 
detectable (Heikkinen and Jarvinen, 2003). The first symptoms occur within 16 hours and 
peak on days 1-3 of infection. The median duration of illness is 9.5 to 11 days, but it can last 
even up to 16 days in certain populations such as young children and the elderly.                
The symptoms often start with a sore throat and continue with increased mucous secretion 
(runny nose) and sneezing caused by cholinergic stimulation. Nasal obstruction and 
rhinorrhea is caused by vasodilatation and increased vascular permeability of the mucosa 
(Heikkinen and Jarvinen, 2003). At later stages of the infection patients may suffer from 
facial pressure, headache and cough, caused by the big quantity of secreted mucus. Infants 
and young children may have even fever, which is not characteristic for adults. Although 
HRVs cause cytopathic effect (cell rounding, chromatin condensation, deformation of nuclei, 
detachment of the cells from their support, cell lysis) in cultured cells, no histopathological 
changes of the nasal epithelium has been observed in natural infections (Winther, 1994).    
The clinical symptoms are primarily caused by the inflammatory response of the host.    
While HRV infections are typically mild, they are associated with a number of upper and 
lower respiratory tract complications in both children and adults; see reviews (Heikkinen and 
Jarvinen, 2003; Monto et al., 2001; Pitkaranta and Hayden, 1998). Among bacterial 
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complications are acute otitis media (AOM), sinusitis, and pneumonia. Rhinovirus infections 
are associated with exacerbations of chronic respiratory diseases such as asthma (Gern, 2002), 
cystic fibrosis, and chronic obstructive pulmonary disease (COPD) (Anzueto and Niederman, 
2003; Greenberg, 2002). Rhinovirus infection may have serious consequences for elderly 
people and for immunocompromised patients (Falsey et al., 2002). 
 
2.7.2. Antiviral host defense mechanisms 
 
Upon infection, viruses face powerful host defence mechanisms. First, at early time points of 
infection the secretion of type I interferons and proinflammatory cytokines and chemokines 
sets up the "antiviral state" in infected and non infected neighbouring cells. This inhibits viral 
replication, spread, and cell proliferation, and enhances the ability of natural killer cells to 
lyse virally infected cells (Samuel, 2001). Several immune mediators triggering inflammatory 
response have been identified in the context of rhinovirus infection. Among them are type I 
interferons (IFN-α, IFN-β), kinins, leukotrienes, histamine, interleukins (IL-1α, IL-1β, IL-6, 
IL-8, IL-11, IL-16), tumour necrosis factor-α (TNF-α), RANTES (regulated upon activation, 
normal T-cell expressed and secreted), granulocyte macrophage-colony stimulating factor 
(GM-CSF), growth-regulated oncogene-α (Gro-α), epithelial neutrophil-activating protein-78 
(ENA-78), eotaxin 1/2, and macrophage inflammatory protein-1α (MIP-1α) (Donninger et al., 
2003; Einarsson et al., 1996; Gern and Busse, 1999; Heikkinen and Jarvinen, 2003; Kim et al., 
2000; Konno et al., 2002; Message and Johnston, 2004; Schroth et al., 1999; Subauste et al., 
1995; Terajima et al., 1997; Zhu et al., 1996; Zhu et al., 1997). Different stress signals, such 
as increased levels of reactive oxygen intermediates (ROIs) and the presence of double 
stranded RNA, induce interferon production in the infected cells. DsRNA also increases the 
expression of Toll-like receptor 3 (TLR3) in infected host cells (Hewson et al., 2005), thereby 
enhancing the innate immune response. The cytokine production leads to increased 
endothelial cell permeability which allows the migration of immune cells to the site of 
infection. The clinical symptoms of rhinovirus infections are mainly caused by the activity of 
the host immune system; reviewed in (Kirchberger et al., 2007). The interferons released from 
infected cells diffuse to adjacent cells in the tissue, and activate the transcription of more than 
30 genes via the JAK-STAT signal transduction pathway. Among these antivirally active 
proteins are the dsRNA-dependent protein kinase R (PKR), the 2'-5' oligoadenylate synthetase 
(OAS), endoribonuclease L (RNAse L), and a great number of other genes involved in the 
fundamental cellular metabolism. These proteins require also dsRNA as a co-factor to become 
activated, which is a characteristic condition for viral infections. Upon contact with dsRNA 
molecules PKR gets activated by autophosphorylation and gives rise to inhibition of both 
viral and cellular protein synthesis by phosphorylation of eIF2α (Kimball, 1999). OAS 
produces a series of short oligoadenylates containing an unusual 2’-5’-phosphodiester linkage 
(2’-5’-oligo(A)). These activate RNAseL which inhibits translation by efficient cleavage of 
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all types of ssRNAs (both viral and cellular RNAs including rRNA) (Castelli et al., 1998a; 
Castelli et al., 1998b).  
 
Viral growth can also be limited by post-translational modifications; e.g. the IFN-inducible 
RNA-specific adenosine deaminase (ADAR1), a host RNA-editing enzyme, can introduce 
mutations into de novo synthesized viral genomes.  
 
The immune response is mediated almost entirely by the innate system (e.g., complement, 
professional phagocytes, and natural killer cells) which removes viruses in a few days, still 
before the adaptive immune system becomes fully activated. Therefore, neutralizing 
antibodies are not made in sufficient amounts to effectively protect against the next rhinovirus 
infection, even by the same serotype. Moreover, the existence of more than 100 serotypes and 
the low level of antibody cross protection between them is a further reason for catching colds 
several times during our life.   
 
2.7.3. Therapeutic treatments and antiviral strategies 
 
Symptomatic treatments  
 
There are a number of treatments focused on relieving the symptoms, increasing the comfort 
of the patient, and limiting complications (Anzueto and Niederman, 2003; Heikkinen and 
Jarvinen, 2003; Turner, 2001). In order to reduce fever and soreness of the throat non 
steroidal anti-inflammatory drugs such as aspirin or paracetamol, as well as localised versions 
targeting the throat (often delivered in lozenge form) are used. Nasal decongestants such as 
pseudoephedrine or oxymetazoline reduce the inflammation in the nasal passages and help to 
open the airways by constricting the dilatated blood vessels. First generation anti-histamines 
such as brompheniramine, chlorpheniramine, diphenhydramine and clemastine are frequently 
used for the reduction of sneezing and rhinorrhea. Ipratropium bromide, an anti-cholinergic 
nasal spray has been shown to reduce rhinorrhea by 30 % in natural colds. As cough 
medications, both mucolytic agents and cough suppressants are frequently used. 
 
 
Antiviral treatment strategies 
 
The large number of HRV serotypes is a great challenge for vaccine development. To date no 
vaccines against these viruses are available, because of little-to-no cross-protection between 
the different serotypes. Therefore, the strategy is to target specific steps of the infection cycle, 
like cell susceptibility, viral attachment, uncoating, RNA replication, and viral protein 
processing, to develop anti-HRV compounds; reviewed in (De Palma et al., 2008; Rotbart, 
2002; Turner, 2001). The following section provides a brief overview about the different 
antiviral approaches against HRVs.  
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Inhibition of virus entry by different capsid binding agents 
 
The determination of three-dimensional structures of rhinoviruses by X-ray crystallography 
has created the possibility to design several capsid-binding compounds. These chemicals 
block viral infection by inhibiting viral uncoating and/or viral attachment to host cell 
receptors.  
 
The WIN series of compounds (Fig. 9) manufactured by the Sterling Winthrop Research 
Institute (McKinlay et al., 1992) played a remarkable role in the development of antiviral 
agents against both rhino- and enteroviruses. These small (~300 D) hydrophobic flexible 
organic compounds displace the natural pocket factor, bind inside the hydrophobic pocket 
with high affinity (Andries et al., 1991; Grant et al., 1994; Mosser and Rueckert, 1993; Smith 
et al., 1986), and make the virus more resistant to uncoating by increasing the stability of the 
capsid (Rombaut et al., 1991). These antiviral compounds block the attachment of major 
group HRVs and the uncoating of both major and minor group serotypes (Gruenberger et al., 
1991; Pevear et al., 1989; Smith et al., 1986), and also stabilize rhinoviruses in vitro against 
denaturation by acidification and heat (Fox et al., 1986). However, clinical trials with WIN 
compounds (e.g. Disoxaril) or other capsid binders (e.g. Pirodavir) were not successful due 
to side effects (Rotbart, 2002; Turner et al., 1993) or the lack of clinical benefit (Hayden et al., 
1995). Later, a new generation of capsid-binding drugs with better pharmacokinetics and 
metabolic stability with broad and potent antiviral activity were developed. The most 
successful agent in this series was Pleconaril which did not even show any adverse side 
effects (Florea et al., 2003; Hayden et al., 2002; Hayden et al., 2003a). However, due to 
interference with the pharmacokinetics of other drugs it was first rejected by the Food and 
Drug Administration (FDA) in 2001. Then, later in 2007, a phase II clinical trial was 
completed with this substance (De Palma et al., 2008).  
 
                                      
 
Figure 9. The chemical formula of the capsid binding agent I(S), also named WIN-52084, manufactured by 
the Sterling Winthrop Research Institute (Badger et al., 1989). 
 
Infection can also be blocked by the inhibition of receptor attachment of virus particles using 
soluble receptor fragments. The soluble ICAM-1, called Tremacamara, reduced 
symptoms to some extent in experimentally induced HRV infections without significant side 
effects (Turner et al., 1999), but after a few passages in vitro viral resistance developed 
(Arruda et al., 1994). Soluble VLDL receptor fragments were also successfully applied to 
inhibit minor group infection in vitro (Marlovits et al., 1998c; Marlovits et al., 1998d).  
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Protease inhibitors  
 
The viral 3C protease is a specific target for the development of antivirals, showing a great 
homology among HRV serotypes and several related picornaviruses, but not with cellular 
proteases. This unique structure together with its essential role in viral replication made 3Cpro 
an excellent target for the development of anti-picornavirus agents to inhibit viral polyprotein 
processing and protein synthesis (Patick and Potts, 1998; Wanga and Chen, 2007). The 
irreversible 3Cpro inhibitor Rupintrivir (AG7088) was the most promising drug candidate 
among the several substances synthesized, but recently it was halted from further 
development due to its inefficient antiviral activity when administered after 24 hours after 
virus inoculation (De Palma et al., 2008; Hayden et al., 2003b). However, novel protease 
inhibitors are still under development (Patick et al., 2005).  
 
 
Inhibitors of viral RNA replication 
 
Viral RNA replication is another specific target for antiviral therapy. Enviroxime inhibits the 
replication of rhino- and enteroviruses, even if it is administered several hours post infection. 
Initial studies suggested that it inhibits the initiation of positive-strand RNA synthesis by 
targeting 3A (Heinz and Vance, 1995), but its action turned out to be more complex and the 
exact molecular mechanism is still unclear (Brown-Augsburger et al., 1999). Unfortunately, it 
showed intolerance to oral dosing and only limited activity after intranasal administration 
despite its high potency in cell culture. Therefore its clinical development was discontinued 
(Anzueto and Niederman, 2003). Novel replication inhibitors keeping the properties of 
Enviroxime with a new chemical core structure were designed, however, so far no clinical 
trials have been reported (Hamdouchi et al., 2003).  
 
 
Decreasing cell susceptibility to HRV infection 
 
Nasal interferon was also tried as a therapeutic agent, since it is known to induce a cellular 
antiviral state. It could prevent rhinovirus infections, but showed just moderate effects when 
administered a day after experimental infection (Hayden and Gwaltney, 1984). Moreover, 
prolonged exposure induced side effects such as nasal irritation and stuffiness, mucosal 
ulceration, destruction of the nasal mucous membrane, and resistance against the drug 
(Hayden et al., 1986; Samo et al., 1983). A novel antiviral strategy is the search for natural or 
artificial peptides or RNAs that, upon expression, modify the cellular processes and thereby 
protect the cells against viral infection. A new peptide inhibitor identified by Poritz et al. by 
screening a high-complexity cDNA library, seems to interfere with the viral RNA-replication 
(Poritz et al., 2003). 
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Small interfering RNA 
 
RNA silencing is also a new strategy to fight virus infection; see reviews (Gadkari, 2005; Tan 
and Yin, 2004). The appearance of double stranded RNA during viral replication would itself 
activate RNA interference, but viruses have evolved mechanisms to suppress this response. 
However, direct introduction of siRNA molecules (or vectors encoding them) into the cells 
were shown to specifically target the viral mRNA for degradation (Merl et al., 2005; Phipps et 
al., 2004). The next step towards clinical applications is the development of efficient siRNA 
delivery systems. 
 
 
2.8. The major group receptor: ICAM-1 
 
The 87 serotypes of the major group HRVs utilize the intercellular adhesion molecule 1 
(ICAM-1, CD-54) as a receptor (Greve et al., 1989; Staunton et al., 1989; Tomassini et al., 
1989). ICAM-1 is a transmembrane glycoprotein, a member of the immunoglobulin (Ig) 
supergene family (Simmons et al., 1988), composed of five glycosylated Ig domains at the   
N-terminus, a transmembrane region, and a short cytoplasmic tail at the C-terminus (Fig. 10). 
ICAM-1 is expressed by several cell types, e.g. at the surface of macrophages, B and             
T lymphocytes, fibroblasts, and cells of the vascular endothelium. It plays an important role in 
immune and inflammatory responses, as it is responsible for the adhesion between endothelial 
cells and leukocytes, allowing subsequent extravasation of leukocytes into the inflamed 
tissues. The ligands important in this process are two integrins, the lymphocyte function 
associated antigen-1 (LFA-1) and the macrophage-1 antigen (Mac-1) (Makgoba et al., 1988). 
The expression of ICAM-1 is regulated by cytokine signalling; it is normally present at the 
surface of cells at low concentrations (van de Stolpe and van der Saag, 1996), and cytokines 
like interleukin-1 (IL-1) and tumor necrosis factor alpha (TNFα) greatly increase its levels. 
Since an increased cytokine level is also a part of the host defense responding to rhinovirus 
infection, major group viruses increase the expression of their own receptor (Grunberg et al., 
2000; Whiteman et al., 2003). 
 
Residues important for HRV binding are located at the tip of domain 1 (D1), in the DE, BC 
and FG loops. Reconstruction of cryo-electron microscopy images of a soluble recombinant 
two-domain fragment of ICAM-1 (D1D2) in complex with HRV16 or HRV14 showed that 
the receptor binds at the bottom of the canyon (Rossmann et al., 1994). The natural pocket 
factor somewhat interferes with the major group receptor binding, by causing conformational 
changes in the canyon floor. However, due to its bigger affinity, ICAM-1 is able to replace 
this pocket factor and bind inside the canyon, by following a two-step kinetics (Rossmann et 
al., 2002). The interaction seems to be of electrostatic character, since the interacting surfaces 
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show a remarkable charge complementarity (Bella et al., 1999b; Giranda et al., 1990; 
Kolatkar et al., 1999; Olson et al., 1993). The binding site for Mac-1 is located in domain 3 
whereas all other factors bind to domain 1 (Bella and Rossmann, 1999b; Rossmann et al., 
2000) (Fig. 10). Major group HRVs bind exclusively to human ICAM-1, and they do not even 
recognize the homologous ICAM-2 or ICAM-3. ICAM-1 is also used as a receptor by other 
human pathogens like some coxsackievirus A family members (Shafren et al., 1997a), and 
erythrocytes infected by the malarial parasite Plasmodium falciparum (Berendt et al., 1992; 
Ockenhouse et al., 1992).  
 
         
 
Figure 10. Schematic structure of ICAM-1. Each Ig domain is represented by a circle closed by one or two 
disulfide bonds. Amino acid numbers indicate the beginning and end of each domain. Lollipop-shaped structures 
indicate N-linked glycosylation sites. The approximate locations of binding sites of LFA-1, Mac-1, human 
rhinoviruses, fibrinogen, and Plasmodium falciparum-infected erythrocytes (PFIE) are indicated (Bella et al., 
1999; Bella and Rossmann, 1999, 2000) 
 
 
2.9. Minor group receptors: members of the LDLR family 
 
2.9.1. Identification of the minor group receptors  
 
Twelve HRV types, the minor group, use members of the low-density lipoprotein receptor 
(LDLR) family (Herz and Bock, 2002) for cell attachment and entry. The first minor group 
receptors identified were LDLR and the large subunit of the α2-macroglobulin receptor/ 
LDLR-related protein (LRP) (Hofer et al., 1992). Further investigations showed that soluble 
recombinant fragments encompassing the binding repeats of human LDLR and of human very 
low-density lipoprotein receptor (VLDLR) bind minor group HRVs. Such soluble 
minireceptors interfere with attachment to natural cell surface receptors by competition, thus 
inhibiting viral infection in a concentration dependent manner (Marlovits et al., 1998a, b; 
Marlovits et al., 1998c).  
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2.9.2. Members of the LDLR family 
 
The structurally closely related cell surface receptors belonging to the LDL receptor gene 
family fulfil diverse functions in different organs, tissues, and cell types; they are ubiquitously 
expressed and highly conserved throughout different species. Family members expressed in 
mammals (Fig. 11) include the low-density lipoprotein receptor (LDLR) (Brown and 
Goldstein, 1986; Yamamoto et al., 1984), the very low-density lipoprotein receptor (VLDLR) 
(Sakai et al., 1994), apolipoprotein E receptor 2 (apoER2) (Kim et al., 1996), the LDLR 
related protein (LRP) (Herz et al., 1988), LRP5, LRP6, megalin (also known as gp330 or 
LPR2) (Saito et al., 1994), LRP1b (Liu et al., 2000) and multiple epidermal growth factor 
containing protein 7 (MEGF7) (Nakayama et al., 1998).  
         
 
 
Figure 11. The LDLR family. The domain organization of the core family members is illustrated schematically. 
Abbreviations: LDLR, low-density lipoprotein receptor; VLDLR, very-low-density lipoprotein receptor; 
ApoER2, apolipoprotein E receptor 2; LRP, LDL-receptor-related protein (Beglova and Blacklow, 2005). 
 
 
The modular architecture of these proteins has allowed the evolution of complex and highly 
specialized functions. All family members share common motifs: complement-type A repeats 
(ligand binding domains), epidermal growth factor (EGF) precursor homology domains,       
β-propeller domains, a single transmembrane region, and a short cytoplasmic tail with an 
internalization signal. The ligand binding domain(s) of these receptors is/are built by several 
cysteine rich complement-type A repeats, LDLR has 7, VLDLR has 8, and LRP contains 
31 such repeats. They can bind many unrelated proteins, such as apolipoproteins, proteases, 
protease-inhibitor complexes, signaling molecules such as reelin, and several other types of 
proteins and low-molecular weight compounds. The ligand binding repeats are formed by 
roughly 40 residues arranged in two loops, held together by three disulfide bonds. The 
coordination of calcium is essential for the correct folding as well as for the maintenance of 
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the 3D structure of the repeats (Rudenko and Deisenhofer, 2003). The EGF-like repeats 
(named so because of their homology to the epidermal growth factor) are small, disulfide 
containing modules which also possess Ca2+ binding sites. The YWTD β-propeller is built of 
six blades, each made up of a β-sheet with four antiparallel strands. Its name comes from the 
characteristic YWTD (Tyr-Trp-Thr-Asp) consensus sequence found on the second strand of 
each blade. At the carboxy terminus of the extracellular portion of LDLR, VLDLR and 
ApoER2, there is a highly O-glycosylated region rich in serine and threonine residues. The 
intracellular regions of these receptors possess an internalization signal, an NPxY motif 
which directs the receptors into clathrin-coated pits.  
 
 
2.9.3. The diverse functions of LDLR family members 
 
The functions of LDLR family members (Fig. 12) are much more diverse than originally 
thought. They bind proteases, protease inhibitors, signaling molecules, heat shock proteins, 
vitamin carriers, toxins, antibiotics and many other molecules (Basu et al., 2001; Gliemann, 
1998; Herz, 2001b; Howell and Herz, 2001; Schneider and Nimpf, 2003). These receptors are 
not only important in endocytic uptake of their ligands, but also in many cellular functions, 
including migration, pericellular proteolysis, signal transduction, antigen presentation and 
synaptic plasticity. The LDL-receptor-related protein (LRP) and megalin, two scavenging 
receptors produced in the liver and kidney, respectively, bind to more than two-dozen 
different ligands each (Nykjaer and Willnow, 2002). 
 
 
                       
 
Figure 12. Cellular activities and putative functions of members of the LDLR family (Nykjaer and Willnow, 
2002) 
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The multifunctionality of these receptors is achieved in part by the number of complement-
type A repeats (e.g. 31 in LRP and 36 in megalin) and the use of co-receptors. Interaction 
with diverse cell-surface proteins such as seven-transmembrane-span receptors, ion channels, 
adhesion molecules or glycosylphosphatidylinositol (GPI)-anchored proteins provides 
activities not usually observed for endocytic receptors. The molecular interactions of this 
protein family with other cell-surface proteins are reviewed in (Nykjaer and Willnow, 2002). 
 
2.9.4. LDL-receptor 
 
The LDL-receptor is the prototype of the LDLR gene family; see a recent review (Jeon and 
Blacklow, 2005). This 120 kD cell-surface glycoprotein mediates the cellular uptake of 
cholesterol-containing lipoprotein particles, playing an important role in the homeostatic 
control of blood cholesterol level (Brown and Goldstein, 1986). This occurs in all nucleated 
cells but mainly in the liver which removes ~70 % of LDL from the circulation. 
 
 
The LDLR gene and its expression 
 
The LDL-receptor was originally identified by Brown and Goldstein in 1973, during their 
search for the molecular basis of familial hypercholesterolemia (Brown and Goldstein, 1986; 
Goldstein et al., 1985; Hobbs et al., 1990). A decade later its gene was cloned and sequenced. 
It is more than 45 kb long and contains 18 exons resulting in a 5.3 kb long mRNA (Russell et 
al., 1984; Yamamoto et al., 1984). The expression of the LDL-receptor gene is regulated 
by the intracellular cholesterol level (Sudhof et al., 1985; Zubay, 1998). The synthesised 
LDLR is co-translationally directed into the ER by its N-terminal hydrophobic signal 
sequence which is then cleaved off. In the ER receptor associated protein (RAP), a specific 
molecular chaperone, binds to the ligand binding repeats of LDLR and prevents its premature 
interaction with ligands. RAP dissociates from the receptors in early Golgi compartments and 
recycles back to the ER (Herz and Marschang, 2003). The LDL-receptor is subjected to   
post-translational glycosylation by the processing machineries of the ER and the Golgi. The 
final molecular mass is dependent on the degree of N- and O-glycosylation and ranges 
between 115 and 160 kD (Cummings et al., 1983; Tolleshaug et al., 1982; Yamamoto et al., 
1984). Concomitantly with this maturation, the receptor travels through the secretory pathway 
and finally the mature protein appears at the cell surface in coated pits.  
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Ligand binding of LDLR 
 
LDL-receptor binds to two proteins: to the 400 kD apolipoprotein B-100 (apoB-100) with a 
lower, and to the 34 kD apolipoprotein E (apoE) with a higher affinity. These are both 
essential components of plasma lipoproteins. 
 
Approximately 65-70 % of plasma cholesterol in humans circulates in the form of LDL 
(Brown and Goldstein, 1974a, b) which is the most important physiologic ligand of the   
LDL-receptor. The ~180-250 Å LDL particle contains a single copy of the 4536 residues long 
glycoprotein apoB-100 (Chen et al., 1986; Knott et al., 1986) that binds to LDLR with a 
stoichiometry of 1:1 (van Driel et al., 1989). For a review about the structure of apoB-100 in 
LDL particles see (Segrest et al., 2001).  
 
LDLR also binds to lipoproteins that contain multiple copies of apoE, such as β-migrating 
forms of very low-density lipoprotein (β-VLDL) or certain intermediate- (IDL) and high-
density lipoproteins (HDL) (Innerarity and Mahley, 1978; Innerarity et al., 1978; Mahley and 
Innerarity, 1983; Weisgraber et al., 1978). Lipoproteins containing ApoE recognize all the 
core members of the LDLR family possessing tandem repeats of LDL-A modules (LDLR, 
VLDLR, apoER2, LRP-1, and LRP-2). ApoE is a small two-domain protein (299 residues) 
(Aggerbeck et al., 1988; McLean et al., 1984; Rall et al., 1982; Wetterau et al., 1988) which 
has four known isoforms in humans. The E2 isoform is defective in receptor binding 
(Weisgraber et al., 1982), and the less common E4 allele is considered a risk factor for 
Alzheimer’s disease (Strittmatter et al., 1993). The N-terminal domain of apoE takes part in 
LDLR binding, whereas the C-terminal domain is required for incorporation into lipoproteins 
(Innerarity et al., 1983; Wetterau et al., 1988). Complexation of apoE with lipid is a 
requirement for high-affinity interaction with its receptors; the delipidated apoE shows at least 
500-fold lower affinity (Innerarity et al., 1979; Pitas et al., 1979; Weisgraber et al., 1994; 
Wilson et al., 1991). 
 
 
Recycling of the LDLR 
 
The same LDLR molecule can be used several times for internalization of ligands. Its 
recycling is shown in Fig. 13. Plasma lipoproteins bind to LDL receptors which cluster at the 
surface of cells in clathrin-coated pits. Subsequently, the lipoprotein-receptor complexes are 
taken up via endocytosis (Anderson et al., 1977; Anderson et al., 1976; Anderson et al., 1978). 
Within the lumen of endocytic vesicles the LDL-receptor undergoes conformational changes 
which lead to ligand release (Beglova et al., 2004b; Jeon and Blacklow, 2005). While the 
lipoproteins are delivered to lysosomes, the receptors are returned to the cell surface in a 
 29
process called receptor recycling (Brown and Goldstein, 1983; Goldstein et al., 1985; Jeon 
and Blacklow, 2005)  
 
             
 
 
 
Figure 13. Endocytosis and intercellular routes of LDLR. The receptor-ligand complex is internalized via 
clathrin-coated vesicles which then fuse with early endosomes. At the low-pH environment of the early 
endosome LDL dissociates from the receptor and is transported to late endosomes in large carrier vesicles that 
move along microtubules. Transport vesicles carrying lysosomal hydrolases from the Golgi apparatus then fuse 
with late endosomes which mature to lysosomes where LDL is degraded and cholesterol is released. The LDL 
receptor is recycled from early endosomes to the plasma membrane (Cooper, 2000).  
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The modular architecture of LDLR  
 
The mature 839 residues long human LDLR is a modular type 1 transmembrane protein, 
composed of various independently folded domains with different functions (Russell et al., 
1984; Sudhof-TC et al., 1985; Sudhof et al., 1985; Yamamoto et al., 1984). Figure 14 shows 
the structural architecture of the receptor with molecular details elucidated by different 
research groups. 
 
 
   
 
Figure 14. Domain organization of the LDLR. Boxed references next to structural representations indicate the 
cited publication from which the respective structure has been reproduced (Herz, 2001a). 
 
The ligand binding domain (292 residues at the N-terminus) contains seven homologous 
cysteine rich repeats which are referred to as LDL receptor type A (LA) repeats or 
occasionally complement-type A repeats because such modules are also present in the 
terminal components of the complement cascade (Chakravarti et al., 1989; DiScipio et al., 
1988; Haefliger et al., 1987; Howard et al., 1987; Rao et al., 1987; Stanley et al., 1985). The 
three-dimensional structure of the ligand binding repeats has been determined both by    
NMR-spectroscopy (Daly et al., 1995) and X-ray crystallography (Fass et al., 1997). 
Furthermore, the X-ray structure of the whole extracellular domain of human LDLR at low 
pH (Rudenko et al., 2002), and also the interdomain flexibility measured by NMR have been 
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reported (Beglova et al., 2004a). Each of ~40 residues long repeat is formed by two loops 
which are held together by three disulfide bonds in a conserved I-III, II-V, and IV-VI pattern 
(Bieri et al., 1995a; Bieri et al., 1995b). As shown in Fig. 15, each repeat coordinates a single 
Ca2+ ion which is essential for both correct folding and maintenance of the three-dimensional 
structure (Atkins et al., 1998; Bieri et al., 1998; Fass et al., 1997). The ligand binding repeats 
are connected with short flexible linkers (Bieri et al., 1998; Kurniawan et al., 2000; North and 
Blacklow, 1999) which allow for conformational rearrangements, and enable binding to many 
different ligands.  
 
                                            
 
Figure 15. 3D X-ray structure of the fifth ligand-binding module of LDLR (PDB accession code 1AJJ). The 
critical bound calcium ion is illustrated as a (red) sphere. Side chains are superimposed on a (grey) ribbon trace 
of the module backbone. Cysteines and additional residues are labeled as reference points (Fass et al., 1997; Jeon 
and Blacklow, 2005).  
 
The ligand binding repeats of LDLR are similar but not identical in their sequence. Conserved 
are the six cysteins, two hydrophobic residues near the N-termini, and an acidic cluster near 
the C-termini of the modules (Fig. 16). Mutagenesis studies of the seven LA modules have 
shown that the different repeats are not functionally equivalent in ligand binding. LA repeats 
3-7 and also the first EGF-like repeat (EGF A) are essential for LDL (apoB-100) binding. In 
contrast, deletion of module five abrogates only high-affinity binding to β-VLDL (apoE) 
(Esser et al., 1988; Russell et al., 1989). The first two LA repeats contribute to LDL and       
β-VLDL binding only to a small extent (Sass et al., 1995). 
 
  
 
Figure 16. Sequence alignment of all LA modules from the database, illustrated using a sequence logo. The 
relative representation of each amino acid residue at every position in the sequence is proportional to the size of 
the letter at that site. Highly conserved are the six cysteines, two hydrophobic residues (Phe and Ile) in the N-
terminal half of the module, and the cluster of acidic residues near the C-terminal end of the module (Crooks et 
al., 2004; Jeon and Blacklow, 2005). 
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Adjacent to the ligand binding domain there is a 400 residues long region with remarkable 
similarity to the epidermal growth factor (EGF) precursor, called EGFP domain. It is 
composed of two cysteine-rich calcium-binding EGF-like repeats (EGF-A and -B) (Malby et 
al., 2001), followed by a six bladed β-propeller containing a conserved YWTD                  
(Tyr-Trp-Thr-Asp) motif (Springer, 1998), and a third EGF repeat (EGF-C). The EGFP 
domain controls the processes of lipoprotein release triggered by low endosomal pH, and the 
recycling of LDLR to the cell surface (Davis et al., 1987a). 
 
The EGFP domain can be divided into two distinct parts: the EGF-AB domain pair 
(Kurniawan et al., 2001; Saha et al., 2001) and the β-propeller-EGF-C domain pair (Jeon et al., 
2001; Rudenko et al., 2002) which both have a fixed interdomain relationship through the 
whole physiologic pH range. The structure of the EGF-AB pair shows an extended, rod-like 
conformation (Fig. 17), with an interdomain interface defined by calcium coordination and 
hydrophobic interactions.  
 
                           
 
Figure 17. Structure of the EGF-AB domain pair [PDB accession code 1HJ7]. The intermodule interface is 
stabilized by a bound calcium ion (green) and hydrophobic packing of Phe 323 (blue) against the aliphatic 
portion of Glu 351 and the hole around Gly 352 (blue). The side chains of calcium-coordinating residues are 
illustrated ( purple) (Jeon and Blacklow, 2005; Saha et al., 2001). 
 
The YWTD domain, as confirmed by its 1.5 Å resolution X-ray structure (Jeon et al., 2001), 
is a six-bladed β-propeller, and shows an unexpected packing interface between the propeller 
and the third EGF module (E3 or EGF-C). Although the EGF-B module was also present, its 
position was disordered in the crystals (Fig. 18).  
 
                       
 
Figure 18. Structure of the YWTD β-propeller-EGF-C domain pair (PDB accession code 1IJQ). Ribbon 
representations of the YWTD domain and the adjacent C-terminal EGF-like module (E3) of the LDL receptor, 
coloured to point out the six YWTD repeats of the β-propeller (Jeon et al., 2001). 
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Downstream of the EGFP domain, at the C terminal end of the extracellular receptor region 
there is an O-linked sugar domain, a 58-residue sequence rich in serine and threonine that 
undergoes O-linked glycosylation (Cummings et al., 1983; Yamamoto et al., 1984). It is 
thought to function as a hydrophilic spacer that keeps lipophilic ligands (e.g. lipoproteins) 
away from the lipid bilayer of the plasma membrane. The deletion of this domain did not 
impair receptor function (Davis et al., 1986a). The receptor is anchored in the plasma 
membrane by a single transmembrane region composed of 25 hydrophobic amino acids 
(Yamamoto et al., 1984). The intracellular portion of LDLR is 50 residues long and 
contains a short NPxY (Asp-Pro-x-Tyr) sequence motif which is highly conserved in LDL 
receptors of several species (Chen et al., 1990). In the human LDL receptor this sequence is 
NPVY. It directs clustered receptors into clathrin-coated pits (Chen et al., 1990; Davis et al., 
1986b) by mediating interaction of the receptor with the endocytosis machinery as well as 
with different cytoplasmic adaptor and scaffold proteins (Davis et al., 1987a; Davis et al., 
1987b; Gotthardt et al., 2000; Herz and Bock, 2002; Rudenko and Deisenhofer, 2003).  
 
 
Naturally occurring mutations in LDLR 
 
Inherited loss of function mutations of the LDLR are the cause of the relatively common 
human genetic disease familial hypercholesterolemia (FH) (Hobbs et al., 1992; Ishibashi et al., 
1993; Norman et al., 1999; Tolleshaug et al., 1983). It is characterized by the defective 
catabolism of LDL and elevated plasma lipoprotein and cholesterol levels, causing 
accelerated arterosclerosis and coronary artery disease. More than 1000 mutant alleles causing 
FH have been already identified; (http://www.ucl.ac.uk/fh/ (Wilson et al., 1998) and 
http://www.umd.necker.fr/ LDLR/Home page.html (Villeger et al., 2002)). The frequency of 
heterozygotes carrying a defective or inactive allele is about 1 in every 500 persons 
worldwide; therefore FH is one of the most common human inborn errors of metabolism. 
Heterozygotes have a high plasma LDL concentration and a substantially increased risk for 
coronary artery disease while two defective copies cause severe premature atherosclerosis 
which typically leads to death at a very early age (Jeon and Blacklow, 2005). Many point 
mutations were found to be clustered in repeat 5 of the ligand binding domain (Blacklow and 
Kim, 1996; Fass et al., 1997), and also in the EGFP domain (Jeon et al., 2001). FH mutations 
have traditionally been separated into the following five classes depending on the nature of 
the receptor defect (Jeon and Blacklow, 2005): null alleles which synthesize no receptors 
(class 1), transport-defective alleles which are completely or partially defective in reaching 
the cell surface (class 2), binding-defective alleles (class 3), internalization-defective alleles 
which fail to cluster in coated pits (class 4) and recycling-defective alleles (class 5) (Hobbs et 
al., 1990). A sixth class of mutation exhibits a sorting defect in polarized epithelial cells 
(Koivisto et al., 2001). 
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2.9.5. VLDLR 
 
The VLDL receptor shows the same domain organization as the LDL receptor, except that it 
has 8 ligand-binding repeats. The entire human VLDLR gene is approximately 40 kb long and 
contains 19 exons. The high sequence similarity between the genes of VLDLR and LDLR, 
and the almost complete conservation of exon and intron positions suggest that they have a 
common ancestor gene. VLDLR is much more conserved between different species than 
LDLR (Oka et al., 1994). It is most abundant in heart and skeletal muscle, and is also 
expressed in lower amounts in the kidney, brain, ovary, testis, lung, and adipose tissue, all of 
which utilize lipoprotein-derived free fatty acids as an energy source (Gafvels et al., 1993). 
VLDLR is a multi-ligand receptor and its ligand specificity partially overlaps with that of 
LRP. VLDLR is specific for apoE (Niemeier et al., 1996; Takahashi et al., 1996; Takahashi et 
al., 1995), and thus binds VLDL, β-VLDL and IDL, but not LDL. Additionally, VLDLR 
binds lipoprotein-A (Argraves et al., 1997), the ternary complex of the serine protease 
urokinase plasminogen activator with its inhibitor and receptor (Argraves et al., 1995; 
Heegaard et al., 1995), lipoprotein lipase (Argraves et al., 1995), thrombospondin-1 
(Mikhailenko et al., 1997), and receptor associated protein (RAP) (Hiesberger et al., 1995; 
Simonsen et al., 1994), a chaperone responsible for proper folding and subcellular trafficking 
of LDLR family members (Battey et al., 1994; Savonen et al., 1999). Furthermore, VLDLR 
together with apoER2 plays an important role in mammalian brain development. Both 
receptors bind the large extracellular matrix protein reelin (Trommsdorff et al., 1999) which is 
required for neuronal migration and correct layer formation in the cerebellum and the cerebral 
cortex (D'Arcangelo et al., 1999; Hiesberger et al., 1999). Two isoforms of VLDLR have 
been reported, a cell surface expressed form possessing the O-linked sugar domain, and a 
secreted form lacking this domain (Iijima et al., 1998; Magrane et al., 1999; Magrane et al., 
1998). The EGF-precursor domain is responsible for low pH induced release of ligands inside 
endosomes also in the case of VLDLR (Mikhailenko et al., 1999). 
 
 
2.9.6. LRP-1 
 
LDL receptor-related protein-1 (LRP-1), found to be identical with the α2-macroglobulin 
receptor (Strickland et al., 1990) is expressed mainly in the liver, lung, and brain, also to 
significant amounts in the intestine and muscle, and at lower levels in the spleen, thymus, 
heart, kidney, and bone. This large (~600 kD) glycoprotein contains 31 complement-type and 
several epidermal growth factor-like repeats arranged in four clusters (Herz et al., 1988) (Fig. 
12). The precursor of LRP-1 is post-translationally cleaved into two subunits, a large subunit 
(525 kD) containing the ligand binding domain, and a small subunit (85 kD) containing the 
transmembrane and cytoplasmic regions. The large subunit is non-covalently associated with  
 35
the small subunit which anchors the receptor in the plasma membrane. The 100 amino acid 
long cytoplasmic domain carries two NPxY, one YxxL, and two di-leucine motifs, the YxxL 
motif being the dominant signal for LRP-1 endocytosis (Li et al., 2000). The complexity of 
LRP-1 allows for its multifunctionality, binding many structurally and functionally unrelated 
ligands (Herz and Strickland, 2001; Strickland et al., 1994). LRP-1 plays a major role in 
hepatic uptake of lipoproteins such as β-VLDL and chylomicron remnants (Beisiegel et al., 
1991; Beisiegel et al., 1989; Kowal et al., 1989; Willnow et al., 1992). As an endocytic 
receptor for proteases and protease inhibitors, LRP-1 regulates proteolytic processes in the 
blood circulation, including fibrinolysis and coagulation (Nykjaer and Willnow, 2002). It is 
also important for brain development and function by regulating neurite growth (Nathan et al., 
1994) and calcium influx into neurons (Bacskai et al., 2000). Amongst other ligands LRP-1 
internalizes α2-macroglobulin-protease complexes (Strickland et al., 1990), tissue-type 
plasminogen activator (tPA) complexed with plasminogen activator inhibitor type-1 (PAI-1) 
(Bu et al., 1993), urokinase plasminogen activator (uPA)-PAI-1 complexes (Herz et al., 1992), 
the protease factors IXa and Xa, factor VIII complexed with van Willebrand factor, 
Pseudomonas exotoxin A (Kounnas et al., 1992; Willnow and Herz, 1994), and lactoferrin 
(Willnow et al., 1992). Many of the LRP-1 ligands (including chylomicron remnants and 
factors VIII and IXa) adhere initially to heparan sulphate proteoglycans (HSPGs) which serve 
as low-affinity but high-capacity reservoirs acting as primary docking sites to sequester and 
present ligands to LRP-1 (Kolset and Salmivirta, 1999; Nykjaer and Willnow, 2002; 
Sarafanov et al., 2001). For normal processing of LRP-1 binding to the ER chaperone 
receptor associated protein (RAP) is necessary, which promotes proper folding, prevents 
premature binding to endogenously produced ligands (Bu et al., 1995; Bu and Rennke, 1996; 
Willnow et al., 1996), and allows for trafficking of the receptor to the cis-Golgi apparatus 
(Willnow, 1998).  
 
2.9.7. Interactions of minor group HRVs with their cellular receptors 
 
Cryo-electron microscopy reconstruction of a complex between HRV2 and a soluble VLDLR 
fragment encompassing the first three ligand binding repeats fused to maltose binding protein 
(MBP-V1-3) (Ronacher et al., 2000) revealed that the receptor binds at the small star-shaped 
dome of the icosahedral five-fold axis (Hewat et al., 2000). Somewhat later also the X-ray 
structure of HRV2 complexed with the VLDLR fragment V23 was solved, and the interacting 
residues at the binding interface were identified (Verdaguer et al., 2004). Since the 
conformations of V2 and V3 repeats are very similar and they could not be distinguished in 
the crystal structure, the sequence of repeat 3 was chosen to build the three dimensional 
model (Fig. 19). 
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The binding interface in the receptor includes an exposed tryptophan that is highly conserved, 
as well as acidic residues which are also necessary for the folding and maintenance of calcium 
coordination. The viral binding site is formed only by residues of the HI- and BC-loop of VP1, 
including a lysine which is conserved in all minor group serotypes. This lysine is the most 
important residue that forms ionic and hydrophobic interactions with the negatively charged 
cluster and the conserved tryptophan of the receptor. Additionally, the binding is stabilized by 
further hydrophobic (Ile1226 and Leu1132 of HRV2 with Trp22 of V3) and hydrophilic 
(Lys1228 and Thr1085 of HRV2 with Gln16 of V3) interactions.  
 
 
                         
 
Figure 19. Ribbon diagram of HRV2-V3 interactions as determined by X-ray crystallography. Colour code: 
V3: yellow ribbon; VP1: blue ribbon; neighboring VP1: light blue ribbon. Interface residues are marked 
according to the mode of interaction, ionic interactions in blue, H-bonds in green, hydrophobic interactions in 
rose. Lys 1224 is marked in purple, because it establishes both ionic and hydrophobic contacts (Verdaguer et al., 
2004). 
 
VLDLR binding repeats V2, V3 and V5 have been experimentally shown to bind minor group 
rhinoviruses (Nizet et al., 2005). Based on sequence comparisons of all VLDLR and LDLR 
ligand binding repeats, virus binding of natural receptors was modelled as shown in Fig. 20. 
The repeats shown in red are considered to bind, thereby establishing high avidity           
multi-module attachment. Recently, the VP1 sequences of all HRVs have been determined, 
but except of the single lysine within the HI loop, no obviously conserved residues were 
found in the minor group (Palmenberg et al., 2009; Vlasak et al., 2003). Three dimensional 
modeling of the different VP1 proteins, based on the known 3D structures of 5 HRV types, 
suggests that the lysine together with an overall positive surface potential is crucial for the 
establishment of ionic interactions with negatively charged acidic residues of the receptors 
(LDLR, VLDLR, LRP-1). Despite the conserved lysine in all minor group HRVs, the exact 
mode of receptor binding probably differs from type to type due to the high variability of 
residues within the exposed loops. A good example for this is HRV1A which has even 
different receptor specificity, binding only to the murine homologue of the LDLR 
(Reithmayer et al., 2002).  
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Figure 20. Model of virus binding by LDLR and VLDLR. The binding repeats are arranged around the star 
shaped dome of the 5-fold symmetry axes of the viral capsid. Repeats shown in red are considered binders, based 
on sequence comparisons with the VLDLR repeat V3 which has been resolved by X-ray crystallography in 
complex with HRV2. Such multi module attachment generally results in a high binding avidity. Modules without 
colour most probably do not bind because they lack residues known to be involved in interaction with virus. 
 
 
2.10. The β-propeller of LDLR plays a central role in intracellular 
ligand release  
 
Following lipoprotein binding, LDLR-lipoprotein complexes internalize through clathrin-
coated pits and traffic to sorting endosomes, where lipoprotein release occurs (Anderson et al., 
1977; Maxfield and McGraw, 2004). Lipoprotein release requires a functional EGFP 
homology domain and an acidic pH (Davis et al., 1987a). More than half (54 %) of human FH 
point mutations are located within the EGFP domain (Varret et al., 1998; Wilson et al., 1998). 
Mutant LDLR receptors with deleted EGFP homology domain (ΔEGFP) or EGF-AB domain 
pair (ΔAB) (which both are also naturally occurring FH mutations) are unable to release 
bound LDL or β-VLDL and show a recycling defect (Davis et al., 1987a; Boswell et al., 
2004). The EGFP domain is also responsible for the acid-dependent ligand release by VLDLR 
(Mikhailenko et al., 1999). LDL-release occurs at ~pH 6, which corresponds to the luminal 
pH of sorting endosomes (Davis et al., 1987a; Maxfield and McGraw, 2004).  
  
Several studies have been carried out to reveal the 3D structure of LDLR both at neutral and 
low pH to provide explanation for the molecular mechanism of ligand release. The β-propeller, 
a part of the EGFP domain, turned out to play the most important role in the process. There 
are three different hypotheses to date how it really happens. 
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I. The β-propeller competes for the lipoprotein binding sites on repeats LA4-LA5 
 
Upon endosomal acidification LDLR adopts a closed conformation by establishing an 
intramolecular contact between its β-propeller domain and its LA repeats 4 and 5 (interface I, 
Fig. 21), as shown in the 3.7 Å resolution crystal structure solved at pH 5.3 (Rudenko et al., 
2002). According to the intramolecular competition model (Beglova et al., 2004a) three 
histidines (H562 and H586 in the β-propeller and H190 in LA5) become protonated at their 
imidazole groups (pKa of ~6), and subsequently establish van der Waals and ionic 
interactions between the β-propeller and the LA repeats. As a consequence, the β-propeller 
becomes a better ligand for the LA repeats, and induces the release of the LDL particle by 
competition. Various deletion and domain swap studies showing that the β-propeller and 
especially the mentioned His residues are necessary for the release of bound lipoproteins 
(Beglova et al., 2004a) have strengthened this hypothesis. 
 
                                                A                                                      B  
 
             
 
 
Figure 21. Ribbon trace of the LDL receptor structure determined at endosomal pH. A) The central ligand-
binding modules, LA4 and LA5, form long-range contacts with the YWTD β-propeller domain and are 
highlighted in orange and red, respectively. The boxes enclose two interdomain interfaces that may be regulated 
by the change in pH that occurs upon moving from the cell surface to the endosome. The coordinates used for 
the figure are from PDB accession code 1N7D (Rudenko et al., 2002). B) Close-up view of interface I. The three 
interface histidines lie within the box at the centre of the interface (Beglova et al., 2004a). 
 
 
A second, less extensive interface (interface II, Fig. 21) found in the low pH structure of 
LDLR was first thought to serve as a hinge allowing the ligand binding repeats to arc back 
over the propeller domain. However, it turned out that the conformation of the LA7-EGF-A-
EGF-B domains is fixed throughout the whole physiologically relevant pH range, and it rather 
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constrains the flexible ligand-binding repeats to be in the neighbourhood of the propeller, so 
that receptor closure via intramolecular competition can readily occur at acidic pH (Fig. 22) 
(Beglova et al., 2004a).  
 
 
                    
 
 
 
Figure 22. How fixed and flexible domain-connections permit interconversion between open and closed 
conformations. LA7, EGF-A, and EGF-B constitute a rigid scaffold that is invariant with pH. The numbers of 
small wavy lines correspond to the flexibility of LA modules (Beglova et al., 2004a). 
 
 
II. The β-propeller causes lipoprotein release via an allosteric mechanism  
 
The kinetics of lipoprotein dissociation showed that the EGFP homology domain rather 
interacts with LA 4 and 5 via binding to a site different from the lipoprotein binding site, and 
the three interface histidines have little impact on the acid-dependent transition between the 
open and closed state of the LDLR (Fig 23.) (Zhao and Michaely, 2008). The mutant protein 
with H190, H562, and H586 all substituted with alanine was defective in lipoprotein release 
but showed normal acid-dependent conformational change, suggesting that adoption of the 
closed conformation is not sufficient to drive lipoprotein release. In the allosteric model 
proposed by Zhao and colleagues the conformational change of the ligand binding repeats 
caused by their low pH induced engagement with the EGFP homology domain is responsible 
for lipoprotein release. 
  
 40
 
 
 
Figure 23. Model of lipoprotein release by LDLR conformational changes. LDLR is shown in blue, 
lipoprotein in grey, and apolipoprotein in red. Only the EGF homology domain and LA5 of the LDLR are 
depicted. In the proposed allosteric model (A), lipoproteins bind to the LDLR via E187, D203, and E208 (apoE) 
or via E187 (apoB100) (1st and 2nd panels of A). Upon acidification the EGF homology domain contacts LA5 
(3rd panel of A), which drives a conformational change in LA5 that involves H190, H562, and H586. The 
conformational change in LA5 disrupts the binding sites for apolipoproteins, thereby driving release (4th panel 
of A). This new model stands in contrast to the previous model (panel B). In the previous model, lipoproteins 
bound to the same surface as the EGF homology domain (top two panels of B). The previous model also 
proposed that, as lipoprotein dissociates, the EGF homology domain replaces lipoprotein via an interaction that 
requires protonation of H190, H562, and H586 (bottom two panels of B) (Zhao and Michaely, 2008). 
 
 
III. The decreaseing Ca2+ concentration within acidifying endosomes leads to partial 
unfolding of the ligand binding repeats  
 
Recently, an additional mechanism for LDLR ligand release was proposed, namely the partial 
unfolding of ligand binding repeats due to the decrease of calcium concentrations within 
acidifying endosomes (Arias-Moreno et al., 2008). Upon acidification of the endosome Ca2+ is 
released to the cytoplasm, and the endosomal Ca2+ concentration drops from the extracellular 
level of 0.5-2 mM to 5 μM within 10 min (Gerasimenko et al., 1998). Previous in vitro 
experiments that led to the competition model (Beglova et al., 2004a; Rudenko et al., 2002) 
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were all carried out at extracellular Ca2+ concentrations. Arias-Moreno and colleagues, 
however, have shown that the affinity of LA5 for Ca2+ was markedly decreased at endosomal 
pH. As the isolated LA5 repeat is known to loose its stability when the coordinated Ca2+ is 
removed (Blacklow and Kim, 1996), its affinity for LDL must be also severely reduced. In 
their proposed model the unfolding of ligand binding repeats is the reason for LDL 
dissociation. This model does not necessarily exclude that the partially unfolded LA5 is still 
able to form the intramolecular complex with the β-propeller observed by X-ray 
crystallography (Rudenko et al., 2002), but it still remains to be tested. A similar mechanism 
was recently observed in the case of receptor associated protein (RAP); it dissociates from the 
receptors due to its partial unfolding triggered by histidine protonation at the acidic pH of the 
Golgi (Lee et al., 2006). It thus appears that acid-driven unfolding could be a general cellular 
mechanism to induce dissociation of protein complexes in acidic organelles (Arias-Moreno et 
al., 2008). 
 
 
2.11. Early infection events of Picornaviruses 
 
2.11.1. Receptor usage 
 
The first step in the replication cycle is the attachment of infectious virus particles to host cell 
receptors. The specific recognition of cell surface molecules which are usually expressed by a 
restricted set of cell types and particular host organisms, determines tissue tropism and host 
range. Picornaviruses use a wide repertoire of cell surface molecules for attachment (Table 2), 
such as immunoglobulin-like, short consensus repeat (SCR)-like, low density lipoprotein 
(LRLR)-like molecules, integrins, heparane sulphate, etc. (Flint et al., 2000; Rossmann et al., 
2002). Integrins used by foot-and-mouth disease virus (FMDV) and some echoviruses, are 
noncovalently linked, heterodimeric molecules consisting of a variety of α and β subunits, 
functioning in cell-cell interactions and signal transduction. Several immunoglobulin-like 
molecules are used as picornavirus receptors, such as intercellular adhesion molecule 1 
(ICAM-1) used by major group HRVs and some coxackievirus A types, vascular cell 
adhesion molecule 1 (VCAM-1) used by encephalomyocarditis virus (EMCV), coxackievirus-
adenovirus receptor (CAR) used by some coxackievirus B types, and poliovirus receptor 
(PVR/CD155). Some coxackieviruses end echoviruses bind to short consensus repeats (SCRs) 
of decay accelerating factor (DAF/CD55) which functions as a regulator of the complement 
activity protein family. Minor group HRVs attach to endocytic receptors of the LDLR 
superfamily (LDLR, LDLR-related protein and VLDLR). 
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Virus Receptor Type of molecule Coreceptor 
Foot-and-mouth disease virus αVβ3 (vitronectin receptor) integrin  
Foot-and-mouth disease virus  
(cell culture adapted) 
Heparane sulphate glycosaminoglycan  
Encephalomyocarditis virus VCAM-1 
 
Sialylated glycophorin A  
(for hemagglutination only) 
Ig-like 
 
carbohydrate 
 
Poliovirus 1-3 PVR (CD155) Ig-like  
Coxackievirus A13, A18, A21 ICAM-1 Ig-like  
Coxackievirus A21 DAF (CD55) SCR-like ICAM-1 
Coxackievirus A9 αVβ3 integrin  
Coxackievirus B1-6 CAR Ig-like  
Coxackievirus B1, B3, B5 DAF (CD55) SCR-like αVβ6 integrin 
Echovirus 1, 8 αVβ1  integrin β2 microglobulin 
Echovirus 22 αVβ3 integrin  
Echovirus 3, 6, 7,11,12, 13, 20, 
21, 24, 29, 33 
DAF (CD55) SCR-like β2 microglobulin 
Enterovirus 70 DAF (CD55) SCR-like  
Bovie enterovirus Sialic acid carbohydrate  
Hepatitis A virus HAVcr-1 Ig-like, mucin-like  
Major group HRV ICAM-1 Ig-like  
Minor group HRV LDLR-superfamily signalling 
receptors 
 
 
Table 2. Receptors and coreceptors used by members of the Picornaviridae family, adapted from (Flint et 
al., 2000). 
 
Some picornavirus receptors are used only as vehicles for virus delivery into the low pH 
environment of endosomes (e.g. integrins and heparane sulphate used by FMDV). Viruses 
which infect via the endosomal route but are not so sensitive to low pH need a receptor with a 
catalytic activity that uncoats the virus by itself (like PVR poliovirus) or in cooperation with 
the low pH (like ICAM-1 some major group HRV types). 
 
There is a big variability in the receptor usage within the Picornaviridae family. Poliovirus is 
engaged with a single receptor type (all three types use CD155). Different types of 
coxackieviruses, echoviruses and HRVs attach to different, structurally and functionally 
unrelated receptors. The same receptors can also be used by different viruses, like the αVβ3 
integrin (vitronectin receptor) by FMDV, coxackievirus A9 (CVA9) and echovirus (EV) 22; 
the decay accelerating factor by CVA21, CVB1, B3 and B5, enterovirus 70 and several 
 43
echovirus types; or ICAM-1 by major group HRVs and by coxackievirus A13, A18, and A21 
(Flint et al., 2000).  
 
2.11.2. Cell attachment via surface features: canyons and loops 
 
Low resolution (15-25 Å) structures of several picornavirus-receptor complexes have been 
solved by image reconstruction analysis of cryo-electron micrographs, such as HRV 14 
(Kolatkar et al., 1999; Olson et al., 1993), HRV 16 (Kolatkar et al., 1999), and coxsackievirus 
A12 (Xiao et al., 2001) with ICAM-1; poliovirus 1 with PVR (Belnap et al., 2000; He et al., 
2000; Xing et al., 2000); coxsackievirus B3 with CAR (He et al., 2001); echovirus 7 (EV7) 
and EV12 with DAF (Bhella et al., 2004; He et al., 2001; Pettigrew et al., 2006) and HRV2 
with the VLDL receptor (Hewat et al., 2000).  
 
Picornavirus receptors bind either to exposed surface loops on the viral capsid or to structures 
deeply hidden at the bottom of the canyons surrounding the star-shaped mesa of each fivefold 
axis. The first binding mode is represented by integrins serving as receptors for foot-and-
mouth disease virus, decay-accelerating factor binding to some coxackie A and B viruses, and 
LDL-receptors binding to minor group rhinoviruses. These receptors, binding to exposed 
structures of their viruses, only function as docking sites to increase virus concentration at the 
cell surface and/or as internalization vehicles. The viruses using such receptors either show a 
high sensitivity to low pH like minor group rhinoviruses and FMDV or they require an 
additional receptor for entry/conversion such as viruses binding to DAF but using CAR 
(coxackievirus B3) or ICAM1 (coxackievirus A21) in addition.  
 
Several members of the Enterovirus genus like poliovirus, some coxackie A and B viruses, 
and major group rhinoviruses hide their receptor binding sites inside the canyon. The 
receptors of these viruses bind to conserved residues and trigger uncoating associated 
conformational changes of the viral capsid. In order to donate some of their binding energy to 
facilitate structural rearrangements, such receptors need to bind at a big surface area, and 
binding inside the canyon is a good strategy to do this (Hogle, 2002). ICAM-1, PVR, and 
CAR (Fig. 24) all bind via their N-terminal domain within the canyon of their cognate viruses, 
but their footprints and binding geometry differ greatly. The PVR has a bigger footprint area 
on the poliovirus surface than ICAM-1 on rhinovirus, and also shows a higher binding affinity 
(Xing et al., 2000). Consistent with this, poliovirus uncoating can be induced by receptor 
attachment itself whereas some major group rhinoviruses (e.g. HRV 16) (Hooverlitty and 
Greve, 1993) need an additional trigger by the low pH. 
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Figure 24. Members of the immunoglobulin superfamily used as picornavirus receptors. Intercellular 
adhesion molecule-1 (ICAM-1); coxsackievirus-adenovirus receptor (CAR); and poliovirus receptor (PVR) used 
as receptors by human rhinoviruses (HRVs) and coxsackievirus A21 (CAV21); coxsackie B viruses (CVB); and 
poliovirus (PV), respectively (Rossmann et al., 2002) 
 
Viruses with structurally hidden, conserved receptor binding sites cannot tolerate big 
structural variability in their binding region, because they might easily lose binding specificity 
as well as their stability due to changes in deeply lying capsid structures. In contrast, viruses 
which bind to cell surface molecules via exposed loops continuously develop new binding 
properties due to the numerous mutations which occur during replication. Enteroviruses e.g. 
show variations in their DAF-binding sites; they bind to DAF at different SCRs, and even 
different regions of the same SCR can be utilized by different viruses (Hafenstein et al., 2007; 
Pettigrew et al., 2006). Changes in the receptor binding site might allow for attachment to 
new receptors, sometimes the virus might even gain the ability to infect new cell lines, which 
plays an important role in cell tropism. 
 
 
2.11.3. Coreceptors and alternative receptors 
 
Some picornaviruses use only a single type of receptor for cell attachment, entry, and 
uncoating, like the major group HRVs which use ICAM-1 or poliovirus which uses the 
poliovirus receptor (PVR)/CD155.  
 
Other viruses need an interaction with more than one cell surface molecules for effective 
infection. Some coxackievirus B isolates (CB1, CB3, and CB5) can attach to cells using 
decay accelerating factor (DAF) (Bergelson et al., 1995; Shafren et al., 1995; Shafren et al., 
1997b), but for cell entry and uncoating they need an additional interaction with the 
coxsackievirus and adenovirus receptor (CAR) (Bergelson et al., 1997; Martino et al., 2000; 
Milstone et al., 2005). The reason is that DAF binds to exposed surface structures outside of 
the canyon (Bhella et al., 2004; He et al., 2001; Pettigrew et al., 2006), where it cannot trigger 
conversion. However, in polarized epithelial cells CAR is concentrated at tight junctions, 
where it is relatively inaccessible for the viruses. Therefore DAF, which is present on the 
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apical surface, has also an important role in infection by capturing and concentrating the virus 
at the cell surface, and by inducing virus transport into the tight junctions (Marsh and 
Helenius, 2006; Shieh and Bergelson, 2002). 
 
Heparan sulphate (HS) glucosaminoglycans are widely expressed at the surface of many cell 
lines and are used by several viruses for cell entry. It is not uncommon that viruses aqiure the 
ability to bind HS in cell culture, and infect cells lacking their original receptor. Examples are 
a mutant HRV89 (Vlasak et al., 2005a) which is able to infect cells lacking ICAM-1, a cell 
culture adapted FMDV which binds to HS additionally to integrins (Fry et al., 1999), and a 
coxackievirus variant CVB3 PD which is able to infect cells lacking both DAF and CAR 
(Zautner et al., 2003). While for FMDV the binding to HS is only the result of a cell culture 
adaptation, this is probably not the case for echoviruses, where also low passage clinical 
isolates of EV6 have this property (Goodfellow et al., 2001). HRV54 naturally has the ablity 
to bind both ICAM-1 and heparane sulphate (Khan et al., 2007). 
 
 
2.11.4. Virus internalization via different pathways  
 
Since viruses are obligate intracellular parasites, they must somehow internalize into their 
host cells. Most non-enveloped viruses hijack natural endocytosis routes by binding specific 
receptors used by cargos under physiologic conditions. Receptor choice is important in the 
selection of the entry route which allows for intracellular trafficking of the virus. Finally, at 
some point of the pathway genome release occurs, induced by specific triggers within 
appropriate organelles. Hijacking the endolysosomal route is a strategy used by several 
viruses, because endocytosis offers several advantages. After endocytosis no viral 
components remain at the cell surface for detection by the host immune system. Viruses are 
transferred deeply inside the cytoplasm exploiting the molecular motors of the infected cells. 
Acidification is generally a trigger for molecular conformational changes in many cellular 
processes, e.g. in ligand release from receptors (LDL from LDLR; the iron from transferrin) 
or in the release of freshly synthesized proteins from their chaperons (LRP from receptor-
associated protein). Many viruses take the advantage of endosomal acidification as a trigger 
for membrane fusion and uncoating. Enveloped viruses generally infect via low-pH induced 
conversion of their envelope protein(s) (like hemagglutinin in the case of influenza (Cross et 
al., 2009)) which then insert(s) into the endosomal membrane assisting in viral fusion.      
Non-enveloped viruses (e.g. members of Picornaviruses) take advantage of the low pH for 
their capsid conversion and RNA release. Moreover, in this work we show that the low-pH 
induced conformational change of a virus receptor can also be beneficial for infection (namely 
the β-propeller switch of LDLR for minor group HRVs).  
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There are four main endocytic routes used by viruses: clathrin-mediated endocytosis, the 
caveolin dependent pathway, non-clathrin non-caveolae pathway and macropinocytosis.  
 
Clathrin-mediated endocytosis (CME) is the best understood one among the different 
cellular entry pathways. Receptors possessing clathrin clustering signal sequences (as YXXφ 
and di-leucine) recruit their cargo into developing clathrin-coated pits (CCPs) which 
subsequently internalize and form small (approx. 100 nm in diameter) clathrin-coated vesicles 
(CCVs), found in all cell types. Clathrin interacts with a number of adaptor or accessory 
proteins, like AP-2 (adaptor protein-2), Eps 15 (epsin 15), SNX9 (sorting nexin 9), actin, 
actin-associated proteins, like N-WASP, Arp2/3 ARH and Dab2, amphiphysin, AP180, and 
dynamin. Receptors such as LDL-receptor, transferrin receptor, receptor tirosin kinases, G 
protein-coupled receptors, and many others are taken up by clathrin-mediated endocytosis. 
Clathrin mediated endocytosis is used by several viruses for cell entry such as Semliki Forest 
virus, vesicular stomatitis virus (Sieczkarski and Whittaker, 2002), adenovirus, (Meier et al., 
2002), Sindbis virus (DeTulleo and Kirchhausen, 1998), canine parvovirus (Parker and 
Parrish, 2000), Hantaan virus (Jin et al., 2002), and certain picornaviruses, like the minor 
group human rhinoviruses (Snyers et al., 2003), FMDV (O'Donnell et al., 2005), and 
coxsackievirus B3 (Chung et al., 2005). 
 
Endocytosis via caveolae (a special type of lipid rafts rich in proteins, cholesterol,     
sphingo- and glycolipids) happens in many, but not all cell types. These small, (~50-100 nm 
in diameter) flask-shaped pits resembling the shape of a cave are especially abundant in 
smooth muscle, type I pneumocytes, fibroblasts, adipocytes, and endothelial cells. The 
cholesterol-binding protein caveolin-1 is responsible for the formation and maintenance of 
caveolae. Caveolae are directly involved in the internalization of membrane components 
(glycosylphosphatidylinositol-anchored proteins and glycosphingolipids), extracellular 
ligands (folic acid, albumin, autocrine motility factor), bacterial toxins (cholera toxin, tetanus 
toxin), and several non-enveloped viruses (Simian virus 40, Polyoma virus) (Pelkmans, 2005; 
Pelkmans and Helenius, 2003). Simian virus 40 (SV40) is the best known virus entering cells 
through caveolae, and it is frequently used as a marker for the caveolar pathway. It enters via 
a two-step transport pathway, from plasma membrane caveolae through an intermediate 
organelle (termed the caveosome) to the smooth ER (Pelkmans et al., 2001). SV40 can also 
use a virus activated cholesterol and tyrosine kinase dependent endocytic pathway from the 
plasma membrane to the ER, that involves neither clathrin nor caveolae (Damm et al., 2005).  
 
Macropinocytosis is the formation of vesicles of variable size (0.5-5µm in diameter)       
filled with large volumes of extracellular fluid. The cell membrane forms ruffles in an     
actin-dependent manner, which then enclose extracellular material non-specifically. 
Macropinosomes can become acidified by fusion with other vesicles such as endosomes and 
lysosomes (Hewlett et al., 1994). Although macropinocytosis is characteristic for specific cell 
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types such as macrophages and dendritic cells, it also happens in non-phagocytosing cell 
types, and occurs mainly upon stimulation by growth factors (Sieczkarski and Whittaker, 
2002). Macropinocytosis is used for cell entry by vaccinia virus, a poxvirus which is too large 
to enter clathrin-coated pits (Mercer and Helenius, 2008). HIV1, which normally enters cells 
by direct fusion with the plasma membrane, can also fuse with the membrane of 
macropinosomes in macrophages, leading to a less efficient infection (Marechal et al., 2001).  
 
It is not always easy to determine which entry route(s) a virus uses. Generally, the receptors 
define the entry pathways, but viruses which use alternative receptors for cell entry, can 
hijack different endocytosis routes. It is e.g. a well known phenomenon that viruses may 
develop the ability to bind heparane sulphate in cell culture, and enter into cells which are 
devoid of the virus receptor (Fry et al., 1999; Vlasak et al., 2005a). HRV54 generally uses 
ICAM-1, but it naturally has the ability to bind also heparane sulphate, and is able to infect 
RD cells that lack ICAM-1 (Khan et al., 2007). Moreover, the endocytic pathways are so 
interconnected that a virus might even use a combination of them, as the bovine 
papillomavirus 1 enters by clathrin-mediated endocytosis and then utilizes the caveolar 
pathway for infection (Laniosz et al., 2008). The knowledge about virus entry is continuously 
growing, and combined with sophisticated microscopic techniques, viruses are preferentially 
used as markers for the investigation of different entry pathways (Pelkmans and Helenius, 
2003). 
 
 
2.11.5. Cell entry of picornaviruses 
 
Picornaviruses use various receptors for cell attachment, and also various endocytic pathways.  
 
Poliovirus uses an entry pathway that requires energy, tyrosine kinases, an intact actin 
cytoskeleton, and cell signaling pathways, but is independent of clathrin, caveolin, flotillin or 
microtubules, and genome release occurs from vesicles that are very close to the cell surface 
(Brandenburg et al., 2007).  
 
FMDV enters cells mainly via clathrin-dependent endocytosis when it binds to integrins 
(O'Donnell et al., 2005). The cell culture adapted variant using heparane sulphate was found 
to enter through a caveolae-mediated pathway which can associate and traffic with endosomes 
(O'Donnell et al., 2008).  
 
Human rhinoviruses utilize different receptors and thus these viruses enter cells by different 
pathways. Members of the minor group use LDLR, VLDLR and LRP for internalization, 
which receptors follow clathrin mediated endocytosis (Snyers et al., 2003). The entry pathway 
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of major group rhinoviruses using ICAM-1 is not known in detail. Former times it was 
proposed that they follow a clathrin mediated endocytosis (DeTulleo and Kirchhausen, 1998). 
However, ICAM-1 lacks a typical clathrin localization signal, and even functions as a viral 
receptor when its cytoplasmic tail is replaced with a GPI-anchor (Staunton et al., 1992). 
Multivalent ICAM-1 ligands such as immunobeads have been shown to enter cells via 
macropinocytosis (Muro et al., 2003). It was recently shown that HRVs using ICAM1 enter 
rhabdomyosarcoma cells also by a particular type of macropinocytosis (Khan et al., 2010). 
 
A number of enteroviruses use (DAF) as a receptor, which can be found in lipid rafts. 
Infection by a DAF-using strain of echovirus 11 (E11) is dependent on cholesterol and an 
intact cytoskeleton, which is an indication that this virus uses lipid rafts for cell attachment 
(Stuart et al., 2002). Coxsackievirus B4 also requires functional lipid rafts for attachment, and 
then it is delivered to the Golgi (Triantafilou and Triantafilou, 2004). The group B 
coxsackievirus receptor, CAR, is found in the epithelial tight junction. Coxsackievirus B entry 
needs a component of the tight junction called occludin, and occurs by a process that 
combines aspects of caveolar endocytosis with features of macropinocytosis (Coyne et al., 
2007). Echovirus 1 enters cells using caveolin-mediated endocytosis, and apparently uncoats 
from the caveosome (Pietiainen et al., 2004). 
 
 
2.11.6. Uncoating and RNA release to the cytoplasm 
 
In order to protect the genome viral capsids must be stable enough to withstand extracellular 
conditions e.g. mechanical shearing, UV irradiation, dehydration, enzymatic attack, extremes 
of pH, ionic strength, and temperature, etc. For efficient infection however, once they reach 
their target cells and encounter specific trigger(s) wihin the appropriate cellular compartment, 
they must become sufficiently unstable to allow for genome release. 
 
The final stage of assembly for many viruses involves proteolytic processing (maturation 
cleavage) of a structural protein (generally a surface glycoprotein for enveloped viruses or a 
capsid protein of a non-eveloped virus), which sets up a metastable state. Facing the 
appropriate trigger (receptor binding, endosomal acidification or both) the viral capsid 
proceeds to a lower energy state which is usually accompanied by exposing hydrophobic 
sequences that can attach to membranes. In enveloped viruses this membrane attachment 
facilitates fusion of the viral envelope with the cell membrane. In non-enveloped viruses the 
hydrophobic sequences must either generate a pore into a cellular membrane or disrupt it to 
facilitate entry and/or genome release (Hogle, 2002). In most picornaviruses the autocatalytic 
cleavage of VP0 into VP2 and V4, and the subsequent rearrangements of VP4 and the N-
terminal extensions of VP1 and VP2 are responsible for locking the virus in the metastable 
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state. Mutations which prevent the maturation cleavage result in the production of             
non-infectious provirions as shown for poliovirus (Ansardi and Morrow, 1995), FMDV 
(Knipe et al., 1997), human rhinovirus 14 (Lee et al., 1993), hepatitis A virus (Bishop and 
Anderson, 1993) and Swine vesicular disease virus (Rebel et al., 2003). No maturation 
cleavage occurs in parechoviruses (Stanway et al., 2000). The present information about the 
RNA release of picornaviruses stems from the comparison of high resolution X-ray structures 
of different viral stages: the native virus, the immature provirion, virus-receptor complexes, 
and empty capsids. These are only snapshots of stable intermediates, which have to be then 
combined with genetic, biophysical, and biochemical observations to model the whole 
process. When facing the appropriate triggers (receptor binding and/or low pH), most 
picornaviruses undergo a capsid conversion by externalizing hydrophobic patches, like the 
myristoyl-VP4 and the N-terminal extensions of VP1 in poliovirus (Fricks and Hogle, 1990) 
and rhinovirus (Hewat and Neumann, 2002; Hewat and Blaas, 2004). While the conversion to 
A-particle is irreversible, transient and reversible exposure of VP4 and the N-terminal 
extension of VP1 occur at physiological temperatures in a process termed “breathing” (Li et 
al., 1994). In contrast to the stable virion, the generated hydrophobic A-particles are sensitive 
to proteases. The A-particle is infectious, as it still contains the RNA genome, and is 
hydrophobic which allows its association with cellular membranes.  
 
The role of receptor in virus conversion depends on the stability of the virus, and on the 
nature of virus-receptor binding. Receptors binding at the viral surface, like LDL-receptors, 
integrins, heparane sulphate or decay accelerating factor (DAF) are not able to induce viral 
conversion; uncoating of viruses using such receptors exclusively depends on the low pH 
within endosomes. Receptors which bind deeply inside the canyon like ICAM-1, poliovirus 
receptor or CAR have the potential to induce conformational change of the viral capsid; 
whether they do, it depends on the certain virus. Receptor-sensitive viruses like poliovirus, 
HRV3, and HRV14 all can be converted by the attachment of their receptors at neutral pH. 
HRV16 however, is not converted by ICAM-1 binding alone, it also needs the low pH 
(Hoover-Litty and Greve, 1993).  
 
After virus conversion the RNA leaves the capsid (uncoating) and penetrates through its 
surrounding membrane e.g. the plasma membrane (poliovirus) or the endosomal membrane 
(HRVs). Except of binding viruses and assisting in their conversion, picornavirus receptors 
also have additional roles in infection such as handing over the converting virus to the 
membrane or keeping the virus bound even during RNA egress. HRV2, the most investigated 
minor group HRV, loses the affinity to its receptors upon its low pH induced conversion, 
which can cause its dissotiation (Brabec et al., 2003). LDLR however, also undergoes 
conformational changes at low pH, which could be the reason for virus release as well. 
Modeling virus conversion at the plasma membrane of HeLa cells, which express LDLR, 
VLDLR, and LRP as receptor candidates, a big amount of native HRV2 was released from 
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the cells (Brabec et al., 2003). However, in our system using LDLR as the only virus receptor, 
HRV2 was found to be released upon its conversion and was directly handed over to the 
endosomal membrane (Konecsni et al., 2009). Whether in natural infectons the receptor keeps 
the virus bound until conversion occurs and subsequently hands it over to the membrane or it 
releases the virus still being native, influences the efficiency of infection greatly. 
 
Picornaviruses, which depend on their receptor for conversion, remain bound, and their 
receptors also assist in RNA penetration, e.g. by holding the virus close to the plasma 
membrane (poliovirus receptor) or by disruption of the endosomal membrane (ICAM-1 in the 
case of major group rhinoviruses). The complex of poliovirus and the exodomain of its 
receptor linked to liposomes via a Ni-NTA anchor has been reconstructed by cryoelectron 
microscopy (Bubeck et al., 2005). The results suggest that binding via multiple receptors 
brings the viral 5-fold axis close to the membrane, allowing the insertion of multiple copies of 
VP4 and the N termini of VP1 proteins into the lipid bilayer upon conversion into the           
A-particle form. Cryo-EM pictures about HRV3-soluble ICAM-1 complexes formed at 4ºC 
followed by heating to 37ºC have shown that the receptor remains bound during, and even 
after RNA egress (Xing et al., 2003). 
 
The low pH and/or the attachment to the receptor induce the conversion from native virus 
(150S) to A-particle (135S). Subviral particles can also be produced in vitro. Exposure of 
HRV2 to pH 5.0 primarily results in 135S particles, and heating to 50-56ºC for some minutes 
primarily generates empty 80S particles (Gruenberger et al., 1991; Korant et al., 1972) 
(Lonberg-Holm and Noble-Harvey, 1973; Lonberg-Holm and Yin, 1973; Noble and  
Lonberg-Holm, 1973). Poliovirus can be converted by warming in hypotonic buffers in the 
presence of millimolar levels of calcium ions (Curry et al., 1996; Wetz and Kucinski, 1991). 
In the absence of calcium the conversion proceeds directly to empty 80S particles, suggesting 
that calcium is required to stabilize the A-particle, and that depletion of calcium at some stage 
during the normal entry process may serve as a trigger for RNA release (Hogle, 2002).  
 
 
Conversion from A-particle to empty B-particle, and penetration of the viral RNA into 
the cytosol 
 
For efficient infection it is not enough that the RNA is released from the viral capsid, but it 
also has to penetrate through the membrane of the endosome/vesicle/organelle in which the 
virus has converted, to reach the cytosol, the place of replication. The RNA penetration of 
picornaviruses happens either by pore formation (minor group HRVs, poliovirus) or by 
disruption of the endosomal membrane (major group HRVs) (Brabec et al., 2005; Fuchs and 
Blaas, 2008; Tosteson et al., 2004).  
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The viruses which penetrate by pore formation (e.g. poliovirus and minor group rhinoviruses) 
previously attach to the membrane via their externaized hydrophobic patches, and via their 
VP4 proteins which have been released from the capsid upon conversion. Multiple copies of 
VP4 are believed to form channels in the membrane (Davis et al., 2008; Tosteson et al., 2004) 
which allow for RNA penetration. The situation is different for major group rhinoviruses 
which disrupt the endosomal membrane, as believed, via molecular constraints induced as the 
rigid ICAM-1 molecules follow the conformational changes of the bound virus (Fuchs and 
Blaas, 2008). It is interesting why major group HRVs disrupt the membrane but poliovirus 
forms pores, since their receptors belong to the same protein family. When the ICAM-1 
molecules were not so long and rigid, which hinders the converted capsid to associate with the 
membrane, maybe also the major group HRVs could form pores.  
 
FMDV is extremely sensitive to low pH, and its capsid is known to be disassembled to 12S 
pentamers still at the pH of early endosomes (Grubman and Baxt, 2004). A mutant FMDV 
which is unable to perform the maturation cleavage of VP0 into VP2 and VP4 is                
non-infectious, but also disassembles at low pH (Knipe et al., 1997). This indicates that a 
functional VP4 is necessary for infection, most probably for pore formation, to assist RNA 
penetration. Comparing the most investigated members of picornaviruses the A-particle 
seems to be an important intermediate, which, by associating with membranes, helps the RNA 
to be released vectorially into the cytosol and not into the lumen of the endosome. The quick 
disassembly of FMDV raises the question whether the A-particle is generally needed for RNA 
penetration or only the membrane-inserted VP4 proteins are really important. It is a further 
question whether FMDV has a short lived A-particle form which cannot be detected because 
of a rapid RNA penetration or the quick capsid disassembly (perhaps still in the receptor 
attached form) allows for a rapid pore formation by the soluble VP4s and for RNA 
penetration without a pre-existing A-particle. Recently it has been shown that another 
member of the Aphthovirus genus, the Equine rhinitis A virus, also dissociates to pentamers 
at mildly acidic pH but its dissociation is preceded by the transient formation of empty 80S 
particles (Tuthill et al., 2009). This suggests that also the A-particle form should exist but 
because of the quick uncoating process it could not be detected so far. Whether the A-particle, 
which is quite generally formed in many picornaviruses, is an indispensable intermediate to 
assist RNA penetration or the viral RNA itself has the potential to penetrate through the 
formed channels (e.g. by high affinity of VPg to membrane-inserted VP4) still remains a 
question. 
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3. Objectives 
 
Human rhinoviruses use two different types of receptors for cell attachment and entry. Most 
of the viruses (87 types) belong to the major group, binding to the human intercellular 
adhesion molecule 1 (ICAM-1). The remaining 12 types of the minor group attach to 
members of the low-density lipoprotein receptor (LDLR) superfamily including LDLR,   
very-low-density lipoprotein receptor (VLDLR), and LDLR-related protein (LRP). Following 
attachment and internalization HRVs are transferred into endosomal compartments where the 
low pH and/or the virus-destabilizing activity of ICAM-1 trigger structural changes 
(conversion into subviral particles, i.e. virus uncoating) leading to RNA-delivery into the 
cytosol, where the replication takes place. While the major group receptor ICAM-1 actively 
induces virus uncoating, LDLR is considered to be just a vehicle for delivery of the virus into 
endosomes, where the low pH would be the unique trigger for uncoating. However, at the low 
pH prevailing in endosomes LDLR releases its bound natural ligand (LDL), and adopts a 
closed conformation via its β-propeller domain binding to the ligand-binding repeats LA 4 
and LA 5. Since rhinoviruses are also sensitive to low pH, conformational modifications of 
both LDLR and minor group HRVs might take place concomitantly. Whether the virus is 
released by the receptor still in its native or its converted form might influence the efficiency 
of infection. While in the first case the virus would convert in the fluid phase of the endosome 
and diffuse back to the endosomal membrane for productive RNA release, in the second case 
it would be directly handed over from the receptor to the membrane upon its conversion. The 
latter is predicted to result in a higher efficiency of viral RNA release into the cytoplasm of 
the host cell. Since the β-propeller domain of LDLR is necessary for the release of bound 
LDL, we aimed at comparing the behaviour of wt and β-propeller deficient LDLR with 
respect to endosomal virus release and the efficiency of infection. As the virus should be also 
released from a propeller deficient receptor (due to its own conversion), differences between 
the two scenarios would point to the β-propeller having an impact on rhinovirus infection. 
This would indicate that LDLR is not just a simple vehicle for virus delivery. CHO ldla7 cells 
that are deficient in endogenous LDLR (Krieger et al., 1981) and had been transfected to 
stably express either native or β-propeller-negative human LDLR (Beglova et al.) were used 
in the experiments, because no human cell line lacking both VLDLR and LRP is available. In 
order to separately consider virus-receptor interaction and later steps of the infection, low pH 
induced virus conversion and release was investigated by using the plasma membrane of the 
cells as a model for the inner side of the endosomal membrane. To assess the impact of the β-
propeller in HRV infection, virus attachment, internalization, uncoating, capsid degradation, 
infection kinetics (using a CHO-adapted HRV2 variant), and the intracellular fate of LDLRs 
were investigated. 
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4. Materials and methods 
 
4.1. Chemicals, reagents and buffer solutions 
 
4.1.1. Chemicals 
 
All chemicals were obtained from Sigma (Sigma, St. Louis, Mo.) or Merck (Darmstadt, 
Germany), unless specified otherwise. WIN 52084-2 was a kind gift of Dan Pevear, 
ViroPharma.  
4.1.2. Cell culture materials, media and buffer solutions 
 
Cell culture media and supplements were from Gibco BRL, cell culture dishes from Iwaki,   
T-175 flasks from NuncTM, T-162, T-75 and T-25 flasks, 6 well, 12 well and 24 well plates 
from Costar, and plastic tubes from Falcon. 
HeLa-H1 cells were cultured in minimal essential medium (MEM) supplemented with 10 % 
heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin, and 100 
µg/ml streptomycin. For infection of HeLa cells MEM containing 30 mM MgCl2 and 2 % 
FCS (infection medium) was used.  
CHO cells were cultured in Ham’s F-12 medium with 5 % FCS, 2 mM L-glutamine,           
100 U/ml penicillin and 100 µg/ml streptomycin. Transfected CHO cells were maintained in 
the same medium containing the selection agent geneticin (G418) at 1 mg/ml. CHO-infection 
medium was Ham’s F-12 containing 30 mM MgCl2 and 2 % FCS, without geneticin.  
Phosphate buffered saline (PBS) was 3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 
135 mM NaCl, pH 7.4. 
Hank’s balanced buffer solution (HBBS) was 137 mM NaCl, 5.4 mM KCl, 0.25 mM 
Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM MgSO4, 4.2 mM NaHCO3. It was used 
for washing and for incubation of CHO cells at 4°C during virus binding experiments and 
other cellular assays. 
Radio-immunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 1 mM EDTA, 0.1 % Na-deoxycholate , 0.1 % SDS and 1 % Triton X-100) was used for 
cell lysis prior to radio-immunoprecipitation and/or scintillation counting. 
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Isotonic MES buffers of different pH. For virus binding/release experiments isotonic        
30 mM MES buffers were made of a pH between 4.8 and 7 with increments of 0.2 pH units; 
to ensure isotonicity, the NaCl concentrations were calculated using the web tool „Recipe 
calculator for thermodynamically correct buffers” of the University of Liverpool, 
(http://www.liv.ac.uk/buffers/buffercalc.html). After adding the adequate amount of NaCl,  
the buffers were adjusted to the respective pH with NaOH at 0°C. 
 
 
4.2. Cell lines 
 
HeLa-H1 Ohio (American Type Culture Collection, Manassas, Va.), a subline supporting the 
replication of HRVs, was used for viral titre determination as well as for radiolabeling of 
virus with [S35]-methionine/cysteine. 
 
CHO cells overexpressing wild type and β-propeller negative human LDLR, a kind gift 
of Prof. Stephen Blacklow, Boston, USA, had been prepared by stable transfection of     
CHO-ldla7 cells (a Chinese hamster ovary cell line that lacks functional endogenous LDL 
receptors (Kingsley and Krieger, 1984)) either with wild type human LDLR (termed RF3 
cells) or with an LDLR in which the YWTD β-propeller and the EGF-C domains were  
deleted (termed ΔYC cells) (Beglova et al., 2004a, b).  
 
 
4.3. Culturing and splitting of adherent cell lines 
 
4.3.1. Growing cells  
 
In order to ensure sterile working conditions, manipulations were performed in a laminar 
flow hood. Pipettes and buffers were autoclaved, media were sterile filtered through a micro 
filter (Cameo 25GAS) with a pore size of 0.22 µm.  
 
Cells were cultured either as monolayers in tissue culture flasks, dishes, microtiter well 
plates or for special purposes in suspension at 37°C in a water-saturated atmosphere 
containing 5 % CO2.  
 
When splitting monolayer cells, medium was removed, cells were washed with PBS, than 
harvested with 10 mM EDTA in PBS (5 ml for a 162 cm2 culture flask) incubating at 37°C for 
3-5 min. EDTA chelates Ca2+ions, weakening the interaction between the flask surface and 
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cell adhesion molecules. Detached cells from a 162 cm2 flask were diluted to 14 ml with PBS, 
pelleted in a Heraeus Megafuge at 1200 rcf for 5 min to remove EDTA, and resuspended in 
the desired medium. 
 
4.3.2. Freezing cells  
 
After harvesting cells with 10 mM EDTA in PBS and pelleting, they were resuspended in 
freezing medium (10 v/v % DMSO in FCS) at a cell density corresponding to 54-56 cm2 of 
monolayer cells per ml. The cells were transferred into cryo tubes (Nunc TM) (1 ml per each 
tube) which were placed in a freezing box containing isopropanol allowing slow cooling to     
-80°C. For long term storage at -196°C the tubes were transferred into liquid nitrogen the next 
day.  
 
4.3.3. Thawing cells 
 
Cells in cryo tubes were thawn in a water bath at 37°C until some few pieces of ice were still 
present. They were diluted to 10 ml with medium, and pelleted. The supernatant containing 
toxic DMSO used as a cryo-protectant was discarded, and the cell pellet was resuspended in 
growth medium and transferred into a culture flask. 
 
4.3.4. Splitting cells and seeding them for different assays 
 
 
Plastic ware Surface area   Number of HeLa cells 
 T-225 flask 225 cm2  360 x 105 cells 
 T-175 flask 175 cm2    280 x 105 cells 
 T-162 flask 162 cm2     260 x 105 cells 
 T-75 flask 75 cm2  120 x 105 cells 
 T-25 flask 25 cm2    40 x 105 cells 
 6-well plate  9.4 cm2 / well    15 x 105 cells / well 
12-well plate 4 cm2 / well   6.4 x 105 cells / well 
 24-well plate 2 cm2 / well   3.2 x 105 cells / well 
 48-well plate 0.8 cm2 / well   1.3 x 105 cells / well 
 96-well plate 0.32 cm2 / well 0.51 x 105 cells / well 
  
Table 3. Cell numbers corresponding to the surface of culture flasks/plates used (1 cm2 ~ 1.6 x 105 HeLa 
cells). 
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Seeding cells into 96-well plates for TCID50  
A day prior to infection 1/30 of the cells of a confluent 175 cm2 flask were resuspended in   
10 ml infection medium for each 96-well plate, and 100µl were seeded into each well. The 
plates were incubated at 37°C overnight; cells were ~60 % confluent the next day. 
 
Seeding cells into 6-well plates for binding and infection assays 
A day prior to infection 1/12 of the cells of a confluent 75 cm2 flask or 1/25 of the cells of a 
confluent 162 cm2 flask were resuspended and seeded in 4 ml F-12 infection medium per well. 
The cells were grown at 37°C and were ~60 % confluent the next day. 
 
 
4.4. Viruses: wild type and CHO-adapted HRV2 
 
HRV2 was originally obtained from the American Type Culture Collection (ATCC, Rockville, 
Md., USA). An HRV2 variant adapted to replicate in CHO cells was isolated by blind 
passages alternating between HeLa and CHO-RF3 cells. Cells in a 162 cm2 flask were 
challenged with virus at 10 TCID50/cell at 34°C for 30 min, medium with non-bound virus 
was replaced by fresh infection medium, and cells were incubated for 24 h to allow for 
infection. Virus eventually produced in the CHO cells was liberated by three consecutive 
freeze/thaw cycles and then HeLa cells were infected with the lysates. Whereas initially no 
CPE was seen in the CHO cells, HeLa cells usually lysed after 24 h. However, after 12 cycles 
CPE appeared in the CHO cells and persisted even upon CHO to CHO passaging for more 
than 5 times. The variant population, termed HRV2CHO, replicated in both CHO cell lines but 
with different kinetics (see Results).  
 
 
4.5. Infection  
 
Infection with HRVs was performed at 34°C in infection medium (medium containing 2 % 
FCS, antibiotics, 2 mM glutamine, and 30 mM MgCl2 for monolayer cultures; S-MEM 
supplemented with 2 % HS, antibiotics, 2 mM glutamine, 1 % non-essential amino acids, 1 % 
Pluronic F-68, and 1 mM MgCl2 for suspension cultures) for 1.5 to 3 hours. Then, cells were 
washed twice with PBS to remove unbound virus and further incubated in infection medium 
to allow for virus replication.  
 
In comparative infection experiments using CHO cells, viruses were allowed to bind for 1 h at 
4°C, unbound virus was removed by washing with ice cold HBBS, than the cells were placed 
at 34°C in infection medium. 
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4.6. Preparation of seed virus 
 
HeLa cells were grown to a density of 4x105 cells/ml in a 2 l suspension culture. After 
transfer into 2 l infection medium for suspension cultures, the cells were infected with virus at 
MOI of 1 (one plaque forming unit per cell = 10 TCID50/cell). The culture was incubated with 
stirring at 20 rpm for 16 hours at 34°C allowing for efficient virus production. After pelleting 
at 4.000 rpm (J6B rotor) for 20 min at 4°C, the cells were resuspended in 20 ml PBS and 
broken by Dounce homogenization on ice, than sonicated for 3 min to allow viral particles to 
be released. Cell debris was pelleted at 15,000 rpm (SS34 rotor) for 30 min at 4°C. 
Supernatants containing virus were stored at -80°C in aliquots.  
 
 
4.7. Viral titre determination by TCID50
 
A day before infection 1/30 of the cells of a confluent 175 cm2 flask were resuspended in     
10 ml infection medium for each 96-well plate, and 100 µl were seeded into each well.       
The plates were incubated at 37°C overnight, to be ~50-70 % dense on the day of infection. 
Serial 10-fold dilutions of the virus suspension of unknown titre were prepared, each in 2 ml 
infection medium. The cells were infected with 100 µl per well, using 12 wells for each of the 
8 dilutions. Upon incubation at 34°C for five days, monolayers in wells containing infectious 
virus had lysed completely. The medium was removed and cells were stained with 0.1 % 
crystal violet in water (60-80 µl per well) for 10-15 min. The staining solution was discarded 
and the wells were rinsed with water. While wells containing intact cell monolayers appeared 
violet, empty wells remained unstained because lysed cells detached from the well surface 
and were washed away. From the numbers of infected and non-infected wells the tissue 
culture infectious dose, infecting 50 % of the culture per ml (TCID50/ml), was calculated 
based on the method of Blake and O'Connell, 1993. It has been empirically determined that 
10 TCID50 is approximately equal to one plaque forming unit (pfu).  
 
 
4.8. Radiolabeling of HRV2 
 
HeLa cells were grown in a 162 cm2 flask to about 80 % confluency, washed twice with PBS, 
and incubated with 20 ml methionine/cysteine-free DMEM supplemented with 2 % dialysed 
FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 30 mM MgCl2 
for 4 h at 37°C. The medium was replaced by fresh methionine/cysteine-free medium, and 
virus was added at 1000 TCID50/cell. The cells were incubated for 4 h at 34°C to allow for 
viral internalization and host cell shut off. Fifteen ml of the old medium were replaced by 
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fresh infection medium containing 2 % dialysed FCS. After addition of 1 mCi [35S]-
methionine/cysteine (Hartmann Analytic GmbH, Braunschweig, Germany) incubation was 
continued for 16 h. Cells were broken by 3 cycles of freezing/thawing, debris was removed by 
centrifugation at 20,000 rpm (Ty65 rotor) for 20 min at 4°C. Virus was pelleted at 50,000 rpm 
(Ty65 rotor) for 2 h, and resuspended in 1 ml HBBS supplemented with 2 % FCS overnight at 
4°C. Insoluble material was removed by centrifugation in a table top centrifuge. Remaining 
free radiolabel was removed by 2x pelleting the virus in an Optima TLX (Beckman) table top 
ultracentrifuge (TLA 100.3 rotor) at 70,000 rpm for 1 h. The viral pellet was finally 
resuspended in 200 µl HBBS, 2 % FCS, and stored at 4°C. Incorporated radioactivity was 
quantified by liquid scintillation counting (Tricarb; Packard, Meriden, Connecticut, USA); 
only radiochemically pure virus preparations (i.e. only viral proteins visible in the 
autoradiogram), as checked on a reducing 15 % SDS-PAA gel, were used. To ensure the 
absence of eventually converted and/or damaged particles, the preparations were stored over  
S. aureus-2G2 immune-complexes which were removed by centrifugation before use. 
 
 
4.9. FACS quantification of LDLR expression 
 
CHO cells were detached from 162 cm2 culture flasks by incubation in 5 ml 10 mM EDTA in 
PBS at 37°C for 5 min. The cells were washed with PBS and resuspended in Ham’s F-12 
growth medium to allow for re-saturation of cell surface LDL-receptors with Ca2+ at 37°C for 
30 min. After 2 times washing in ice cold HBBS, the cells were resuspended in ice cold 
FACS-buffer (HBBS supplemented with 2 % FCS) at ~ 2x106 cells/ml, and incubated under 
slow rotation for 1 h at 4°C. Cells were dispensed in 2 ml Eppendorf tubes at ~2x106 
cells/sample, pelleted at 1000 g for 5 min, resuspended in 200µl FACS-buffer containing 
chicken IgY directed against the ligand binding domain of human LDLR (prepared by 
standard techniques in our lab) at 2.5 µg/ml. The cells were then incubated on ice for 1 h by 
gently shaking the tubes every other 10 min. After 3 washes with 1 ml ice cold HBBS, 
phycoerythrin-conjugated donkey anti-chicken secondary antibody (Jackson Immuno 
Research) was added at 1:100 dilution in 200 µl FACS-buffer. After 30 min incubation, the 
cells were washed twice with cold HBBS, resuspended in 1 ml of cold HBBS, transferred into 
5 ml polypropylene FACS tubes, and kept on ice until analyzed. Cell associated fluorescence 
corresponding to receptor expression was measured in a Becton-Dickinson LSR-I flow 
cytometer, using the CellQuest Pro software for data analysis.  
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4.10. FACS-sorting of highly expressing CHO cells  
 
Cells were prepared the same way as for FACS quantification of LDLR expression. Sorting 
was carried out on a Becton-Dickinson FACS-Aria instrument, using two gates as indicated in 
Fig. 25. The gated cell populations were collected into F-12 growth medium, expanded in cell 
culture, and frozen for long term storage. Finally, the higher LDLR-expressing populations 
for both cell lines (shown in red) were expanded to a higher extent to prepare a stock of cells 
with identical receptor expression levels; these batches were used in all further assays. 
 
 
                        
 
 
Figure 25. FACS-sorting of CHO cells to obtain highly expressing populations. Cells collected using the 
upper gate (shown in red) were finally expanded and used for further experiments. 
 
 
4.11. Attachment of radiolabeled HRV2 to cell surface LDLRs 
 
CHO cells expressing wt or truncated LDLR were grown in 6-well plates until about 80 % 
confluency. The growth medium was discarded, cells were washed with ice cold HBBS, 
20,000 cpm of [35S]-labeled HRV2 in ice cold infection medium was added per well, and the 
plates were incubated for 1 h at 4°C for virus binding. Non-bound virus was removed by 
washing 3 times with ice cold HBBS, the cells were lysed with 500 µl RIPA buffer on ice for 
15 min, and transferred into scintillation vials. The wells were washed with 500 µl RIPA 
buffer and with 500 µl HBBS, and the washes were combined with the cell lysates. The 
required volumes of Filter Count scintillation cocktail (5-7 ml) were added to the lysates to 
obtain a clear suspension, and cell associated radioactivity was measured in a liquid 
scintillation counter (Tricarb; Packard, Meriden, Connecticut, USA).  
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4.12. Release of LDLR-bound HRV2 from CHO cells after low-pH 
treatment 
 
CHO cells were grown in 6-well plates until confluent. The medium was removed, cells were 
incubated in cold HBBS for 10 min at 4°C, and challenged with 20,000 cpm of [35S]-labelled 
HRV2 in ice cold CHO infection medium for 1 h at 4°C. Non-bound virus was removed by 
washing with ice cold HBBS, and cells were exposed to isotonic 30 mM MES buffers of pH 
4.8 to 7 (with increments of 0.2 pH units) for 20 min at 4oC. Samples were re-neutralized by 
addition of the adequate volumes of 1 M Tris-base. Virus released into the supernatant and 
remaining cell-associated was quantified separately by scintillation counting.  
 
In a separate experiment the effect of the duration of low pH incubation and re-neutralization 
on virus dissociation was determined. Cells were incubated at pH 5, 6 and 7 for 20, 45 and 90 
min, followed by re-neutralization to pH 7 for 0, 10, and 45 min.  
 
 
 
4.13. Modelling endosomal virus conversion at the plasma 
membrane  
 
4.13.1. Pre-treatment of virus with WIN-compound  
 
In these experiments either untreated or WIN-compound treated radiolabeled viruses were 
used. WIN 52084-2 was dissolved at 0.5 mg/ml in 50 % dimethylsulfoxide (DMSO) and 
stored at -20°C. The working solutions contained WIN 52084-2 at 20 µg/ml and DMSO at     
2 % final concentrations in 150 mM NaCl pH 7.5. For mock treated virus, 2 % DMSO in 150 
mM NaCl pH 7.5 was used for incubation. For each sample to be assayed 30,000 cpm     
[35S]-labelled HRV2 was pre-incubated in 20 µl of 150 mM NaCl pH 7.5 containing WIN 
52084-2 at 20 µg/ml (final concentration) for 30 min at room temperature. Untreated        
virus was pre-incubated in the same buffer without the WIN-compound. Eventually      
present non-native virus was removed by immunoprecipitation with mAb 2G2 - S. aureus 
immunocomplexes. 
 
4.13.2. Virus binding to cell surface LDLRs followed by low pH-induced release 
 
CHO cells were grown in 6-well plates until confluent, and pre-incubated in cold HBBS for 
10 min at 4°C. Then, 20,000 cpm of [35S]-labelled HRV2 (untreated and pre-incubated with 
the antiviral, respectively) in ice cold infection medium was added to each well, and the plates 
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were incubated for 1 h at 4°C for virus binding. Non bound viruses were removed by washing 
3 times with ice cold HBBS. The cells were then incubated in 1 ml cold isotonic buffers of pH 
4.8, 5.2, 5.4, 5.6, 5.8 and 6.2 for 20 min at 4°C, to induce virus conversion at the plasma 
membrane. The low pH incubation was terminated by adding appropriate amounts (0-25 µl) 
of 1 M Tris base to the isotonic incubation buffers to adjust the pH values to neutral. The cells 
were further incubated in the re-neutralized buffers for 20 min at 4oC to allow for release of 
converted viruses. Supernatants (1 ml) were collected in 2 ml Eppendorf tubes, and the cells 
were washed twice with 250 µl HBBS. The washes were combined with the supernatants, and 
300 µl of 6x RIPA buffer was added to each tube in order to accomplish 1x final 
concentration of RIPA buffer for immunoprecipitation. The cells were lysed on ice for 15 min 
by adding 500 µl RIPA buffer into each well, and the lysates were collected in 2 ml 
Eppendorf tubes. The wells were rinsed twice with 500 µl RIPA buffer, the washes were 
combined with the cell lysates, and debris was removed by centrifugation. The two samples 
(supernatants containing the incubation buffers, and the cleared cell lysates) belonging to each 
pH value, were processed separately for sequential immunoprecipitation. 
 
4.13.3. Preparation of Staphylococcus aureus immunocomplexes  
 
500 µl fixed, heat killed S. aureus cells from a 10 % stock suspension were pelleted at 10,000 
rpm for 1 min in a table top Eppendorf centrifuge. The pellet was washed twice with 1 ml 
PBS and twice with 1 ml RIPA buffer. Bacteria were resuspended in 400 µl RIPA buffer and 
then incubated with 100 µl HRV2-antiserum for 1 h shaking at room temperature. Bacteria 
were pelleted, washed three times with RIPA buffer, and finally resuspended in 500 µl RIPA 
buffer containing 0.04 % sodium azide and stored at 4°C until used. Since protein-A binds 
rabbit IgG much better than mouse IgG, mAb 2G2 was bound via rabbit anti-mouse IgG by 
using the same procedure.  
 
4.13.4. Immunoprecipitation and scintillation counting 
 
Supernatants and cell lysates were processed separately for sequential immunoprecipitation. 
First subviral particles were recovered by addition of 20 µl MAb 2G2-S. aureus 
immunocomplexes and incubated for 2 h shaking at room temperature. Bacteria were pelleted 
and washed twice with 200 µl RIPA buffer. Supernatants and washes were combined, and 
remaining native virus was precipitated by 20 µl rabbit HRV2 antibody-S. aureus 
immunocomplexes. Pellets were washed twice with 200 µl RIPA buffer, resuspended in 200 
µl HBBS, and transferred into scintillation vials. Remaining radioactive virus was collected 
from the Eppendorf tubes by washing 2 times with 200 µl HBBS, and added into the 
respective scintillation vials. The required volumes of Filter Count scintillation cocktail were 
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added (5-7 ml) to obtain a clear suspension, and radioactivity of the samples was determined 
in a liquid scintillation counter (Tricarb; Packard, Meriden, Connecticut, USA). Conversion 
of native virus into subviral particles was calculated by dividing the sum of 2G2-precipitated 
counts by the total counts (i.e. the sum of the counts in the 2G2 and anti-HRV2 precipitates). 
Conversion at pH 4.8 was set to 100 % and conversion at pH 7 to 0 %. 
 
 
4.14. Internalization kinetics of LDLR-bound virus 
 
CHO-ldla7 cells expressing human wt LDLR (RF3) and cells expressing human LDLR 
without the β-propeller (ΔYC) were grown until confluent in 6-well plates. After removal of 
the medium and pre-incubation in HBBS for 10 min at 4°C the cells were challenged with 
HRV2 at 100, 50 and 10 TCID50/cell in CHO-infection medium for 1 h at 4°C. Non-attached 
virus was washed away with ice cold HBBS, the medium was replaced with cold infection 
medium, and the cells were placed at 34°C for 0 (control for binding only), 1, 2, 3, 4, 5, 6 and 
10 min. Viral entry was stopped by adding ice cold HBBS and placing the plates on ice. 
Following extensive washing with ice cold HBBS and blocking (in HBBS with 2 % FCS) for 
1 h on ice, virus remaining surface-accessible was quantified in a cell-based ELISA type 
assay (performed on ice); mAb 8F5 (Skern et al., 1987) at 20 µg/ml in HBBS with 2 % FCS 
was added at 4°C for 1 h, cells were extensively washed and incubated with HRP-conjugated 
secondary antibody (diluted 1:20,000 in HBBS, 2 % FCS) at 4°C for 30 min. One ml of a 
solution of 100 µg/ml 3,3’,5,5’-tetramethyl benzidine in 100 mM Na-acetate (pH 5.6), 0.03 % 
H2O2 was added to each well, and the colour reaction was allowed to develop on ice. After 20 
min, 150 µl aliquots were transferred into a new 96-well plate, 75 µl of 1 M H2SO4 was added 
to each well, and A450 was measured in a Labsystem Multiscan RC plate reader. Values 
obtained for non-infected cells (background) were subtracted. 
 
 
4.15. Kinetics of cellular protein synthesis 
 
Protein synthesis rate was determined via time-dependent incorporation of [35S]-labeled 
cysteine/methionine into cellular proteins. CHO cells were grown in 6 well plates to about   
80 % confluence and incubated in methionine/cysteine-free medium (DMEM supplemented 
with 2 % dialysed FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine,  
and 30 mM MgCl2) for 4 h at 37°C. The medium was replaced by 1 ml of fresh 
methionine/cysteine-free medium supplemented with 40 µCi of [35S]-methionine/cysteine   
per well. Incorporation of radioactive amino acids into cellular proteins was monitored by 
incubating the cells at 37°C for 0, 1, 2, 3, and 4 h. After extensive washing with HBBS, cells 
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were lysed in 1 ml of 10 % trichloroacetic acid (TCA) in HBBS, and samples were transferred 
into 2 ml Eppendorf tubes. Wells were rinsed with 400 µl of 10 % TCA in HBBS, and the 
solutions combined. After incubation on ice for 20 min, precipitated cellular proteins were 
pelleted at 10,000 rpm for 2 min in a table top Eppendorf centrifuge. To avoid carry over of 
the pellet, 700 µl of the supernatant was siphoned off, and radioactivity of this half volume of 
total supernatant (S/2), and the pellet with the remaining half volume of supernatant (P+S/2) 
were scintillation counted separately, and pellet-associated counts were calculated.  
 
 
4.16. Kinetics of intracellular virus conversion and degradation 
 
CHO cells were grown in 6 well plates, pre-incubated in cold HBBS for 10 min at 4°C, and 
challenged with 20,000 cpm of [35S]-labelled HRV2 at 4°C for 1 h. Unbound virus was 
removed by extensive washing with ice cold HBBS, and the cells were incubated in 1 ml 
CHO-infection medium at 34oC allowing for virus internalization and endosomal conversion. 
At the times given in the text the cells were lysed without removing the incubation medium 
by adding 200 µl of 6x RIPA buffer. Cell debris was removed by centrifugation. For 
monitoring uncoating, subviral particles were immunoprecipitated with mAb 2G2, and 
remaining native virus with HRV2 antiserum. Liquid scintillation counting was carried out as 
described above, and ratios of 2G2 precipitated counts and total counts were calculated.  
 
Viral capsid degradation was measured the same way, except that only HRV2-antiserum was 
used for immunoprecipitation. Ratios of not precipitable counts and total counts were taken as 
a measure of degradation; set to 0 % at time 0. 
 
 
4.17. Time-dependent co-localization of virus and LDLR  
 
CHO cells were seeded onto 13 mm glass coverslips (Menzel, Braunschweig, Germany) and 
grown until 80 % confluent. Cells were washed with PBS containing 1 mM CaCl2 and 1 mM 
MgCl2 (PBS++), pre-incubated in 200 µl CHO-infection medium for 30 min at 37 °C, cooled 
to 4°C, and challenged with HRV2 at 900 TCID50/cell for 1 h. Unbound virus was removed 
by 3 washes with 2 ml ice-cold PBS++, and the cells were incubated in 500 µl pre-warmed 
CHO-infection medium for 4, 20, and 60 min (chase). The cover slips were transferred into a 
6 well plate on ice and washed with 2 ml of ice-cold PBS++ for 5 min. The cells were fixed for 
30 min with 300 µl 4 % paraformaldehyde (PFA) in PBS++, quenched with 300 µl 50 mM 
NH4Cl in PBS for 10 min, washed 3 times and permeabilized with 300 µl of 0.2 % Triton    
X-100 in PBS for 5 min. Unspecific binding sites were blocked with 200 µl of 10 % goat 
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serum in PBS (Gibco Invitrogen Corp., Paisley, United Kingdom) for 30 min. All antibodies 
were diluted with PBS containing 10 % goat serum. HRV2 was detected with mAb 8F5 (Saito 
et al., 2007) (10 µg/ml) followed by Alexa 568-conjugated goat anti-mouse IgG (1:1000; 
Molecular Probes Incorp., Eugene, OR, USA), and LDLR was detected with chicken anti 
human LDLR IgY (10 µg/ml) and Alexa 488-conjugated goat anti-chicken IgG (1:1000) 
(Molecular Probes). Cells were washed 4 times for 10 min each with 5 ml PBS, and nuclei 
were stained with DRAQ5 (Biostatus, Shepshed Leicestershire, United Kingdom). Cover slips 
were briefly dipped in ddH2O and mounted in Mowiol. Cells were viewed with a Zeiss 
Axiovert 200 microscope (Carl Zeiss, Jena, Germany) equipped with an UltraView ERS laser 
confocal system (PerkinElmer, Shelton, CT, USA). Twelve-bit images of highest resolution 
(1344 x 1024 pixels; no binning) were acquired through a 63x/ 1.4 Plan-Apochromat lens 
(Carl Zeiss, Jena, Germany). Images were taken with the same exposure time and emission 
was discriminated by sequential acquisition. For Z-stack analysis, at least 15 images were 
recorded at 0.2 µm intervals with a piezo-driven Z stage. UltraView software was used to 
correct for background fluorescence and to determine the extent of co-localization.  
 
 
4.18. Kinetics of the infection of CHO cells with HRV2CHO. 
 
CHO cells grown in 6 well plates were challenged with HRV2CHO at 10 TCID50/cell at 4°C 
for 1 h. Non-bound virus was removed by extensive washing with ice cold HBBS and the 
cells were incubated at 34°C in 2 ml CHO-infection medium. At time 0 (to determine bound 
virus) and after 3, 6, 9, 12, 16, 22, 26, 31, and 36 h post infection the cells were subjected to  
3 freeze-thaw cycles, cell debris was removed and the viral titre was determined in HeLa cells.  
 
 
4.19. Effect of HRV2 internalization on the expression and 
lysosomal degradation of LDLR  
 
CHO RF3 and ΔYC cells were seeded onto 13 mm glass cover slips (Menzel, Braunschweig, 
Germany) and grown to 80 % confluence. Cells were washed with PBS++ (PBS containing     
1 mM CaCl2 and 1 mM MgCl2) and pre-incubated in serum-free F12 medium for 1 h at 34ºC. 
HRV2 at 1,500 TCID50/cell was internalized in serum-free F12 medium for 6 h. Cells were 
then cooled, washed, fixed and permeabilized with methanol at -20°C for 10 min, and 
processed for indirect immunofluorescence microscopy for detection of LDLR with chicken 
anti human LDLR IgY (10 µg/ml), and LAMP2 with anti-human CD107B mouse antibody 
(1:400 BD Biosciences, Pharmigen, USA), followed by Alexa-488-conjugated goat anti-
chicken IgG and Alexa 568-conjugated goat anti-mouse IgG, respectively. Nuclei were 
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stained with Hoechst dye (1 μg/ml; for epifluorescence microscopy) and DRAQE5 (1:500; for 
confocal microscopy) and cells were embedded in Moviol. LDLR expression and the extent 
of co-localization with LAMP2 was investigated by epifluorescence microscopy using a Zeiss 
Axioplan 2 fluorescence microscope equipped with a C-Apochromat 40x lens and Axiovision 
software. Confocal microscopy was carried out as described above. 
 
 
4.20. SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
The most widely used method to separate complex protein mixtures is the one-dimensional 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). This method 
utilizes the detergent SDS to solubilize, denature, and impart a uniform, strong negative 
charge to proteins. Thereby, the different proteins are separated according to their size rather 
than to their charge as they move through the polyacrylamide (PAA) matrix towards the 
anode. The migration rate and the separation range is determined by the pore size of the 
matrix and thus by the PAA concentration in the gel (Table 4). 
 
Gel percentage Separation range 
6 % 70-500 kD 
10 % 15-200 kD 
15 % 5-50 kD 
 
                                              Table 4. Separation ranges of different PAA-gels 
 
The recipes of all solutions are listed at the end of this section. The PAA gel is prepared and 
run in a Bio-Rad apparatus (Bio-Rad Laboratories GmbH, Vienna, Austria). A master mix for 
the resolving gel (Table 5.) is prepared by mixing the appropriate amounts of 4x resolving gel 
buffer, dd H2O and acrylamide stock solution. Then APS (a radical starter for initiating 
polymerization) and TEMED (used as a catalyst) are added, the solution is mixed well, 
poured between two glass plates, overlaid with water and polymerized. After removing the 
water, 1.2 ml stacking gel solution is poured on top of the solid resolving gel. A comb is 
inserted immediately and the gel is allowed to polymerize. After removing the comb, the gel 
polymerized between the two glass plates is placed into an electrophoresis tank. The chamber 
is filled with electrophoresis buffer, and protein samples, mixed with 1/5 volume of 5x sample 
buffer and denatured at 95°C for 5 min, are loaded. For SDS-PAGE under non-reducing 
conditions, sample buffer lacking a reducing agent is used. A constant current of 25 mA per 
gel is applied until the front of the bromophenol blue marker reaches the bottom of the gel 
(~45 min). To estimate the molecular weight of samples, size standards are loaded onto the 
gel in parallel.  
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Proteins separated in SDS-PAA gels can be fixed and visualized by staining with Coomassie 
Brilliant Blue staining solution for 20 min (with a limit of detection of 200 ng protein).      
The acetic acid in the staining solution fixes the proteins in the gel. For identification of 
distinct bands the gel is destained either by boiling in H2O or incubation in destaining solution 
until the background is sufficiently clear. Finally, the gel is dried on Whatman paper for         
2 hours at 80°C. 
 
resolving gel mixture 6 % 8 % 10 % 12 % 15 % 20 % 
H2O (ml) 2.75 2.4 2.1 1.75 1.25 0.4 
4x resolving buffer stock (ml) 1.25 1.25 1.25 1.25 1.25 1.25 
acrylamide stock (ml) 1.0 1.35 1.65 2.0 2.5 3.35 
10 % APS (µl) 25 25 25 25 25 25 
TEMED (µl) 2.5 2.5 2.5 2.5 2.5 2.5 
 
       Table 5. Composition of the resolving gel mixture to achieve the desired percentage 
 
 
Stacking gel mixture: 2.5 ml stacking gel solution, 50 μl 10 % APS, 5 μl TEMED 
 
4x resolving gel buffer stock: 1.5 M Tris-HCl, 0.4 % SDS pH 8.8 
 
Acrylamide stock: 30 % acrylamide, 0.4 % bisacrylamide 
 
Stacking gel solution: 12.5 ml 4x stacking gel buffer, 7.5 ml acrylamide solution, 30 ml H2O
  
4x stacking gel buffer: 0.5 M Tris-HCl, 0.4 % SDS pH 6.8 
 
10x electrophoresis running buffer: 250 mM Tris-base, 2 M glycine, 1 % SDS 
 
10 % APS: 10 % ammonium persulfate in H2O 
 
5x sample buffer: 1.6 M Tris-HCl (pH 6.8), 15 % SDS (w/v), 50 % glycerol (v/v),  
25 % β-mercaptoethanol (only for reducing gels), 0.15 mg/ml bromophenol blue 
 
Coomassie Brilliant Blue solution: 45 % methanol, 10 % acetic acid, 0.4 % Coomassie 
Brilliant Blue R 250 
 
Destaining solution: 40 % methanol, 10 % acetic acid 
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5. Results 
 
Early infection events of human rhinoviruses are in the focus of our laboratory since many 
years. According to the present view (Brabec et al., 2003; Fuchs and Blaas, 2008), the minor 
group virus HRV2 is released from its receptors starting at ~pH 6 in early endosomes and is 
transferred in the fluid phase of endosomal carrier vesicles towards late endosomes while the 
receptors recycle. The gradually decreasing pH causes conversion of HRV2 into hydrophobic 
A-particles which then re-attach to the membrane of endosomal carrier vesicles and/or late 
endosomes and release their RNA into the cytosol through a pore. Therefore, minor group 
receptors (LDLR, VLDLR and LRP) are rather considered passive vehicles which deliver the 
virus to the low pH environment of endosomes. Within endosomes LDLR releases its bound 
natural ligand (LDL) by adopting a closed conformation via its β-propeller domain which 
binds to the ligand binding repeats LA4 and LA5 (Beglova et al., 2004a). As rhinoviruses are 
also sensitive to low pH, conformational modifications of both LDLR and minor group HRVs 
might take place concomitantly. We thus aimed to clarify whether the function of the            
β-propeller contributes to HRV infection by influencing viral conversion or virus release from 
the LDL-receptor. 
 
Endosomal virus conversion can be modeled at the plasma membrane by binding virus to cell 
surface receptors at 4ºC (so internalization is blocked) and incubating the cells at acidic pH. 
In a previous work Brabec and colleagues used isotonic acetate-phosphate buffers between 
pH 7.4 and 5.4 to study the conversion of receptor-bound HRV2 at the membrane of HeLa 
cells (Brabec et al., 2003). We aimed to perform a similar experiment but instead of HeLa 
cells which express three different HRV receptors we wanted to work in a single receptor 
system. We have chosen LDLR because the most experimental data regarding the β-propeller 
are provided for this receptor. Since no human cell line expressing LDLR in the absence of 
VLDLR or LRP is available, CHO-ldla7 cells, which are deficient in endogenous LDLR and 
are stably transfected to express either wild-type or β-propeller negative human LDLR 
(Beglova et al., 2004a), were used (Fig. 25). 
                                    
Figure 25. Schematic representation of the LDL-receptors expressed in stably transfected CHO-ldla7 cells; 
modified after (Beglova et al., 2004a).  
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5.1. FACS-sorting and expansion yields homogenous populations 
of CHO cells highly expressing the respective LDLRs. 
 
Immunofluorescence microscopy and fluorescence activated cell sorting (FACS) analysis 
revealed that the two transfected CHO cell lines were not homogenous in LDLR-expression. 
Despite being grown in the presence of the selecting agent geneticin, both RF3 and ΔYC cells 
had a tendency to lose the transfected LDLRs upon prolonged cultivation. In particular, the 
concentration of wt LDLR was comparatively low in most of the cells. Therefore, both cell 
lines were subjected to FACS-sorting, and cells expressing the respective receptors at similar 
levels were collected and expanded. This resulted in reasonably homogenous populations. 
Binding of radiolabeled HRV2 at 4°C was almost identical for both transfected cell lines with 
low background binding (3.9 % ± 0.7 % related to the mean binding of receptor-expressing 
cells) as determined for non-transfected CHO-ldla7 cells that lack functional LDLR (Fig. 26). 
These cells were used for all experiments. 
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Figure 26. Virus binding to CHO cells transfected with wt or β-propeller negative human LDLR after 
FACS-sorting. Cells in 6-well plates were challenged with 20,000 cpm of radiolabeled virus at 4°C for 1 h. 
After removal of non-bound virus cells were lysed in RIPA buffer and associated counts were measured.        
The control ldla7 cells are not transfected and lack functional LDLR. The same level of binding was observed 
for both transfected cell lines. Error bars show standard deviation (n=3). 
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5.2. Modeling endosomal conversion of HRV2 at the plasma 
membrane  
 
The pH difference between the endosomal lumen and the cytosol is well maintained within 
the cell. The acetate buffer used by Brabec and colleagues is membrane permeable (Neubauer 
et al., 1987) and it rather equilibrates the pH at the two sides of the plasma membrane than 
establishes a pH difference. Moreover, the phosphate content of this buffer might deplete Ca2+ 
from the LA repeats of the receptor, reducing the strength of ligand binding by disturbing the 
active protein conformation. As mentioned earlier, partial unfolding of LA repeats due to 
decreasing endosomal Ca2+ concentration might indeed play an important role in ligand 
release from the LDLR (Arias-Moreno et al., 2008). Therefore, we decided to use another 
buffer system for low pH incubation of LDLR-bound virus. In order to better mimic the 
endosomal conditions we chose isotonic buffers based on MES (Good et al., 1966) which 
does not penetrate through biological membranes (www.sigmaaldrich.com) and therefore 
does not disturb the pH difference between the extra- and intracellular space. MES (pKa=6.2) 
buffers well at pH values between 4.8 and 7, possessing the highest buffering capacity        
just within the range where structural changes of receptor and virus occur. Ca2+ was     
omitted from the buffer as decreasing Ca2+ concentration was found in acidifying endosomes 
(Arias-Moreno et al., 2008).  
 
 
5.3. HRV2 is not released from CHO cells upon acidification but 
only after re-neutralization 
 
Under the conditions used by Brabec and colleagues (HeLa cells with native receptor 
expression levels, incubation in acetate-phosphate buffers) about 50 % of receptor-bound 
HRV2 dissociated from the cells upon incubation at pH 6. In our experimental setup       
(CHO cells with ~10x higher receptor levels than HeLa cells; incubation in MES buffers) no 
release of receptor-bound HRV2 was observed at any pH, regardless of the kind of receptor 
(native or truncated) expressed. This was even so upon prolonged (90 min) incubation at pH 5. 
Unexpectedly however, substantial and rapid virus release was noticed upon re-neutralization 
of the cell-bound acidified viruses to pH 7 (which was applied for simultaneous termination 
of the low pH treatment in all samples). Therefore, in a separate experiment the effect of the 
duration of re-neutralization on virus dissociation was determined. In order to represent 
different stages of virus conversion, cells were exposed to isotonic 30 mM MES buffers of pH 
5, 6 or 7 for 20 min at 4ºC, re-neutralized by addition of the required volumes of 1M         
Tris-base, and further incubated for 0, 10 and 45 min. Virus released into the supernatant and 
remaining cell-associated was quantified separately by scintillation counting.  
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Figure 27 shows the effect of re-neutralization on virus dissociation as a function of 
incubation time. The lack of virus release upon acidification suggests that HRV2 was directly 
handed over to the cell membrane as it has converted into hydrophobic A-particles. Since 
membrane-attached A-particles can only dissociate after their conversion into hydrophilic 
empty B-particles (Korant et al., 1972; Lonberg Holm et al., 1976), the re-neutralization      
(or some unknown factor associated with it) should have caused RNA release under our 
conditions. Whether the converted virus being attached to the endosomal membrane also 
experiences a re-neutralization effect in real infections (coming from the cytoplasm through 
virally opened membrane pores) still remains an open question. 
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Fig. 27. Cell-attached HRV2 is not released from CHO cells upon incubation at low pH unless                  
re-neutralized. Radiolabeled HRV2 was bound to CHO cells expressing wt LDLR at 4°C for 1 h. After 
removing non-bound virus, cells were exposed to isotonic 30 mM MES buffers of pH 5, 6, and 7 for 20 min at 
4oC. Incubation buffers were then re-neutralized by addition of required volumes of 1 M Tris-base, and cells 
were further incubated for 0, 10, and 45 min. Cell-associated and released counts were measured. For three 
different stages of virus conversion (pre-treated at pH 5, 6, and 7) the effect of re-neutralization on virus 
dissociation is shown as a function of incubation time. Error bars show standard deviation (n=3). 
 
 
5.4. The propeller deficient LDLR protects HRV2 against 
conversion similarly as a capsid-binding antiviral compound 
 
The role of the β-propeller domain in virus conversion and release from LDLR was 
investigated by mimicking endosomal acidification at the plasma membrane. The 
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experimental setup of Brabec and colleagues was slightly modified. Briefly, [35S]-labelled 
HRV2 was attached to the cells at 4oC for 1 h, unbound virus was washed away with cold 
HBBS, and the cells were incubated in isotonic MES buffers of pH 4.8 to 7 (with increments 
of 0.2 pH units) at 4oC for 20 min. The incubation buffers were then re-neutralized by adding 
the required volumes of Tris-base, and the cells were further incubated for 20 min. Radiolabel 
released into the medium in the form of subviral particles or of native virus was then 
determined by sequential immunoprecipitation. First, A- and B-subviral particles were 
precipitated with Staphylococcus aureus-bound monoclonal antibody 2G2 (Hewat and Blaas, 
2006; Skern et al., 1987), then remaining native virus was recovered with rabbit HRV2 
antiserum. The same procedure was carried out with the cellular fraction after cell lysis with 
RIPA buffer.  
 
Low pH-induced virus conversion was quantified by liquid scintillation counting and is 
depicted as a percentage (total conversion in supernatant plus cell lysates) in Figure 28. 
Similarly to HRV2 bound to HeLa cells (Brabec et al., 2003), the conformational alterations 
of HRV2 bound to CHO cells expressing human wt LDLR (dark squares) also occurred 
within a pH range from < 6 to around 5.4, giving rise to a typical sigmoid curve. However, 
when the virus was bound to β-propeller negative LDLR (light diamonds) the curve was 
shifted towards lower pH values by an increment of about 0.3 pH units. This clearly shows 
that the β-propeller exerts a substantial effect on the conversion of HRV2. As not only the 
virus but also the LDLR undergoes conformational transitions between pH 6 and 5 (Rudenko 
et al., 2002), it is difficult to dissect the contribution of either one on virus-receptor 
dissociation. Capsid-binding drugs such as I(S), also named as WIN-52084 (from the Sterling 
Winthrop company that originally manufactured these compounds) displace fatty acids 
naturally present in the hydrophobic pocket of the capsid, and stabilize HRVs against low-pH 
induced conversion into subviral A-particles (Gruenberger et al., 1991; Kim et al., 1989). 
Therefore, the same experiment was carried out with HRV2 that had been pre-incubated with 
this drug. As also seen in Fig. 28, WIN-stabilization caused a shift in the conversion curve of 
wt LDLR-bound HRV2 (dark grey triangles) towards lower pH values. This shift was almost 
identical to the effect of the β-propeller deletion (light diamonds).  
 
Apparently, in the absence of the β-propeller, the strong binding by the multi-modular 
receptor stabilizes the native virus conformation. This is in line with earlier data of 
Nicodemou et al., demonstrating stabilization of HRV2 by the soluble concatemeric pentamer 
of module 3 of VLDLR (V33333) (Nicodemou et al., 2005). WIN-stabilization and binding to 
the truncated receptor had additive effects, shifting the sigmoid curve even more towards 
lower pH values (light grey circles).  
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Figure 28. Conversion of LDLR-bound HRV2 at the plasma membrane induced by incubation in acidic 
buffers. Radiolabeled HRV2 either untreated or pre-incubated with the antiviral drug WIN-52084 was attached 
to the cells at 4oC for 1 h, non-bound virus was removed, and the cells were incubated at 4oC for 20 min in 
isotonic buffers of the pH values indicated. The buffers were re-neutralized by adding Tris-base, and the cells 
were further incubated for 20 min to allow for virus release. Converted virus was immunoprecipitated with mAb 
2G2, and remaining native virus by anti-HRV2 antiserum from both the supernatants and cell lysates. Total 
conversion at pH 4.8 was set to 100 % and no conversion at pH 7 was set to 0 %. Note that the propeller-
negative LDLR stabilizes the virus against conversion to a similar extent as the antiviral substance, and the two 
different types of protection effects are additive. The respective pH values causing 50 % conversion (inflexion 
points of the curves) under these conditions are projected to the X axis.  
 
Virus particles released into the supernatant were found in 80-100 % as subviral particles at 
any pH value of incubation for all four experimental conditions (data not shown). This 
strongly suggests that the majority of virus particles remained receptor-bound until converted 
and native virus was not released to any significant extent. Most likely, the hydrophobic      
A-particles were directly handed over to the membrane upon their generation, where they 
remained bound until the RNA was released (triggered by re-neutralization of the incubation 
buffers), and only the remaining hydrophilic empty capsids fell off the cell surface.  
 
 
5.5. Both CHO cell lines showed the same kinetics in uptake of 
HRV2  
 
After modeling endosomal events at the plasma membrane, we turned to the investigation of 
intracellular steps of the infection. First, the kinetics of virus internalization was compared in 
the two transfected cell lines. This was derived from the time-dependent disappearance of 
surface-exposed virus. CHO-ldla7 cells expressing human wt LDLR and human LDLR 
lacking the β-propeller were grown in 6-well plates until confluent. The medium was replaced 
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with fresh infection medium, and HRV2 at 100 TCID50/cell was allowed to attach for 1 h at 
4°C. Non-attached virus was washed away with cold HBBS, and the medium was replaced 
with fresh ice cold infection medium. Virus internalization was started in all samples 
simultaneously by placing them at 34°C. At the times indicated, receptor-bound virus 
remaining at the cell surface was quantified in a cell based ELISA type assay (performed on 
ice), using mAb 8F5 followed by HRP-conjugated secondary antibody. The kinetics of virus 
internalization was found to be identical in the two transfected cell lines, as shown in Fig. 29. 
The same experiment was carried out with 100, 50 and 10 TCID50/cell of input virus, with 
essentially the same results. 
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Figure 29. Internalization of HRV2 follows the same kinetics in CHO cells expressing wt and β-propeller 
deficient LDLR. CHO ldla7 cells expressing wt and β-propeller negative LDLR, respectively, were grown to 
confluency and challenged with HRV2 at 100 TCID50/cell for 1 h at 4°C. Non-attached virus was removed and 
ice cold infection medium was added onto the cells. All samples were placed simultaneously at 34°C to start 
virus internalization. At the times indicated receptor-bound virus remaining at the cell surface was quantified by 
a cell based ELISA (performed on ice). Surface exposed virus at time 0 (i.e. prior to warming up) was set to   
100 %. The y-axis was inverted for depiction of the percentage of virus internalization. Error bars show standard 
deviation (n=3). 
 
 
5.6. Conversion of HRV2 to subviral particles is delayed when 
internalized via β-propeller deficient LDLR 
  
We then asked whether the stronger virus-stabilizing effect of the β-propeller negative 
receptor (as revealed for virus bound to the plasma membrane) can also be observed during 
infection. Radiolabeled HRV2 was attached to the cells at 4oC for 1 h, unbound virus was 
washed away with cold HBBS, and the cells were incubated in 1 ml infection medium at 34oC 
to allow for virus internalization and uncoating. At various time points the cells were lysed 
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without removing the incubation medium, by adding 200 µl of 6x RIPA buffer. Sequential 
immunoprecipitation with mAb 2G2 and anti-HRV2 antiserum was carried out as described 
above, and radioactivity in the pellets was determined by scintillation counting. As seen in  
Fig. 30, a clear delay in virus conversion could be measured when the virus was internalized 
by the truncated receptor. This corresponds well with the virus protection effect observed in 
the experiments with plasma-membrane bound HRV2. 
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Figure 30. Endosomal virus conversion is delayed in CHO cells expressing β-propeller negative LDLR. 
Radiolabeled HRV2 was attached to cells grown in 6-well plates at 4oC for 1 h. After removal of unbound virus 
the cells were incubated in 1 ml infection medium at 34oC to allow for virus internalization and uncoating. At the 
time points indicated, the cells were lysed without removing the incubation medium. Converted virus was 
immunoprecipitated with mAb 2G2, and remaining native virus with anti-HRV2 antiserum. Ratios of 2G2 
precipitated counts over all counts were calculated, native virus present at time 0 was set to 100 %. The y-axis 
was inverted for depiction to show the percentage of conversion. Error bars show standard deviation (n=3). 
 
 
5.7. Dissociation of HRV2 from β-propeller deficient LDLR is 
delayed within endosomes 
 
To assess whether wild type and mutant LDLR also exhibit distinct properties with respect to 
receptor-ligand dissociation, the time dependent co-localization of HRV2 and LDLR was 
determined by confocal immunofluorescence microscopy in collaboration with the group of 
Prof. Fuchs (Medical University of Vienna). HRV2 was bound at 4oC to the plasma 
membrane of CHO cells expressing wt or β-propeller negative LDLR that had been grown on 
coverslips. Virus entry was initiated by adding warm medium, and cells were further 
incubated at 34°C to allow for infection. At the times indicated in Fig. 31. cells were fixed, 
permeabilized, and LDLR and HRV2 were detected by specific antibodies followed by Alexa 
488-conjugated goat anti-mouse IgG and Alexa 568-conjugated goat anti-chicken IgG, 
 75
respectively. The percentage of co-localization was calculated from immunofluorescence 
microscopy images, and showed a decrease over time in both cell lines. However, virus 
dissociation from the β-propeller negative receptor was clearly delayed and reduced. This 
again agrees well with the increased virus protecting effect observed for the truncated receptor. 
Apparently, the propeller negative receptor keeps the virus bound in its native state up to later 
time points of the infection.  
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Figure 31. HRV2 dissociation from LDLR is delayed when the β-propeller is deleted. HRV2 was bound at 
4oC to CHO cells grown on coverslips and entry was initiated by adding warm medium. At the times indicated, 
cells were fixed, permeabilized, and LDLR and HRV2 were detected by specific antibodies, followed by     
Alexa 488-conjugated goat anti-mouse IgG and Alexa 568-conjugated goat anti-chicken IgG, respectively.                  
(A) Representative fluorescent images of one focal plane through the perinuclear region are shown after HRV2 
binding (0 min) and 60 min after warming to 34°C. LDLR, green; HRV2, red. Bar: 2 µm. (B) The percent co-
localization of virus and receptor was calculated from immunofluorescence microscopy images as in panel A. 
Co-localization at time zero was set to 100 %. Error bars show standard deviation (n=3).  
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5.8. Cellular protein synthesis is identical in the CHO cell lines 
expressing wt and truncated LDLR  
 
Prior to performing infection kinetics experiments we compared the rate of cellular       
protein synthesis in the two transfected cell lines via incorporation of [35S]-labeled 
cysteine/methionine. Cells were grown in 6-well plates until being subconfluent. The  
medium was replaced with infection medium lacking methionine/cysteine and incubation  
was continued for 4 h. Then, the medium was replaced with fresh infection medium   
supplemented with 40 µCi of [35S]-methionine/cysteine. At the times indicated cells          
were extensively washed and radioactivity incorporated into cellular proteins was   
determined by TCA-precipitation followed by scintillation counting. Fig. 32 shows that       
the protein synthesis rates were identical in both cell lines. This excludes that eventually 
observed differences in virus growth were due to differences in the metabolic activity of the 
two cell lines. 
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Figure 32. Protein synthesis rates are indistinguishable in CHO cells expressing wt and ß-propeller 
deficient LDLR. Subconfluent cells in 6-well plates were pre-incubated with infection medium lacking 
methionine/cysteine for 4 h. After incubation in fresh infection medium supplemented with 40 µCi of           
[35S]-methionine/cysteine cells were extensively washed and radioactivity incorporated into cellular proteins  
was determined by TCA precipitation. Error bars show standard deviation (n=3). 
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5.9. HRV2 internalized via β-propeller deficient LDLR shows a 
delay in infection  
 
Minor group rhinoviruses take advantage of the low endosomal pH for RNA release. Since 
the endosomal pathway terminates with lysosomal digestion of the endocytosed material, 
productive RNA release must happen within a defined time window. Due to the higher   
virus-stabilizing effect of the β-propeller deficient LDLR as compared to wt LDLR, the delay 
in virus conversion might limit the time for productive RNA release. In order to assess 
whether this is indeed the case, we compared the infection kinetics in the two CHO cell lines. 
 
HRVs fail to replicate in non-human cells, complicating infection experiments in CHO cell 
lines. However, adaptation of HRV2 to mouse L cells has been reported (Yin and Lomax, 
1983). The replicating virus variants showed mutations within non-structural proteins. We 
thus attempted the adaptation of HRV2 to grow in CHO cells by blind passages alternating 
between HeLa and CHO cells expressing human wt LDLR. After 12 such passages HRV2 
variants, termed HRV2CHO appeared that replicated in both CHO cell lines. Figure 33 shows 
the corresponding infection kinetics.  
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Figure 33. Infection kinetics of HRV2CHO in CHO cell lines expressing wt and truncated human LDLR. 
Cells seeded in 6-well plates were challenged with HRV2CHO at 10 TCID50/cell at 4°C for 1 h. After removal of 
non-bound virus the cells were incubated at 34°C in 2 ml infection medium. At the times indicated, cells were 
broken by three cycles of freezing/thawing and virus titre was determined. Error bars show standard deviation 
(n=3). 
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There is a clear decrease in virus titre up to about 8 hours post infection, indicating uncoating 
of the internalized virus particles. From about 9 h onwards de novo viral synthesis is evident 
with the titre attaining a plateau after about 30 h. The most obvious difference between the 
two cell lines is manifested between 12 and 26 h; the cells expressing the wt receptor 
produced up to 6 times more virus at 16 h p.i. with a difference of about 5 h in reaching the 
plateau. 
 
 
5.10. The ΔYC LDLR mutant is directed into lysosomes when 
internalizing HRV2  
 
Deletion of the entire EGFP-homology domain of LDLR (ΔEGFP) inhibits the dissociation of 
bound LDL, impairs receptor recycling, and results in lysosomal degradation of the    
receptor-ligand complex (Davis et al., 1987a). Since the β-propeller is involved in the 
conformational changes of LDLR triggered at low pH (Beglova et al., 2004a; Rudenko et al., 
2002), the same must be true also for the ΔYC deletion that was used in our experiments. 
However, contrarily to LDL, HRV2 is a low pH sensitive ligand, suffering conversion at pH 
~5.8, a value encountered during passage through the endosomal pathway. Conformational 
changes of both the virus and the receptor should result in virus dissociation at a certain time 
during infection, regardless of the kind of receptor (wt or propeller-negative). In order to 
study whether this dissociation happens in time to allow for effective receptor recycling 
(LDLRs recycle from early endosomes) or too late for the receptor to be directed into the 
recycling pathway, fluorescence microscopy was employed to detect the extent of LDLR    
co-localization with the lysosomal marker LAMP2 (in collaboration with the group of Prof. 
Fuchs, Medical University of Vienna). 
 
CHO cells expressing wt or β-propeller negative LDLR were grown on coverslips and       
pre-incubated for 30 min in serum-free medium. HRV2 at 1,500 TCID50/cell in serum-free 
medium was added and internalized for 6 h at 34oC (continuous internalization). The cells 
were cooled on ice, washed, fixed and permeabilized with methanol, washed, and incubated 
with monoclonal mouse anti-human LAMP-2 antibody (1:400), followed by Alexa-568 
conjugated goat anti-mouse IgG. To visualize LDL-receptors, the cells were incubated with 
chicken anti-human LDLR IgY, followed by Alexa-488-conjugated goat anti-chicken IgG. 
Nuclei were stained blue with Hoechst dye (for epifluorescence) and Draqe5 (for confocal 
microscopy). As control mock infected cells incubated under the same conditions were used.  
 
Internalization of HRV2 into RF3 cells had no significant influence on the total fluorescence 
and thus expression of wild-type LDLR (Fig. 34A, upper panels). Furthermore, little           
co-localization of LDLR with the lysosomal marker LAMP2 was seen both in the absence and 
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in the presence of HRV2 (Fig. 34B, upper panels). In contrast, in ΔYC cells HRV2 uptake 
resulted in a decrease of mutant LDLR fluorescence levels mainly at the plasma membrane 
(arrows) but not in the perinuclear area (Fig. 34A, lower panels, arrow heads). The decrease in 
plasma membrane expression of mutant receptors appears to be due to their lysosomal 
degradation, as deduced from the higher extent of co-localization of receptors with LAMP2 
(Fig. 34B, lower panels). This means that virus conversion occurs too late for the β-propeller 
negative LDL-receptors to catch the recycling pathway. 
 
                             
 
Figure 34. Continuous HRV2 internalization leads to degradation of mutant but not wild-type LDLR. 
CHO RF3 cells (expressing wt LDLR) and ΔYC cells (expressing β-propeller negative LDLR) were               
pre-incubated in serum-free Ham’s F12 medium, and HRV2 at 1500 TCID50/cell in serum-free medium          
was internalized for 6 h. Cells were then cooled, washed and processed for indirect immunofluorescence 
microscopy for detection of LDLR (green) and LAMP2 (red). Nuclei were stained blue with Hoechst dye (for 
epifluorescence) and Draqe5 (for confocal microscopy). (A) Conventional epifluorescence. All images were 
taken with the same exposure time in the respective channel and identical settings were used for illustration with 
the Axiovison software. Overlay images are shown. Arrow heads indicate perinuclear and arrows indicate 
plasma membrane localization of LDLR. (B) Confocal images were taken by using the same laser power and 
exposure time in the respective channel. Multicolour images shown were obtained with identical grey level 
settings in each channel. Out of 20 sections through the cells, the focal plane through the nucleus is depicted.  
Bar: 2 µm. 
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5.11. Capsid degradation of HRV2 is delayed in cells expressing 
propeller negative LDLR  
 
As demonstrated above, the absence of the β-propeller leads to a delay in virus, uncoating and 
bound virus directs the truncated LDL-receptors to lysosomes for degradation. We thus asked 
whether virus degradation also differs in the two CHO cell lines. The experiment was carried 
out exactly as the uncoating assay (see section 5.6.), but longer incubation time was needed to 
detect viral degradation. Upon digestion the viral capsid loses epitopes recognized by the 
type-specific antiserum, therefore, we took the loss of immunoprecipitable material as a 
measure for capsid degradation. The data in Fig. 35 show that viral capsid degradation was 
delayed and substantially reduced in the cells expressing the truncated receptor.  
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Figure 35. Virus degradation is delayed and reduced in CHO cells expressing β-propeller negative LDLR.  
Radiolabeled HRV2 was attached to the cells at 4oC for 1 h, unbound virus was washed away, and the cells were 
incubated in infection medium at 34oC to allow for virus internalization and uncoating. At the times indicated the 
cells were lysed. Remaining virus and viral protein fragments recognized by the HRV2 antiserum were 
immunoprecipitated and scintillation counted. Radioactivity precipitated at time 0 (corresponding intact virus) 
was set to 100 %, and the y-axis was inverted for depiction to show the percentage of degradation. Error bars 
show standard deviation (n=3). 
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6. Discussion 
 
6.1. Function of the LDLR β-propeller in HRV2 infection 
 
Minor group HRVs enter cells via clathrin-dependent endocytosis (Snyers et al., 2003) upon 
attaching to members of the LDLR superfamily including LDLR, VLDLR, and LDLR-related 
protein (LRP) (Hofer et al., 1994; Marlovits et al., 1998b; Marlovits et al., 1998d). The 
internalized virus then travels through the compartments of the endosomal route (early 
endosomes, endocytic carrier vesicles, late endosomes, lysosomes) and due to the activity of 
the vacuolar H+-ATPase (V-ATPase) (Nishi and Forgac, 2002) experiences a continuously 
decreasing pH. A pH ≤ 5.6 attained in endocytic carrier vesicles and/or late endosomes 
triggers structural changes of the virion, which allow for its membrane-association via 
externalized VP1 N-terminal amphipathic helices. Concomitantly, the internal VP4 capsid 
proteins are released from the capsid (Hewat et al., 2002) and are believed to form pores in 
the endosomal membrane, which allow for RNA release as explicitly shown for HRV2 
(Brabec et al., 2005; Fuchs and Blaas, 2008; Prchla et al., 1995; Schober et al., 1998). As 
structural changes of the virion and infection of HeLa cells can be brought about by the low 
endosomal pH alone when using a surrogate receptor (Baravalle et al., 2004), it was believed 
that the function of LDLR was limited to virus delivery.  
 
However, LDL-receptors do not behave as passive vehicles when internalizing their natural 
ligands such as lipoproteins; their β-propeller domains (at least in cases of LDLR and VLDLR) 
were shown to actively participate in low pH induced ligand release (Beglova and Blacklow, 
2005; Beglova et al., 2004a; Mikhailenko et al., 1999). Therefore, we decided to investigate 
whether the β-propeller also plays a role in minor group rhinovirus infection. We used    
CHO-ldla7 cells deficient in endogenous LDLR (Krieger et al., 1981) that had been stably 
transfected to express either wild-type or β-propeller negative human LDLR (Beglova et al., 
2004a). Untransfected ldla7 cells did not show significant virus binding under our conditions, 
which allowed for the investigation of the propeller function in a single-receptor system.  
 
The endosomal fate of internalized virus can be modeled at the plasma membrane under 
conditions when endocytosis is blocked (working at 4°C), by incubation of receptor-bound 
virus in acidic incubation buffers (Brabec et al., 2003). This experiment helps to investigate 
the influence of receptor-virus interactions on the efficiency of infection, dissecting these 
early events from later steps of the infection cycle. Clearly, this model experiment cannot 
completely mimic the situation within the endosomal lumen such as membrane curvature, 
kinetics of pH changes, volume ratio, and buffering capacity of intraendosomal and cytosolic 
spaces, therefore, one has to be careful when extrapolating the results to natural infections. 
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Nevertheless, when the conditions are well defined, such an experiment helps to elucidate 
distinct steps of the receptor-virus interaction during infection.  
  
 
6.2. Low pH itself is not enough to trigger RNA release from 
membrane-attached HRV2 A-particles 
  
Brabec and colleagues using HeLa cells for virus binding and acetate-phosphate buffers for 
low pH incubation observed substantial release of cell-bound HRV2 upon incubation at pH 6. 
This could not be reproduced with our CHO cells and MES buffers even at lower pH values; 
rather, re-neutralization of the incubation buffers was required for virus being shed into the 
supernatant. Furthermore, the vast majority (80-100 %) of the released particles were in their 
converted state regardless of the pH of acid-treatment. It thus appears that in our case the 
virus either remained receptor-bound in its native state (at pH values > 5.6) or it was directly 
transferred to the membrane upon its conversion (at pH values, < 5.6).  
 
There are more possible reasons for the observed differences. One could be our choice to 
avoid phosphate-containing buffers for low pH incubation. It cannot be excluded that the 
interaction between virus and receptor was weakened via calcium depletion by the phosphate 
content of their buffer which could have caused a partial unfolding of the LA repeats     
(Arias-Moreno et al., 2008). This most probably did not happen with our MES buffers. An 
additional difference is that CHO cells express LDLR at much higher levels than HeLa cells. 
This might led to different virus-receptor stoichiometries of cell-bond virus, as much higher 
amounts of input virus was necessary for HeLa cells to achieve measurable levels of binding. 
It is possible that on average the virus particles were simultaneously docked by more receptor 
molecules with a higher binding strength on CHO cells than on HeLa cells. A further reason 
why the two systems cannot be directly compared is that HeLa cells express also VLDLR and 
LRP which might behave different from LDLR in binding and releasing HRV2. 
 
Based on the present knowledge on HRV uncoating, the only way for the membrane-attached 
hydrophobic A-particles to become hydrophilic B-particles and dissociate from the membrane 
would be RNA release (Korant et al., 1972; Lonberg Holm et al., 1976). Our results thus 
strongly suggest that the low pH induces virus conversion only up to the A-particle form and 
RNA release needs an additional trigger. Whether it is indeed a re-neutralization step (which 
could come from the cytosol through virally opened pores) or another unknown factor which 
was induced by re-neutralization in our model conditions, needs to be further investigated. 
Since RNA release is a quick process and the short lived A-particle is difficult to investigate, 
there is only a little knowledge about this mechanism, based on differences in the 3D 
structures between native and empty capsids (Fuchs and Blaas, 2008; Hewat et al., 2002; 
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Hewat and Blaas, 2004). It also cannot be excluded with certainty that further, still unknown 
intermediates exist.  
 
 
6.3. LDLR binding stabilizes HRV2 against low pH-induced 
conversion 
 
The virus conversion follows a sigmoid curve with arbitrarily set end points of 0 % at pH 7 
and 100 % at pH 5. The transition range for HRV2 is between pH 5.4 and 6.0. During 
infection there is a limited time window for effective RNA release into the cytoplasm of the 
host cell, which starts with capsid conversion and ends with enzymatic digestion and 
inactivation of the virion within lysosomes. In order to clarify whether the function of the 
LDLR β-propeller is important in minor group rhinovirus infection, we first compared the  
pH-dependence of HRV2 conversion bound either to wild type or β-propeller negative          
LDL-receptor. 
 
The results clearly showed that virus bound to propeller deficient LDLR needed lower pH 
values for conversion into subviral particles than virus bound to wt receptor. This indicates 
that the β-propeller domain plays an important role in infection, via weakening the interaction 
between the virus and the ligand binding domain of the receptor. This also indicates that the 
native conformation of the virus is stabilized by the bound receptor. A similar effect has been 
already shown for a recombinant minireceptor composed of 5 copies of the third ligand 
binding repeat of VLDL-receptor (V33333) (Nicodemou et al., 2005). This concatemer 
exhibits much higher avidity for HRV2 as compared to LDLR and consequently might also 
exert a much stronger effect. In this work we could show that even the LDLR binds with 
sufficiently high avidity to protect HRV2 against conversion but this effect is naturally 
repressed by the function of the β-propeller. These results demonstrate that LDLR is indeed 
not just a simple vehicle transporting the virus into endosomes but it actively takes part in the 
uncoating process by tuning virus conversion; it balances high avidity binding against an 
intrinsic ligand-release function.  
 
 
6.4. Is HRV2 released from LDLR in its native or converted state? 
 
Within acidifying endosomes more factors can induce virus dissociation from the LDLR such 
as virus conversion, conformational change of the receptor, and maybe even LA-repeat 
unfolding due to the decrease of endosomal Ca2+ concentration. The virus might be released 
from LDLR either in its native form (and it converts subsequently in the fluid phase of the 
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endosome) or it might leave the receptor upon its conversion (then it is concomitantly handed 
over to the endosomal membrane). The latter case would result in higher infection efficiency.  
 
The decreasing pH and the β-propeller act in concert and weaken the strength of virus-
receptor binding. The various types of minor group HRVs show differences in their pH 
sensitivity (Khan et al., 2007) and most probably also in their binding avidity to LDLR. The 
higher is the pH stability of the virus, the longer the virus-receptor binding is maintained at 
decreasing pH passing through the endo-lysosomal pathway. Also, the higher is the binding 
avidity, the longer the virus remains receptor-bound and stabilized against conversion. As we 
have shown, high pH stability or too big stabilization effect by the receptor delays virus 
conversion and decreases the time window for effective RNA release. 
 
Our data demonstrated that HRV2 was released from LDLR upon its conversion. However, 
generalization of our result for all minor group HRVs is not possible, since each virus type 
might have a different combination of pH sensitivity and binding avidity to LDLR. It is 
possible that minor group HRV types also exist with high pH stability and low receptor 
binding avidity which could be released from LDLR by the activity of the β-propeller still in 
their native state. In the case of HRV2 the decreasing pH and the β-propeller finally abrogated 
the virus-receptor binding but virus release happened only at a pH value which has already 
caused virus conversion as well.  
 
 
6.5. The β-propeller accelerates the release of HRV2 from LDLR, 
which is essential for receptor recycling  
 
Deletion of the entire EGFP-homology domain (ΔEGFP) of LDLR inhibits the dissociation of 
bound LDL. As ligand release is essential for LDLR recycling, the receptor-ligand complex is 
fated for lysosomal degradation (Davis et al., 1987a; Hobbs et al., 1992; Miyake et al., 1989). 
The X-ray structure of LDLR at acidic pH (Rudenko et al., 2002) confirmed that the function 
of the β-propeller domain is responsible for the low pH-associated conformational changes. 
Therefore, there is a strong reason to believe that the ΔYC mutant lacking both the propeller 
and the third EGF-homology domain (used in our experiments) behaves identically with 
respect to ligand release and receptor recycling as the ΔEGFP mutant of Davis and colleagues. 
In contrast to LDL, HRV2 is able to leave the β-propeller deficient receptor due to its low pH 
induced conversion. LDLR normally recycles from early endosomes (Maxfield and McGraw, 
2004) but when virus remains bound due to the propeller deletion, recycling might be 
impaired. We thus asked whether HRV2 leaves the mutant receptor early enough to allow for 
efficient receptor recycling. Co-localization of LDLR with the lysosomal marker LAMP2 
revealed that similarly to the natural ligands, HRV2 directs β-propeller deficient LDLR into 
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the degradative pathway. This indicates that the virus remains bound to the ΔYC-LDLR until 
bifurcation towards receptor recycling is no more possible.  
 
 
6.6. Viral capsid degradation is delayed in cells expressing 
propeller negative LDLR 
 
The propeller deficient LDLR is not able to release bound LDL and consequently the whole 
complex is degraded. Hijacking the endosomal route, HRV is anyhow destined for 
degradation; therefore it is extremely important to release its RNA into the cytoplasm before 
hydrolytic enzymes harm the capsid making it incompetent for RNA release. The β-propeller 
domain influencing virus conversion raised the question whether its deletion also affects virus 
degradation.  
 
Our results showed that capsid degradation was delayed and substantially reduced when the 
propeller was deleted from the LDLR. This cannot be explained by increased recycling of 
virus-receptor complexes, since the truncated receptors are rather directed to lysosomes by the 
bound virus. We know that the virus leaves the mutant receptor at a time already late for 
receptor recycling, which suggests that virus conversion occurs either in endosomal carrier 
vesicles or late endosomes. This leads to a reduced time-window for the penetration of viral 
RNA into the cytosol, which starts later, at lower pH, and shortly before the degradative 
inactivation of the virus. Despite lysosomes are considered to be responsible for virus 
degradation, there are studies indicating that proteolytic digestion already starts in late 
endosomes (Pillay et al., 2002; Tjelle et al., 1996). Thus, the delayed virus conversion caused 
by the mutant receptor might have increased the amount of virus particles becoming 
inactivated before RNA release. The A-particle that fails to release its RNA remains 
membrane-associated, and might even more withstand enzymatic digestion, being protected 
by the membrane which wraps tightly around it. This could have been a possible reason for 
the observed delay in viral capsid degradation. Additionally, a part of the membrane-
associated viral particles might have escaped from the lysosomal route, being associated with 
vesicles budding from late endosomes which communicate with the trans-Golgi network 
(Maxfield and McGraw, 2004). These assumptions still need to be verified. 
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6.7. The role of LDLR in minor group rhinovirus infection 
 
The infection efficiency of minor group HRVs depends on complex molecular mechanisms 
composed of several interconnected factors, such as the time window available for effective 
RNA release, the correct orientation of viral RNA release (into the cytoplasm versus the inner 
space of multivesicular endosomes), the compatibility of viral replication with the molecular 
mechanisms of the infected cell, success in evading host defence mechanisms, etc. 
 
The time window available for RNA release of minor group rhinoviruses is defined by the 
relation of viral pH sensitivity and virus-receptor binding avidity. Both factors depend on the 
capsid properties of the particular virus type. Thus, the balance between the optimal   
receptor-virus interaction and infection efficiency is an important factor driving viral 
evolution. 
 
The main result of our studies was the clear proof that the LDLR is not just a simple vehicle 
for delivery of minor group rhinoviruses into endosomes. This receptor rather actively 
contributes to the efficiency of infection. The virus is endowed with the capacity for high-
avidity multi-module binding that combines with an intrinsic ligand release mechanism of the 
receptor. High-avidity binding allows for infection at low virus concentrations, which is often 
the case in natural infections. However, as we have demonstrated, too strong receptor binding 
decreases infection efficiency by maintaining the virus in its native conformation and 
reducing the time window for effective RNA release. Altogether, using LDLR, which 
integrates high avidity binding with an intrinsic ligand release mechanism, is a better choice 
for the virus as using a receptor with a simply lower binding avidity.  
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7. Appendix 
 
7.1. Abbreviations 
 
 
 
μg   microgram 
μl   microliter 
°C   Celcius centigrade 
3D                    3 dimensional 
Å                      Angstöm 
ADAR             adenosine deaminase 
AOM               acute otitis media 
AP    alkaline phosphatase 
apoB-100        apolipoprotein B-100 
apoE                apolipoprotein E  
ApoER2           apolipoprotein E receptor 2 
APS                 ammonium persulfate 
ATP                 adenosine triphosphate       
bp   base pairs 
BSA   bovine serum albumin 
CAR                coxackie-adenovirus receptor 
CD-54             cluster of differentiation 54, identical molecule with ICAM-1  
cDNA             complementary desoxiribonucleic acid 
CHO-cell        Chinese hamster ovary cell 
CHO-ldla7     mutant of CHO cell lacking functional LDL-receptor 
COPD             chronic obstructive pulmonary disease 
CPE   cytopathic effect  
cpm   radioactive counts per minute 
C-terminus      carboxy-terminus of a peptide/protein 
D                      Dalton 
ddH2O             double distilled water 
DAF                 decay accelerating factor 
DMEM  Dulbecco’s modified essential medium 
DMSO             dimethyl sulfoxide 
DNA   desoxyribonucleic acid 
dsRNA            double stranded ribonucleic acid 
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DTT   dithiothreitol 
EDTA   ethylenediamine tetraacetate 
EGF                 epidermal growth factor 
EGFP               epidermal growth factor precursor 
eIF2α               eukaryotic translation initiation factor 2α 
eIF4G              eukaryotic translation initiation factor 4G 
ELISA            enzyme-linked immunosorbent assay 
EM                  electron microscopy 
ENA                epithelial neutrophil-activating protein 
ER                  endoplasmatic reticulum 
FACS    fluorescence activated cell sorter 
FCS                fetal calf serum 
FDA               Food and Drug Administration 
FH                  familial hypercholesterolaemia 
G418              geneticin  
GM-CSF        granulocyte macrophage-colony stimulating factor 
gp330             glycoprotein 330 
GPI                glycosylphosphatidylinositol 
Gro                 growth-regulated oncogene 
h                     hour 
HBBS             Hank’s balanced buffer solution 
HDL               high-density lipoprotein 
HRV   human rhinovirus 
HRV2CHO            human rhinovirus adapted to replicate in CHO cells 
HS                   horse serum 
HSPG             heparane sulfate proteoglycan 
ICAM-1  intercellular adhesion molecule 1 
IDL                 intermediate density lipoprotein 
IFN                 interferon 
Ig                    immunoglobulin 
IL                    interleukin 
IRES   internal ribosomal entry site  
JAK-STAT       Janus kinase - Signal Transducers and Activators of          
                                    Transcription
kb   kilobase 
kD              kilodalton 
LAMP             lysosome associated membrane protein 
LA-repeat        LDL receptor type A repeat 
LDL   low-density lipoprotein  
LDLR   low-density lipoprotein receptor 
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LFA                 lymphocyte function associated antigen 
Lp                   lipoprotein 
LRP   LDL-receptor related protein 
MAb   monoclonal antibody 
MAb-2G2        monoclonal antibody 2G2 
Mac–1             macrophage–1 antigen 
MBP                maltose binding protein 
mCi                  milliCurie 
MEGF7            multiple epidermal growth factor containing protein 7 
MEM               minimal essential medium 
MES                morpholinoethanesulphonic acid 
mg   milligram 
min   minute 
MIP                 macrophage inflammatory protein 
ml   milliliter 
MOI   multiplicity of infection 
mRNA  messenger RNA 
ng   nanogram 
nm   nanometer 
NMR               nuclear magnetic resonance 
NPVY              peptide motif with asparagine-proline-valine-tyrosine 
NPxY               peptide motif with asparagine-proline-any aminoacid-tyrosine  
N-terminus       amino-terminus of a peptide/protein 
OAS                 oligoadenylate synthetase 
ORF                 open reading frame 
P1, P2, P3        regions of the viral polyprotein 
PAA    polyacrylamide 
PAGE   polyacrylamide gel electrophoresis 
PAI-1               plasminogen activator inhibitor type-1 
PBS    phosphate buffered saline 
PDB                 protein database 
PFA                 paraformaldehyde 
pH                    negative logarithm of the H-ion concentration 
pKa                         negative logarithm of the acid dissociation constant 
PKR                 protein kinase R 
PVR                 poliovirus receptor 
RANTES         regulated upon activation, normal T-cell expressed and secreted 
RAP                 receptor associated protein 
RF3 cells          CHO-ldla7 cells expressing human wt LDLR 
RIPA                radio-immunoprecipitation assay 
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RNA   ribonucleic acid 
RNAi               ribonucleic acid interference 
RNAse L          endoribonuclease L 
ROI                  reactive oxygen intermediate 
rpm   revolutions per minute 
s   seconds 
S   Svedberg constant 
S. aureus          Staphylococcus aureus 
SDS   sodium dodecyl sulphate 
SDS-PAGE      sodium dodecyl sulphate polyacrylamide gel electrophoresis 
siRNA              silencing ribonucleic acid 
ssRNA             single stranded ribonucleic acid 
TCA                 trichloroacetic acid 
TCID50             tissue culture infectious dose 50  
TEMED          tetramethylethylenediamine  
TNF                 tumor necrosis factor 
TLR3               Toll-like receptor 3 
tPA                  tissue-type plasminogen activator 
U/ml               enzymatic unit / milliliter 
uPA                 urokinase plasminogen activator 
UTR                untranslated region 
V repeats         ligand binding repeats of VLDL-receptor 
V33333           concatemeric pentamer of module 3 of VLDLR 
VLDL             very low-density lipoprotein 
VLDLR           very low-density lipoprotein receptor 
VP   viral protein 
VPg   viral protein genome-linked 
WIN                 name of an antiviral compound  
X-ray               Röntgen radiation 
YWTD            peptide motif with tyrosine-tryptophane-threonine-asparagine  
β-VLDL           β-migrating forms of very low-density lipoprotein 
ΔAB-LDLR     LDLR with deleted EGF-AB domain pair  
ΔEGFP-LDLR LDLR with deleted EGFP homology domain  
ΔYC-LDLR    LDLR with deleted YWTD β-propeller and EGF-C domains  
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7.2. Taxonomy of picornaviruses 
 
The data are taken from www.picornaviridae.com
 
The family Picornaviridae belongs to the order Picornavirales and consists of 8 genera: Enterovirus, 
Cardiovirus, Aphthovirus, Hepatovirus, Parechovirus, Erbovirus, Kobuvirus and Teschovirus, plus three 
proposed genera named "Sapelovirus", "Senecavirus" and "Tremovirus". The two human rhinovirus species 
have been moved to the genus Enterovirus; the genus Rhinovirus no longer exists. 
 
The genus Enterovirus consists of 10 species: Human enterovirus A, Human enterovirus B, Human 
enterovirus C, Human enterovirus D, Simian enterovirus A, Bovine enterovirus, Porcine enterovirus A, 
Porcine enterovirus B, Human rhinovirus A and Human rhinovirus B. 
 
The species Human enterovirus A consists of 21 serotypes: coxsackievirus A2 (CV-A2), CV-A3, CV-A4, CV-
A5, CV-A6, CV-A7, CV-A8, CV-A10, CV-A12, CV-A14, CV-A16, enterovirus 71 (EV-71), EV-76, EV-89, 
EV-90, EV-91 and the simian enteroviruses EV-92, SV19, SV43, SV46 and A13. 
 
The species Human enterovirus B consists of 59 serotypes: coxsackievirus B1 (CV-B1), CV-B2, CV-B3, CV-
B4, CV-B5 (incl. swine vesicular disease virus [SVDV]), CV-B6, CV-A9, echovirus 1 (E-1; incl. E-8), E-2, E-3, 
E-4, E-5, E-6, E-7, E-9 (incl. CV-A23), E-11, E-12, E-13, E-14, E-15, E-16, E-17, E-18, E-19, E-20, E-21, E-24, 
E-25, E-26, E-27, E-29, E-30, E-31, E-32, E-33, enterovirus 69 (EV-69), EV-73, EV-74, EV-75, EV-77, EV-78, 
EV-79, EV-80, EV-81, EV-82, EV-83, EV-84, EV-85, EV-86, EV-87, EV-88, EV-93, EV-97, EV-98, EV-100, 
EV-101, EV-106, EV-107 and the simian enterovirus SA5. 
 
The species Human enterovirus C consists of 18 serotypes: poliovirus (PV) 1, PV-2, PV-3, coxsackievirus A1 
(CV-A1), CV-A11, CV-A13, CV-A17, CV-A19, CV-A20, CV-A21, CV-A22, CV-A24, EV-95, EV-96, EV-99, 
EV-102, EV-104 and EV-105. Human enterovirus C is the type species of the genus Enterovirus.  
 
The species Human enterovirus D consists of three serotypes, EV-68, EV-70 & EV-94. Human rhinovirus 
(HRV) 87 has been reclassified as a strain of EV-68. 
 
The species Simian enterovirus A consists of three simian viruses isolated during the 1950's (SV4, SV28 and 
SA4) and A-2 plaque virus. The close molecular relationships of all four viruses suggests that they all belong to 
a single serotype, simian enterovirus A1 (SEV-A1). 
 
The species Bovine enterovirus consists of at least two serotypes: bovine enterovirus (BEV) 1 and BEV-2. 
However, it has recently been proposed that the bovine enteroviruses should be divided into two distinct species, 
each containing a number of types (Knowles, 2005; Zell et al., 2006). 
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The species Porcine enterovirus B (PEV-B) consists of a two serotypes: porcine enterovirus 9 (PEV-9) and 
PEV-10. Serotypes 1 to 7 and 11 to 13 have been reclassified and assigned to a new genus, Teschovirus. 
 
The species Human rhinovirus A consists of the following 74 serotypes: HRV-1, 2, 7, 8, 9, 10, 11, 12, 13, 15, 
16, 18, 19, 20, 21, 22, 23, 24, 25, 28, 29, 30, 31, 32, 33, 34, 36, 38, 39, 40, 41, 43, 44, 45, 46, 47, 49, 50, 51, 53, 
54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 71, 73, 74, 75, 76, 77, 78, 80, 81, 82, 85, 88, 89, 90, 94, 
95, 96, 98 and 100. 
The recently reported candidate new HRV serotype, Hanks2102, is a HRV-21 by VP1 sequencing. 
The species Human rhinovirus B consists of the following 25 serotypes: HRV-3, 4, 5, 6, 14, 17, 26, 27, 35, 37, 
42, 48, 52, 69, 70, 72, 79, 83, 84, 86, 91, 92, 93, 97 and 99. 
 
The genus Cardiovirus consists two species, Encephalomyocarditis virus and Theilovirus. EMCV is 
represented by a single serotype of the same name while the theiloviruses are comprised of Theiler's murine 
encephalomyelitis virus (TMEV), Vilyuisk human encephalomyelitis virus (VHEV), Thera virus (TRV;  isolated 
from rats), Saffold virus (SAFV; isolated from humans) 1-8. The cardioviruses are most closely related to 
members of the genera Senecavirus, Aphthovirus and Erbovirus and to the recently recognised cosaviruses. 
 
The genus Aphthovirus consists of two species, Foot-and-mouth disease virus and Equine rhinitis A virus. 
Recent nucleotide sequence data has shown that bovine rhinoviruses (three serotypes previously classified as 
tentative members of the now defunct genus Rhinovirus) should be re-classified in the genus Aphthovirus. 
 
The genus Hepatovirus consists of two species, Hepatitis A virus and (the as yet unnamed) "Avian 
encephalomyelitis-like viruses". The later is a tentative member of the genus. A proposal is currently being 
considered by the ICTV to formally name "Avian encephalomyelitis-like viruses" as "Avian 
encephalomyelitis virus" and to place it in a new genus with the provisional name "Tremovirus". 
 
The genus Parechovirus is comprised of two species, Human parechovirus and Ljungan virus.  
 
Erbovirus, a genus within the family Picornaviridae containing a single species, Equine rhinitis B virus 
(ERBV) with two serotypes, ERBV-1 and ERBV-2. These two viruses were formerly known as equine 
rhinovirus 2 and equine rhinovirus 3, respectively. 
 
The genus Kobuvirus consists of two species, Aichi virus and Bovine kobuvirus. A third candidate species has 
recently been described in pigs (Porcine kobuvirus). 
 
The genus Teschovirus consists of a single species, Porcine teschovirus. 
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Low pH-Triggered Beta-Propeller Switch of the Low-Density
Lipoprotein Receptor Assists Rhinovirus Infection
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Minor group human rhinoviruses (HRVs) bind three members of the low-density lipoprotein receptor
(LDLR) family: LDLR proper, very-LDLR (VLDLR) and LDLR-related protein (LRP). Whereas ICAM-1, the
receptor of major group HRVs actively contributes to viral uncoating, LDLRs are rather considered passive
vehicles for cargo delivery to the low-pH environment of endosomes. Since the Tyr-Trp-Thr-Asp -propeller
domain of LDLR has been shown to be involved in the dissociation of bound LDL via intramolecular
competition at low pH, we studied whether it also plays a role in HRV infection. Human cell lines deficient in
LDLR family proteins are not available. Therefore, we used CHO-ldla7 cells that lack endogenous LDLR. These
were stably transfected to express either wild-type (wt) human LDLR or a mutant with a deletion of the
-propeller. When HRV2 was attached to the propeller-negative LDLR, a lower pH was required for conversion
to subviral particles than when attached to wt LDLR. This indicates that high-avidity receptor binding
maintains the virus in its native conformation. HRV2 internalization directed the mutant LDLR but not wt
LDLR to lysosomes, resulting in reduced plasma membrane expression of propeller-negative LDLR. Infection
assays using a CHO-adapted HRV2 variant showed a delay in intracellular viral conversion and de novo viral
synthesis in cells expressing the truncated LDLR. Our data indicate that the -propeller attenuates the
virus-stabilizing effect of LDLR binding and thereby facilitates RNA release from endosomes, resulting in the
enhancement of infection. This is a nice example of a virus exploiting high-avidity multimodule receptor
binding with an intrinsic release mechanism.
Human rhinoviruses (HRVs), members of the picornavirus
family of nonenveloped, single-stranded positive-sense RNA vi-
ruses, are the major cause of the common cold. Based on phy-
logeny, they are divided into two species, HRV-A and HRV-B.
For cell entry, HRVs use two different types of receptors; 87
major group viruses bind human intercellular adhesion molecule
1 (ICAM-1) (44), while 12 types (the minor group) attach to
members of the low-density lipoprotein receptor (LDLR) family,
including LDLR, very-LDLR (VLDLR), and LDLR-related pro-
tein (LRP) (46). All minor group HRVs are HRV-A, but major
group HRVs belong to either species. Recently, a new clade
tentatively termed HRV-C was identified (23), but its properties
with respect to receptor binding and entry have not been eluci-
dated.
The minor group virus HRV2 enters via clathrin-dependent
endocytosis (41). This is not unexpected since LDLRs possess
a clathrin localization signal in their C-terminal cytoplasmic
domains. However, when the clathrin-dependent pathway is
blocked, similar to physiologic ligands, HRV2 might also ex-
ploit other endocytosis routes (3). After cell entry, HRVs of
both receptor groups end up in endosomal compartments. For
major group HRVs either ICAM-1 alone or in concert with the
low-pH environment triggers conversion into subviral parti-
cles; concomitantly, the virion is uncoated, and the genomic
RNA is released (33). In contrast, structural changes and in-
fection of the minor group viruses exclusively depend on the
low endosomal pH, and it was believed that the function of
LDLRs was limited to virus delivery (8).
Exposure to pH 3 inactivates all HRVs, and this property
was originally used as a means for their classification (43).
However, most HRVs already convert into subviral particles
and thereby lose infectivity at much higher pH values. For
example, HRV2 readily experiences conformational modifica-
tions below a threshold pH of 5.6 in vitro and in vivo (16, 34),
and inactivation occurs within a range of 0.6 pH units ac-
cording to a sigmoid progression. On the other hand, some
major group viruses were found to be more stable (20).
During infection, native virus is first converted into subviral
A-particles that still contain RNA but have lost the innermost
capsid protein VP4. They no longer attach to their respective
receptors but are hydrophobic because of externalization of
the amphipathic N termini of VP1 that are believed to insert
into the lipid bilayer of the endosomal membrane (28). In a
next step, the RNA is transferred into the cytosol, leaving
behind empty hydrophilic subviral B particles. These processes
are strongly coordinated, as indicated by the in vitro mem-
brane-disrupting activity of VP4 (11). VP4 appears to also play
an essential role in RNA transfer. Furthermore, when VP0 is
not cleaved into VP2 and VP4 during viral maturation, the
virions bind to their receptors and undergo all structural tran-
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ries, University Departments at the Vienna Biocenter, Department of
Medical Biochemistry, Medical University of Vienna, Dr. Bohr Gasse
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sitions but fail to initiate infection most probably because the
RNA does not arrive in the cytosol (26).
The conformational modifications of the major group virus
HRV14 result in disruption of the endosome; on the other
hand, the minor group virus HRV2 opens a pore in the mem-
brane for the RNA to enter the cytosol and the endosome
remains largely intact (35, 39). In the latter case, empty parti-
cles are left and are shuttled to lysosomes for degradation.
Conversely, HRV14 capsid proteins arrive, together with the
viral RNA in the cytosol. Therefore, the capsid is degraded to
a much lesser extent since it fails to reach the lysosomes.
C-terminal from the ligand-binding domain, LDLR pos-
sesses an epidermal growth factor (EGF)-precursor homology
(EGFP) domain with two cysteine-rich EGF-like repeats
(EGF-A and -B), a six-bladed -propeller with characteristic
Tyr-Trp-Thr-Asp (YWTD) motives, and a third EGF repeat
(EGF-C). The three-dimensional structure of LDLR at pH 5.3
shows a closed conformation, in which ligand binding repeats
L4 and L5 fold back toward the -propeller, establishing an
intramolecular interaction (37). This involves lysine and tryp-
tophan residues similar to those conferring binding of VLDLR
to HRV2 (45) and LDLR to receptor-associated protein at
neutral pH (13). Moreover, a number of histidine residues in
the propeller become partly protonated and establish addi-
tional ionic interactions with buried negatively charged resi-
dues of the two ligand binding repeats. This intramolecular
competition for the ligand-binding repeats is believed to be
responsible for the release of bound LDL at low pH. However,
recent mutagenesis experiments suggest that the three histi-
dines supposed to participate in this competition are rather
involved in an allosteric mechanism lowering the affinity of the
ligand for the receptor at the low endosomal pH (48).
Since virus conversion and release from the receptor is trig-
gered by acid pH in any case, we sought to determine whether
competition by the -propeller played any role in viral infec-
tion. Comparing the behavior of wild-type (wt) and propeller-
deficient LDLR in HRV2 infection, we demonstrate that the
-propeller promotes infection by facilitating virus conversion
and RNA release in the appropriate endosomal compartments
within a suitable time window. These results show that minor
group receptors are not just passive vehicles for virus delivery
but actively contribute to infection.
MATERIALS AND METHODS
Chemicals. All chemicals were obtained from Sigma (St. Louis, MO) or Merck
(Darmstadt, Germany) unless specified otherwise. WIN-52084-2 (kindly pro-
vided by Dan Pevear, ViroPharma) was dissolved at 0.5 mg/ml in 50% dimethyl
sulfoxide and stored at 20°C. Tissue culture plates and flasks were from Iwaki
(Bibby Sterilin, Stone, Staffordshire, United Kingdom).
Buffer solutions. Isotonic 30 mM MES (morpholinoethanesulfonic acid) buff-
ers were adjusted to a pH between 4.8 and 7.0 with 0.2 increments. To ensure
isotonicity, the NaCl concentrations were calculated by using the web tool “Rec-
ipe Calculator for Thermodynamically Correct Buffers,” of the University of
Liverpool, (http://www.liv.ac.uk/buffers/buffercalc.html). After addition of the
adequate amount of NaCl, the buffers were brought to the respective pH with
NaOH at 0°C. Hanks balanced buffer solution (HBBS; 0.137 M NaCl, 5.4 mM
KCl, 0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM MgSO4, 4.2
mM NaHCO3) was used for washes, as well as for incubation of CHO cells at 4°C
as specified in the text. Radioimmunoprecipitation assay (RIPA) buffer (50 mM
Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1% sodium deoxycholate, 0.1%
sodium dodecyl sulfate, 1% Triton X-100) was used for cell lysis prior to radio-
immunoprecipitation and/or scintillation counting.
Cell lines. HeLa-H1 Ohio cells (American Type Culture Collection, Manassas,
VA), a subline supporting the replication of HRVs, were used for HRV2 pro-
duction and labeling with [35S]methionine-cysteine, as well as for titer determi-
nation. CHO-ldla7 Chinese hamster ovary cells lacking functional endogenous
LDLRs (22) but stably transfected to overexpress native human LDLR (termed
RF3 cells) or LDLR in which the YWTD -propeller domain and the EGF-C
domain are deleted (termed YC cells) (5, 6), kindly provided by Stephen
Blacklow (Boston, MA), were used in all other experiments.
Cell culture medium. HeLa-H1 cells (for short HeLa) were cultured in min-
imal essential medium (MEM) supplemented with 10% heat-inactivated fetal
calf serum (FCS), 2 mM L-glutamine, 100 U of penicillin/ml, and 100 g of
streptomycin/ml (Gibco/Invitrogen Corp., Paisley, United Kingdom). For infec-
tion of HeLa cells, MEM containing 30 mM MgCl2 and 2% FCS (infection
medium) was used. CHO cells were cultured in Ham F-12 medium with 5% FCS,
2 mM L-glutamine, 100 U of penicillin/ml, and 100 g of streptomycin/ml. RF3
and YC cells were maintained in the same medium containing 1 mg of Gene-
ticin (G418)/ml. CHO-infection medium was Ham F-12 containing 30 mM
MgCl2 and 2% FCS, without Geneticin. Cells were grown at 37°C, and infection
was carried out at 34°C under a 5% CO2 atmosphere.
Virus. HRV2 was originally obtained from the American Type Culture Col-
lection. An HRV2 variant adapted to replicate in CHO cells was isolated by blind
passages alternating between HeLa and CHO-RF3 cells. Cells in a 162-cm2 flask
were challenged with virus at 10 50% tissue culture infective doses (TCID50)/cell
at 34°C for 30 min, medium with nonbound virus was replaced by fresh infection
medium, and cells were incubated for 24 h to allow for infection. Virus eventually
produced in the CHO cells was liberated by three consecutive freeze-thaw cycles,
and HeLa cells were infected with the lysates. Whereas initially no cytopathic
effect (CPE) was seen in the CHO cells, HeLa cells were usually lysed after 24 h.
However, after 12 cycles CPE appeared in the CHO cells and persisted even
upon CHO to CHO passaging for more than five times. The variant population,
termed HRV2CHO, replicated in both CHO cell lines but with different kinetics
(see below).
Radiolabeling of HRV2. HeLa cells were grown in a 162-cm2 flask until ca.
80% confluent, washed twice with phosphate-buffered saline (PBS), and incu-
bated with 20 ml of methionine-cysteine-free Dulbecco modified Eagle medium
supplemented with 2% dialyzed FCS, 100 U of penicillin/ml, 100 g of strepto-
mycin/ml, 2 mM L-glutamine, and 30 mM MgCl2 for 4 h at 37°C. The medium
was replaced by fresh methionine-cysteine-free medium, and virus was added at
1,000 TCID50/cell. The cells were incubated for 4 h at 34°C to allow for viral
internalization and host cell shutoff. Portions (15 ml) of the old medium were
replaced by fresh infection medium containing 2% dialyzed FCS. After the
addition of 1 mCi of [35S]methionine-cysteine (Hartmann Analytic GmbH,
Braunschweig, Germany), incubation was continued for 16 h. Cells were broken
by three cycles of freezing-thawing, and debris was removed by centrifugation at
20,000 rpm (Ty65 rotor) for 20 min at 4°C. Virus was pelleted at 50,000 rpm
(Ty65 rotor) for 2 h and suspended in 1 ml of HBBS supplemented with 2% FCS
overnight at 4°C. Insoluble material was removed by centrifugation in a benchtop
centrifuge. Remaining free radiolabel was removed by pelleting two times in a
Beckman Optima TLX benchtop ultracentrifuge (TLA 100.3 rotor) at 70,000
rpm for 1 h. The viral pellet was finally resuspended in 200 l of HBBS–2% FCS
and stored at 4°C. Incorporated radioactivity was quantified by liquid scintillation
counting (Tricarb; Packard, Meriden, CT); only radiochemically pure virus prep-
arations (i.e., only viral proteins visible in the autoradiogram), as checked on a
reducing 15% sodium dodecyl sulfate-polyacrylamide gel, were used. To ensure
the absence of subviral particles, the preparations were stored over S. aureus-2G2
immunocomplexes that were removed by centrifugation before using the virus.
The monoclonal antibody (MAb) 2G2 specifically recognizes subviral particles
(31).
FACS quantification of LDLR expression. CHO cells were detached from
162-cm2 culture flasks by incubation in 5 ml of 10 mM EDTA in PBS at 37°C for
5 min. The cells were washed with PBS and resuspended in Ham F-12 growth
medium to allow for resaturation of cell surface LDLRs with Ca2 at 37°C for 30
min. After two washes in ice-cold HBBS, the cells were resuspended in ice-cold
fluorescence-activated cell sorting (FACS) buffer (HBBS supplemented with 2%
FCS) at 2  106 cells/ml, followed by incubation under slow rotation for 1 h at
4°C. The cells were dispensed in 2-ml Eppendorf tubes at 2  106 cells/sample,
pelleted at 1,000 g for 5 min, resuspended in 200 l of FACS buffer containing
chicken immunoglobulin Y (IgY) directed against the ligand-binding domain of
human LDLR (prepared by standard techniques) at 2.5 g/ml. The cells were
then incubated on ice for 1 h by gently shaking the tubes every other 10 min.
After three washes with 1 ml of ice-cold HBBS, phycoerythrin-conjugated don-
key anti-chicken secondary antibody (Jackson Immunoresearch) was added at
1:100 in 200 l of FACS buffer. After 30 min of incubation, the cells were washed
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twice with cold HBBS, resuspended in 1 ml of cold HBBS, transferred into 5-ml
polypropylene FACS tubes, and kept on ice until analyzed. Cell-associated flu-
orescence corresponding to receptor expression was measured in a Becton Dick-
inson LSR-I flow cytometer, using the CellQuest Pro software for data analysis.
Quantification of cell attachment of HRV2. CHO cells expressing wt or trun-
cated LDLR were grown in six-well plates until ca. 80% confluent. The growth
medium was discarded, the cells were washed with ice-cold HBBS, 20,000 cpm of
35S-labeled HRV2 in ice-cold infection medium was added per well, and the
plates were incubated for 1 h at 4°C for virus binding. Unbound virus was
removed by three washes with ice-cold HBBS, and the cells were lysed in 500 l
of RIPA buffer on ice for 15 min and transferred into scintillation vials. The wells
were washed with 500 l of RIPA buffer and with 500 l of HBBS, the washes
were combined with the cell lysates, and the cell-associated radioactivity was
measured in a liquid scintillation counter (Tricarb).
Release of LDLR-bound HRV2 from CHO cells after low-pH treatment. CHO
cells were grown in six-well plates until confluent. The medium was removed, and
the cells were incubated in cold HBBS for 10 min at 4°C and challenged with
20,000 cpm of 35S-labeled HRV2 in ice-cold CHO infection medium for 1 h at
4°C. Unbound virus was removed by washing the samples with ice-cold HBBS,
and the cells were exposed to isotonic 30 mM MES buffers of pH 4.8 to 7.0 (with
increments of 0.2 pH units) for 20 min at 4°C. Samples were reneutralized by the
addition of the adequate volumes of 1 M Tris base. The virus released into the
supernatant and remaining cell-associated virus were quantified separately by
scintillation counting as described above. In a separate experiment, the effect of
the duration of low-pH incubation and reneutralization on virus dissociation was
determined. Cells were incubated at pH 5.0, 6.0, and 7.0 for 20, 45, and 90 min,
followed by reneutralization to pH 7.0 for 0, 10, and 45 min.
Modeling endosomal virus conversion at the plasma membrane and influence
of WIN-52084-2. The capsid-binding drug was dissolved at 0.5 mg/ml in 50%
dimethyl sulfoxide. For each assay 30,000 cpm of 35S-labeled HRV2 was prein-
cubated in 20 l of 150 mM NaCl (pH 7.5) containing WIN-52084-2 at a final
concentration of 20 g/ml for 30 min at room temperature. As a control, the
virus was preincubated in the same solution without the WIN compound. Even-
tually, the non-native virus was removed by immunoprecipitation with MAb
2G2-S. aureus immunocomplexes prepared as follows. A 500-l portion of fixed,
heat-killed S. aureus cells from a 10% stock suspension was pelleted at 10,000
rpm for 1 min in a benchtop Eppendorf centrifuge. The pellet was washed twice
with 1 ml of PBS and twice with 1 ml of RIPA buffer. Bacteria were resuspended
in 400 l of RIPA buffer, and 100 l of rabbit HRV2-antiserum was added,
followed by incubation for 1 h at room temperature. Bacteria were pelleted,
washed three times with RIPA buffer, and finally resuspended in 500 l of RIPA
buffer containing 0.04% sodium azide. Since protein A binds rabbit IgG much
better than mouse IgG, MAb 2G2 was bound via rabbit anti-mouse IgG by using
the same procedure.
CHO cells were grown in six-well plates until confluent and preincubated in
cold HBBS for 10 min at 4°C. After challenge with 20,000 cpm of 35S-labeled
HRV2 (untreated and preincubated with the antiviral, respectively) in CHO
infection medium at 4°C for 1 h, unbound virus was removed, and the cells were
further incubated in isotonic buffers of pH 4.8 to 7.0 for 20 min at 4°C as
described above. The buffers were reneutralized, and the cells were further
incubated for 20 min at 4°C to allow for virus release. Supernatants (1 ml) were
collected in 2-ml Eppendorf tubes, the cells were washed twice with 250 l of
HBBS, the washes were combined with the supernatants, and 300 l of 6 RIPA
buffer was added. The cells were lysed in 500 l of RIPA buffer on ice for 15 min
and collected in 2-ml Eppendorf tubes. The wells were rinsed twice with 500 l
of RIPA buffer, and the washes were combined with the cell lysates. Debris was
removed by centrifugation. Supernatants and cell lysates were processed sepa-
rately for sequential immunoprecipitation. First, subviral particles were recov-
ered by the addition of 20 l of MAb 2G2-S. aureus immunocomplexes, followed
by incubation for 2 h at room temperature. Bacteria were pelleted and washed
twice with 200 l of RIPA buffer. Remaining native virus in supernatants and
washes was precipitated with 20 l of rabbit HRV2 antibody-S. aureus immuno-
complexes. Pellets were washed twice with 200 l of RIPA buffer and scintilla-
tion counted. Conversion of native virus into subviral particles was calculated by
dividing the sum of 2G2-precipitated counts by the total counts (i.e., the sum of
2G2 and anti-HRV2 precipitated counts). Conversion at pH 4.8 was set to 100%
and conversion at pH 7.0 to 0%.
Kinetics of virus conversion. CHO cells were grown in six-well plates, prein-
cubated in cold HBBS for 10 min at 4°C, and challenged with 20,000 cpm of
35S-labeled HRV2 at 4°C for 1 h. Unbound virus was removed by extensive
washing with ice-cold HBBS, and the cells were incubated in 1 ml of CHO
infection medium at 34°C, allowing for virus internalization and uncoating. At
the times given in the text, the cells were lysed without removing the incubation
medium by adding 200 l of 6 RIPA buffer. Cell debris was removed by
centrifugation. To monitor the uncoating, subviral particles were immunopre-
cipitated with MAb 2G2, and the remaining native virus was immunoprecipitated
with HRV2 antiserum, followed by quantification by liquid scintillation counting
as described above, and the ratios of 2G2 precipitated counts over total counts
were calculated.
Time-dependent colocalization of virus and LDLR. CHO cells were seeded
onto 13-mm glass coverslips (Menzel, Braunschweig, Germany) and grown until
80% confluent. Cells were washed with PBS containing 1 mM CaCl2 and 1 mM
MgCl2 (PBS), preincubated in 200 l of CHO infection medium for 30 min at
37°C, cooled to 4°C, and challenged with HRV2 at 900 TCID50/cell for 1 h.
Unbound virus was removed by three washes with 2 ml of ice-cold PBS, and
the cells were incubated in 500 l of prewarmed CHO infection medium for 4,
20, and 60 min (chase). The coverslips were transferred into a six-well plate on
ice and washed with 2 ml of ice-cold PBS for 5 min. The cells were fixed for
30 min with 300 l of 4% paraformaldehyde in PBS, quenched with 300 l of
50 mM NH4Cl in PBS for 10 min, washed three times, and permeabilized with
300 l of 0.2% Triton X-100 in PBS for 5 min. Nonspecific binding sites were
blocked with 200 l of 10% goat serum in PBS (Gibco/Invitrogen) for 30 min. All
antibodies were diluted with PBS containing 10% goat serum. HRV2 was de-
tected with MAb 8F5 (40) at 10 g/ml, followed by Alexa 568-conjugated goat
anti-mouse IgG (1:1,000; Molecular Probes, Eugene, OR), and LDLR was de-
tected with chicken anti-human LDLR IgY (10 g/ml) and Alexa 488-conjugated
goat anti-chicken IgG (1:1,000; Molecular Probes). Cells were washed four times
for 10 min each time with 5 ml of PBS, and nuclei were stained with DRAQ5
(Biostatus, Shepshed, Leicestershire, United Kingdom). Coverslips were briefly
dipped in double-distilled H2O and mounted in Mowiol. Cells were viewed with
a Zeiss Axiovert 200 microscope (Carl Zeiss, Jena, Germany) equipped with an
UltraView ERS laser confocal system (Perkin-Elmer, Shelton, CT). Twelve-bit
images of highest resolution (1,344  1,024 pixels; no binning) were acquired
through a 63/1.4 Plan-Apochromat lens (Carl Zeiss). Images were taken with
the same exposure time, and emission was discriminated by sequential acquisi-
tion. For Z-stack analysis, at least 15 images were recorded at 0.2-m intervals
with a piezo-driven Z stage. UltraView software was used to correct for back-
ground fluorescence and to determine the extent of colocalization.
Effect of HRV2 internalization on LDLR expression. RF3 and YC cells were
preincubated in serum-free Ham F-12 medium for 1 h at 34°C. HRV2 at 1,500
TCID50/cell was internalized in serum-free Ham F-12 medium for 6 h. Cells were
then cooled, washed, fixed, and permeabilized with methanol at 20°C for 10
min and processed for indirect immunofluorescence microscopy for the detection
of LDLR (see above) and LAMP2 (anti-human CD107B mouse antibody 1:400;
BD Biosciences/Pharmingen), followed by Alexa 488-conjugated goat anti-
chicken IgG and Alexa 568-conjugated goat anti-mouse IgG, respectively. Nuclei
were stained with Hoechst dye (1 g/ml; for epifluorescence microscopy) and
DRAQE5 (1:500; for confocal microscopy), and cells were embedded in Mowiol.
LDLR expression and the extent of colocalization with LAMP2 was investigated
by epifluorescence microscopy using a Zeiss Axioplan 2 fluorescence microscope
equipped with a C-Apochromat 40 lens and Axiovision software. Confocal
microscopy was carried out as described above.
Kinetics of the infection of CHO cells with HRV2CHO. CHO cells grown in
six-well plates were challenged with HRV2CHO at 10 TCID50/cell at 4°C for 1 h.
Unbound virus was removed by extensive washing with ice-cold HBBS, and the
cells were incubated at 34°C in 2 ml of CHO infection medium. At time zero (to
determine bound virus) and at 3, 6, 9, 12, 16, 22, 26, 31, and 36 h, the cells were
subjected to three freeze-thaw cycles, cell debris was removed, and the virus
titers were determined in HeLa cells.
RESULTS
At pH 5.3 LDLR releases LDL via intramolecular compe-
tition of its -propeller domain for the ligand binding repeats
L4 and L5 (5, 6, 37) or, as more recently suggested, via allo-
steric conformational changes (48). Since conversion of HRV2
into subviral particles during infection also occurs at similar
pH values in late endosomes (16), structural changes of recep-
tor and virus might take place concomitantly. Therefore, we
sought to determine whether the -propeller function was also
important for minor group rhinovirus infection. Since human
cells defective in expression of the receptors recognized by
minor group HRVs are not available, all experiments were
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carried out using CHO cells lacking endogenous LDLR as a
consequence of a mutation (ldla7 cells) (25). These cells were
transfected to stably express human wt LDLR (RF3 cells) or a
mutant receptor lacking the YWTD–-propeller and the
EGF-C domain (YC cells).
Immunofluorescence microscopy and FACS analysis re-
vealed that the expression levels of the LDLRs in the two cell
lines were not identical (not shown). In particular, despite
being grown in the presence of the selecting agent Geneticin,
the concentration of wt LDLR was comparatively low in most
of the cells. Therefore, both cell lines were subjected to FACS
sorting, and cells expressing the respective receptors at similar
levels were collected and expanded. This resulted in reasonably
homogeneous populations; binding of radiolabeled HRV2 at
4°C was almost identical for both cell lines (ca. 70%  3.5% of
total input virus) with low background binding (3.9%  0.7%
related to the receptor-expressing cells) as determined for non-
transfected CHO-ldla7 control cells that lack functional
LDLR. These cells were used for all experiments.
Structural changes and uncoating of HRV2 at the low en-
dosomal pH can be mimicked at the plasma membrane by
incubation of receptor-bound virus in acidic buffers (8). Since
dissociation of the virus from its receptor when still in its native
conformation might strongly decrease productive infection, we
first investigated the possible role of the -propeller domain in
this process. The experiments were carried out with the two
CHO cell lines by incubation of plasma membrane-bound virus
in low-pH buffer. To avoid depletion of the Ca ions that are
necessary to maintain the receptor in its native conformation,
we used MES buffer instead of the acetate-phosphate buffers
applied in the previous study (8).
HRV2 remains attached to CHO cells upon acidification
unless reneutralized. 35S-labeled HRV2 was bound to wt
LDLR and mutant LDLR expressed on the respective CHO
cell line for 1 h at 4°C. Unbound virus was washed away with
ice-cold HBBS, and bound virus was exposed to a series of
isotonic MES buffers of pH 4.8 to 7.0 for 20 min. In contrast to
the previous results with HeLa cells (8), we found that the
CHO cells did not release bound virus at any pH value, not
even from the cells expressing wt LDLR on prolonged incu-
bation at the lowest pH. This is most probably the result of the
10-fold-higher LDLR expression level in the transfected cells
than in HeLa cells. It suggests that HRV2 either remained
receptor bound in its native form or had converted to subviral
particles that were handed over to the cell membrane. How-
ever, substantial and rapid virus release was noticed after re-
neutralization to pH 7.0 (data not shown). The hydrophobic
A-particles associate with liposomes (28), whereas the hydro-
philic empty B-particles do not (24, 28). Therefore, these data
imply that HRV2, when bound to CHO cells and exposed to
low pH, dissociates from the cells uniquely upon reneutraliza-
tion in the form of empty capsids.
LDLR binding stabilizes HRV2 against low pH-induced con-
version. We next set out to identify the nature of the viral
material remaining bound and being released. The experiment
above was repeated, and subviral particles and native virus in
the supernatant were determined by sequential immunopre-
cipitation with MAb 2G2 that specifically recognizes subviral
particles (18, 31) and rabbit anti-HRV2 IgG. This method has
been extensively used previously for quantification of the con-
version of HRV2 into subviral particles (3, 19, 34). The same
procedure was carried out with the cellular fraction after cell
lysis with RIPA buffer. Immunoprecipitates were quantified by
liquid scintillation counting (Fig. 1). Similar to the results with
HeLa cells (8), the conformational alterations of HRV2 bound
to CHO cells expressing wt LDLR occurred within a pH range
from	6.0 to5.4, following a typical sigmoid curve. However,
when virus was bound to -propeller-negative LDLR, the
curve was shifted toward lower pH values by 0.3 pH units.
Capsid-binding drugs, such as I(S), also named WIN-52084
(from the Sterling Winthrop company that originally manufac-
tured them), displace fatty acids naturally present in the hy-
drophobic pocket of the capsid and protect HRVs against low
pH-induced conversion into subviral A-particles (16, 21).
Therefore, the same experiment was carried out with HRV2
that had been preincubated with this drug. Stabilization by the
compound also resulted in a shift of the conversion curve of wt
LDLR-bound HRV2 toward lower pH values. This increase in
stability at low pH was almost identical to that caused by
truncated LDLR. Apparently, in the absence of the -propel-
ler domain the high-avidity attachment of the receptor via
several ligand-binding modules stabilizes the native conforma-
tion of the virus. This is in line with earlier data of Nicodemou
et al. (32), who demonstrated stabilization of HRV2 by the
soluble concatemeric pentamer of module 3 (V33333) of
VLDLR in vitro. Stabilization by WIN-52084 and the -pro-
peller negative receptor were additive, shifting the sigmoid
curve even more toward lower pH values (Fig. 1). Under our
experimental conditions virtually no virus was released from
the cells upon acidification. However, upon reneutralization, a
large percentage was found in the cell supernatant, and 80 to
100% of it was in the form of subviral particles at any pH value
for all four experimental conditions (data not shown).
Upon endocytosis in HeLa cells, HRV2 is shuttled from
FIG. 1. Conversion of LDLR-bound HRV2 at the plasma mem-
brane by incubation in isotonic buffers of different pH. Radiolabeled
HRV2 either untreated or preincubated with the antiviral capsid-
binder WIN-52084 was attached to the cells at 4°C for 1 h, unbound
virus was removed, and the cells were incubated at 4°C for 20 min in
isotonic buffers with the pH values indicated. The buffers were reneu-
tralized by adding Tris base, and the cells were further incubated for 20
min to allow for virus release. Converted virus was immunoprecipi-
tated with MAb 2G2 and remaining native virus with anti-HRV2
antiserum from both the supernatants and cell lysates. Total conver-
sion at pH 4.8 was set to 100%, and no conversion at pH 7.0 was set to
0%. Note that the propeller-negative LDLR stabilizes the virus against
its conversion to a similar extent as the antiviral substance; the two
different types of protection effects were additive.
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early to late endosomes within endosomal carrier vesicles
(ECV). The RNA is released from the virus either in ECV or
in late endosomes (4), and the remaining empty capsids move
on to lysosomes, where they are degraded. Therefore, produc-
tive RNA release must happen within a window of opportunity
in the correct compartment. The experiments mimicking the
situation in endosomes at the plasma membrane suggest that
the -propeller might facilitate virus conversion at compara-
tively higher pH values at earlier times. Thereby, the time
window for RNA release would be longer, which could influ-
ence the efficiency of infection. Therefore, we investigated viral
conformational changes during cell entry.
Conversion of native HRV2 to subviral particles is delayed
when internalized via -propeller-deficient LDLR. Radiola-
beled HRV2 was attached to the cells at 4°C for 1 h, unbound
virus was washed away with cold HBBS, and the cells were
incubated in infection medium at 34°C to allow for virus inter-
nalization and conversion in endosomes. At various times, the
cells were lysed by adding RIPA buffer without removing the
incubation medium. Subviral particles and remaining native
virus were recovered by sequential immunoprecipitation with
MAb 2G2 and anti-HRV2 antiserum and determined by liquid
scintillation counting. The percentage of virus conversion was
calculated as the ratio of 2G2-precipitated counts over total
precipitated counts and set to 0% at time zero. As seen in Fig.
2, virus conversion was strongly delayed and reduced when
entry occurred via the truncated receptor.
The dissociation of HRV2 from the two forms of LDLR
within endosomes was also assessed via the time-dependent
colocalization of HRV2 and LDLR by confocal immunofluo-
rescence microscopy. HRV2 was bound to the plasma mem-
brane of CHO cells expressing the respective receptor on ice,
and the cells were further incubated at 34°C for the times
indicated in Fig. 3. Virus and receptor were differentially la-
beled with suitable specific antibodies and visualized (Fig. 3A).
Colocalization was determined by using UltraView software
(Fig. 3B). In agreement with virus-receptor dissociation in
early endosomes (8), colocalization of HRV2 and receptor
rapidly decreased in time. Furthermore, when the virus en-
tered via the -propeller-negative receptor, this dissociation
occurred at a substantially slower rate and only to a minor
extent.
Infection is delayed when HRV2 is internalized via -pro-
peller-deficient LDLR. Most HRVs fail to replicate in nonhu-
FIG. 2. Viral conversion is delayed and reduced in CHO cells ex-
pressing the -propeller-negative LDLR compared to wt LDLR. Ra-
diolabeled HRV2 was attached to cells grown in six-well plates at 4°C
for 1 h, unbound virus was washed away, and the cells were incubated
in 1 ml of infection medium at 34°C, allowing for virus internalization
and uncoating. At the time points indicated, the cells were lysed with-
out removing the incubation medium. Converted virus was immuno-
precipitated with MAb 2G2 and remaining native virus was immuno-
precipitated with anti-HRV2 antiserum and scintillation counted. The
percentage of virus conversion was calculated as 2G2-precipitated
counts divided by total precipitated counts and set to 0% at time zero.
Note the delay and lower extent of uncoating when the virus enters via
the truncated receptor. Error bars indicate the means  the standard
deviations (SD) (n 
 3).
FIG. 3. HRV2 dissociation from LDLR is delayed when the -pro-
peller is deleted. HRV2 was bound at 4°C to CHO cells grown on
coverslips, and entry was initiated by adding warm medium. At the
times indicated, the cells were fixed and permeabilized, and LDLR and
HRV2 were detected by specific antibodies, followed by Alexa 488-
conjugated goat anti-mouse IgG and Alexa 568-conjugated goat anti-
chicken IgG, respectively. (A) Representative fluorescent images of
one focal plane through the perinuclear region are shown after HRV2
binding (0 min) and 60 min after warming to 34°C. LDLR, green;
HRV2, red. (B) The percent colocalization of virus and receptor was
calculated from immunofluorescence microscopy images as in panel A.
Colocalization at time zero was set to 100%. Error bars indicate the
means  the SD (n 
 3).
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man cells, and challenge of the CHO cell lines with HRV2 did
not result in productive infection. However, adaptation of
HRV2 to mouse L cells has been reported (47). The variants
showed mutations within nonstructural viral proteins, indicat-
ing that receptor binding was not affected. We thus used the
same strategy for adapting HRV2 to replicate in hamster cells.
After 12 blind passages alternating between RF3-CHO cells
and HeLa cells, a population of HRV2 variants, termed
HRV2CHO, was selected that caused CPE and multiplied in
both CHO lines. Figure 4 depicts the infection kinetics of
HRV2CHO in the two lines. The virus titer decreased at the
early times after challenge, indicating uncoating of incoming
virus. From about 9 h onward, replication was evident with the
virus titer attaining a plateau after about 30 h. The most ob-
vious difference between the two cell lines is seen between 12
and 26 h; the cells expressing the wt receptor produced up to
6 times more virus at 16 h postinfection, with a difference of5
h in reaching the plateau.
HRV2 directs the -propeller-deficient LDLR to lysosomes.
Deletion of the entire EGFP-homology domain of LDLR has
been shown to inhibit dissociation of bound LDL, impairs
receptor recycling, and results in lysosomal degradation of the
receptor-ligand complex (10). Since the -propeller is the main
player in the conformational changes at low pH (5, 37), we
thought it likely that the YC deletion mutant used in our
experiments behaves identically. To assess whether HRV2 in-
ternalization results in degradation of the mutant LDLR, we
studied colocalization of LDLR with the lysosomal marker
LAMP2 by fluorescence microscopy. CHO cells expressing wt
or -propeller-negative LDLR were grown on coverslips and
incubated for 30 min in serum-free medium, and HRV2 at
1,500 TCID50/cell was continuously internalized for 6 h at
34°C. The cells were chilled, washed, fixed, permeabilized, and
incubated with mouse anti-LAMP2 antibody, followed by Al-
exa 568-conjugated goat anti-mouse IgG. LDLRs were re-
vealed with chicken anti-LDLR IgY, followed by Alexa
488-conjugated goat anti-chicken IgG. For control purposes,
mock-infected cells were incubated under the same conditions.
Internalization of HRV2 into RF3 cells had no significant
influence on the total fluorescence and thus on the concentra-
tion of wt LDLR (Fig. 5A, upper panels). Furthermore, little
colocalization of LDLR with the late endosome/lysosome
marker LAMP2 was seen in the absence and in the presence of
HRV2 (Fig. 5B, upper panels). In contrast, in YC cells
HRV2 uptake resulted in decreased LDLR levels mainly at the
plasma membrane (arrows) but not in the perinuclear area
(Fig. 5A, lower panels, arrowheads). The decrease in plasma
membrane localization of the mutant receptors appears to be
due to their lysosomal degradation as deduced from the higher
extent of colocalization of receptors with LAMP2 (Fig. 5B,
FIG. 4. Infection kinetics of CHO cell-adapted HRV2 in cells ex-
pressing wt and -propeller-negative LDLR. Cells seeded in six-well
plates were challenged with HRV2CHO at 10 TCID50/cell at 4°C for 1 h.
After the removal of unbound virus, the cells were incubated at 34°C.
At the times indicated, the cells were broken by three cycles of freeze-
thawing, and the virus titer was determined. Note the significant delay
in virus production in the cells expressing the truncated receptor. Error
bars indicate means  the SD (n 
 3).
FIG. 5. Continuous HRV2 internalization leads to degradation of
mutant but not wt LDLR. RF3 and YC cells were preincubated in
serum-free Ham F-12 medium, and HRV2 at 1,500 TCID50/cell was
internalized for 6 h. Cells were cooled, washed, and processed for
indirect immunofluorescence microscopy for the detection of LDLR
(green) and LAMP2 (red). Nuclei were stained with Hoechst dye (for
epifluorescence) and DRAQE5 (for confocal microscopy). (A) Con-
ventional epifluorescence microscopy. All images were taken with the
same exposure time in the respective channel and identical settings
were used for illustration with the Axiovision software. Overlay images
are shown. Arrowheads indicate perinuclear and arrows indicate
plasma membrane localization of the receptors. (B) Confocal images
were taken by using the same laser power and exposure time in the
respective channel. Multicolor images shown were obtained with iden-
tical gray level settings in each channel. Of 20 sections through the
cells, the focal plane through the nucleus is depicted. Bar, 2 m.
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lower panels). Collectively, this indicates that the virus directs
the truncated receptor to lysosomes.
DISCUSSION
LDL has been shown to dissociate from plasma membrane
LDLR at pH 	5.5 (10); if the entire EGFP-domain or the
-propeller together with the EGF-C domain is absent from
the receptor, LDL release is reduced to 10% compared to
100% for wt LDLR (6, 7). The 3D X-ray structure of LDLR
determined at pH 5.3 revealed an intramolecular interaction
between modules LA4 and LA5 and the -propeller and
thereby nicely explained the underlying mechanism at the mo-
lecular level (37). In the present study we took advantage of
CHO-ldla7 cells that are deficient in the endogenous receptor
but had been stably transfected to overexpress human wt
LDLR (RF3 cells) and LDLR lacking the -propeller, to-
gether with the EGF-C domain (YC cells). We demonstrated
that the -propeller domain is not only important for the LDL
metabolism but also exerts a similar function in the conversion
and release of minor group HRVs, exemplified by HRV2.
LDLR is thus not only a vehicle for virus delivery, but it also
fine-tunes the location and timeliness of RNA transfer into the
cytosol. By comparing cells expressing either wt LDLR (RF3)
or LDLR whose -propeller was deleted (YC cells), it be-
came clear that, in the absence of this latter domain, HRV2
was less readily released from the receptor and the structural
changes associated with uncoating and required for RNA re-
lease were only observed at a lower pH. The final conversion to
80S particles appears to be facilitated by reneutralization. We
are currently investigating whether this could also occur in vivo
via pores in the endosomal membrane, allowing for the exit of
protons. We also compared the two forms of the receptor with
respect to infection and virus production. Since HRV2 fails to
replicate in rodent cells, it was adapted to grow in these cells by
a series of blind passages alternating between RF3 and HeLa
cells. The resultant HRV2 variant (termed HRV2CHO) grew to
roughly one-fifth of the titer attained in HeLa cells. It was
previously shown that adaptation to mouse cells by a similar
protocol does not modify the viral capsid but rather introduces
mutations into nonstructural proteins (17, 27). Therefore, it is
highly unlikely that receptor interaction is modified in this
variant, and it was legitimate to use it for our analyses. As a
consequence of -propeller deletion, the infection was delayed
and less efficient. Stabilization of HRV2 by a receptor con-
struct carrying five copies of V3, the third module of VLDLR
arranged in tandem, has been noted earlier (32). This effect is
most probably due to the strong multivalent attachment of the
receptor modules around the fivefold axes of icosahedral symme-
try (36). It appears that even LDLR, in which only repeats 1, 2, 4,
and 5 possess the tryptophan essential for virus binding (45),
exhibits sufficient avidity for protecting the virus against confor-
mational changes at low pH.
Conversion of the virus to subviral particles in endosomes
and viral de novo synthesis were delayed in YC cells com-
pared to RF3 cells. These data indicate that wt LDLR facili-
tates viral conformational modification and subsequent steps
such as virus release from the receptor, RNA uncoating, and
RNA transfer into the cytoplasm. This is brought about by the
-propeller that supposedly competes with the virus for ligand-
binding repeats LA4 and LA5. Our data correlate well with the
results for LDL release mentioned above; only ca. 15% of
HRV2 was released from the mutated receptor in YC cells
and 70% of HRV2 was released from the wt receptor in RF3
cells after 60 min internalization.
Endocytosed ligands are transported through the endocytic
pathway to lysosomes and thereby become exposed to an in-
creasingly lower pH; pH 6.5 to 6.0 in early endosomes, pH 5.5
to 5.0 in late endosomes, and pH 4.5 to 4.0 in lysosomes.
Sorting of LDL from transferrin, a marker of the recycling
pathway, occurs in early (sorting) endosomes within 2 to 4 min
(12, 15, 30). However, the low-pH structure of LDLR was
analyzed at pH 5.3 (5, 6, 37). This raises the question of which
additional factors may aid ligand release in early endosomes.
Since binding of ligands to the LDLR family is Ca2 depen-
dent (9), a mildly acidic pH and a low endosomal Ca ion
concentration could cooperatively facilitate ligand dissociation
as shown in in vitro experiments (1). Since the V-ATPase is
electrogenic, inward proton transport has to be balanced by
inward chloride and/or outward cation (K, Na, and Ca2)
movement. Indeed, upon pinching-off the plasma membrane,
endocytic vesicles rapidly alter their internal milieu from one
corresponding to the extracellular environment (pH neutral
and high concentrations of chloride, sodium, and calcium ions)
to an acidic pH. Although the endosomal chloride concentra-
tion is lowered to 17 mM within 3 min, it subsequently
increases to 60 mM as the pH decreases to 5.3 along the
lysosomal pathway (42). In contrast, a continuous decrease in
endosomal Ca2 was observed; its concentration dropped
within 3 min to 29 M and to 3 M after 20 min (14).
Indeed, various calcium channels (e.g., a “transient receptor
potential-like Ca-channel” [38]) and various mucolipin calcium
channels (29) were identified in endosomal subcompartments
that exhibit distinct properties and therefore may contribute to
low endosomal calcium as well as to endosomal pH regulation.
Lack of ligand dissociation from LDLR affects receptor traf-
ficking. For -VLDL, the EGFP domain had no influence on
binding, internalization, and degradation, but the mutant
LDLRs failed to recycle. This resulted in a time-dependent
loss of mutant receptors, presumably due to their lysosomal
degradation (10). Taken together, the failure to dissociate li-
gand from LDLR results in receptor trafficking to lysosomes
(2). This is in line with our results that demonstrate that HRV2
directs the mutant receptor to lysosomes.
Based on the earlier finding that virus is released from its
receptor in the native state at the pH prevailing in early en-
dosomes (8), we rather expected that propeller-deficient
LDLR would increase the efficiency of infection by holding the
virus close to the endosomal membrane until conversion oc-
curs. In contrast, our conversion assays showed that the virus
was not released at any pH values, unless the incubation buff-
ers were reneutralized. These results do not necessarily con-
tradict previous data on HeLa cells (8), where release of native
HRV2 at pH 6.0 was shown, for the following reasons. (i)
HeLa cells express, in addition to LDLR, LRP and VLDLR.
Infection of HeLa cells is inhibited to 80 to 90% by receptor-
associated protein (M. Brabec et al., unpublished results),
which is indicative for a preferential role of LRP1 and/or
VLDLR in HRV2 entry. (ii) Intracellular trafficking of HRV2
bound to LRP1 may be distinct from LDLR. (iii) The low-pH
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buffers used by Brabec et al. contained phosphate but lacked
calcium and thus facilitated release of native virus (see above).
Whether the virus dissociates from the receptor when still in its
native state or just upon conversion most probably depends on
the interrelation of multiple factors, such as the avidity of
virus-receptor binding and the pH range of virus conversion
compared to that of the receptor switch.
Taken together, our results underscore the role of the -pro-
peller in LDLR for minor group HRV infection. LDLR is thus
not just a simple vehicle for delivery of the virus into endo-
somes but is also a well-chosen carrier combining high-avidity
multimodule binding with an intrinsic release mechanism. If
the release mechanism is impaired, the virus fails to undergo
conversion at the correct time, and the correct intracellular
compartment and infection is less efficient.
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